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Superparamagnetic nanoparticles have been under intensive investigation in various 
biomedical applications. However, it is still a challenge to synthesize high quality water 
stable ultrafine magnetite nanoparticles for better magnetic performance and less side 
effects in clinical MRI and thermotherapy (magnetic hyperthermia). In this work, 
monodispresed and control sized hydrophobic superparamagnetic magnetite (Fe3O4) 
nanoparticles have been synthesized by thermal decomposition method optimizing the 
reaction parameters like temperature, time, solvent and surfactant effects. These 
hydrophobic Fe3O4 nanoparticles are converted into hydrophilic (i.e. water soluble) by 
functionalization and polymeric encapsulation to make them useful for biomedical 
applications. Direct synthesis of hydrophilic Fe3O4 nanoparticles and nanoclusters with 
high saturation magnetization (Ms ~ 73 - 86 emu/g) have also been performed using one-
step polyol method. The Fe3O4 nanoparticles and nanoclusters are systematically 
characterized to identify their structure, surface coating, magnetic properties, 
cytotoxicity, cellular uptake, magnetic resonance imaging (MRI) contrast and specific 
absorption rate (SAR) properties. In vitro experiments have demonstrated high cellular 
uptake and low cytotoxicity and the AC magnetic field heating experiments showed 
effectiveness in temperature rise and 60-74% cancer cell death due to magnetic 
hyperthermia. The Fe3O4 nanoclusters yielded high specific absorption rate (SAR~500 
Watt/g) values as compared to the Fe3O4 nanoparticles (SAR~135 Watt/g) upon exposure 
to AC magnetic field. The Fe3O4 nanoparticles have showed high r2* relaxivity (617.5 s-
1mM-1) and very promising contrast in vivo tumor imaging. Thus, the Fe3O4 nanoparticles 
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1.1. Brief Introduction on Magnetism 
Magnetism originates from electron spins and electron movement. Electrons in an atom 
govern magnetic properties in two different ways: 1) electron acting as a spinning 
charged sphere. The spin is a quantum mechanical property and can be oriented in one of 
two directions, in the Up. (↑) direction or the Down. (↓) direction; 2) the effect of the 
electron circulating around the nucleus of the atom, which resembles a current loop. The 
flow of charge in a circular current loop produces magnetic lines of force known as a 
dipole [1]. There are various forms of magnetism that arise depending on how the dipoles 
interact with each other. Figure 1.1 shows a schematic representation of the different 
types of arrangements of magnetic dipoles in ferro-, antiferro- and ferrimagnetic 
materials below a “critical temperature”. Above this temperature, the magnetic moments 
randomize due to thermal energy and hence the material displays paramagnetic behavior. 
This temperature is known as Néel temperature (TN) for antiferromagnetic materials and 
Curie temperature (TC) for ferromagnetic and ferrimagnetic materials. It is to note that 
ferromagnetic and ferrimagnetic substances are important for commercial applications. 
                  (a)                                 (b)                               (c)                            (d) 
 
Figure 1.1. Different orientations of magnetic dipoles: (a) paramagnetic, (b) 
ferromagnetic, (c) antiferromagnetic, and (d) ferrimagnetic [2]. 
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To minimize the energy, a ferromagnet or ferrimagnet is split up into domains in which 
all dipoles are ordered along a preferential direction (Figure 1.2). This direction changes 
from domain to domain, and hence the bulk magnetic materials may as a whole be 
unmagnetized, even though they are magnetized on the length scale of the domains. 
When placed in the presence of a sufficiently large external magnetic field, the spins in 
each domain rotate parallel to the direction of the applied magnetic field until all the 
dipoles are aligned to give the saturation magnetization (Ms). When the applied field is 
decreased, the magnetization decreases. In multi-domain bulk materials, demagnetization 
occurs primarily via spin rotation through the domain walls. If the demagnetization curve, 
during the removal of the applied field, does not follow the initial magnetization curve, 
the material displays hysteresis, which is the lag observed in Figure 1.3. Remanence  
magnetization  (Mr)  is  the  magnetization  remaining  at  zero  applied  field  (H  =  0). 
The magnetic field applied in the negative direction required to return the magnetization 





Figure 1.2. Dipole alignments in bulk ferromagnetic materials [2]. 
 
















Figure 1.3. Magnetization (M) vs. applied field (H) for ferromagnetic (solid line), 
paramagnetic (broken line), and diamagnetic materials (dotted line). Hc represents the 
coercive field of the material, MS the saturation magnetization, Mr the remanent 
magnetization, and χi the initial susceptibility [2]. 
 
1.2. Magnetism of Nanosized Particles 
Nanosized particles have physical and chemical properties that are characteristic of 
neither the atom nor the bulk counterparts. Quantum size effects and the large surface 
area of magnetic nanoparticles dramatically change some of the magnetic properties and 
exhibit superparamagnetic phenomena, surface magnetism and quantum tunnelling of 
magnetization, because each particle can be considered as a single magnetic domain [3]. 
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1.2.1. Single Domain Particles 
In large magnetic particles, it is well known that there is a multidomain structure, where 
regions of uniform magnetization are separated by domain walls. The width of a domain 
wall (δ΄) is a function of the magnetocrystalline anisotropy (K), the exchange energy 
(Eex) and lattice spacing (a) of the crystal structure (Equation 1.1). 
 
                                                                     ------------------------ (1.1)                                                                                                 
The formation of the domain walls is a process driven by the balance between the 
magnetostatic energy (∆EMS), which increases proportionally to the volume of the 
materials and the domain-wall energy (Edw), which increases proportionally to the 
interfacial area between domains. If the sample size is reduced, there is a critical volume 
below which it costs more energy to create a domain wall than to support the external 
magnetostatic energy of the single-domain state.  The critical size of a spherical particle, 







≈ , where µ0 is the vacuum permeability, and M is the saturation 
magnetization [4]. Thus, the particles having size below the critical size (Ds, single 
domain size) is considered as single domain particles. This Ds typically lies in the range 
of a few tens of nanometers and depends on the material. It is influenced by the 
contribution from various anisotropy energy terms. Typical values of Ds for some 








piδ  ′ =  
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Table 1.1. Estimated maximum single-domain size (Ds) for spherical particles [4-6].    
 
Table 1.2. The influence of the shape of Fe particles on the coercivity [8]. 
 
The demagnetization is dependent on coherent rotation of the spins, which results in large 
coercivity in small nanoparticles [7]. The large coercive force in single domain particles 
is not only due to the magnetocrystalline anisotropy but also the shape anisotropies for 
nonspherical particles. The shape anisotropy increases as the aspect ratio of a particle 
Material Ds (nm) 
Fe 14 
hcp Co 15 
fcc Co 7 
Ni 55 
Fe3O4 128 
γ – Fe2O3 166 
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increases (Table 1.2). Therefore, elongated single-domain particles display large coercive 
forces.  The coercive force is also dependent on particle size as shown in Figure 1.4.  As 









Figure 1.4. Coercivity as a function of particle size (Dp is the superparamagnetic size and 
Ds is the single domain particle size) [8].  
 
1.2.2. Superparamagnetism 
The superparamagnetism can be understood by considering the behavior of a well-
isolated single-domain particle. The magnetic anisotropy energy per particle which is 
responsible for holding the magnetic moments along a certain direction can be expressed 
as follows: 2( ) sinE KVθ θ= , where V is the particle volume, K is the anisotropy 
constant and θ is the angle between the magnetization and the easy axis [4]. The energy 
barrier KV separates the two energetically equivalent easy directions of magnetization. 
With decreasing particle size, the thermal energy, kBT, exceeds the energy barrier KV 
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(Equation 1.2) and the magnetization is easily flipped i.e. there is no more preferential 
orientation of the moment in the particle.  
25 BKV k T< ------------------------ (1.2) 
The magnetic moment of the particle may fluctuate behaving as a paramagnet. Thus, a 
single domain particle appears to be superparamagnetic when temperature is over the 
critical temperatures as given in equation 1.2 (Figure 1.5) [9]. Such a system has no 
hysteresis and the data of different temperatures superimpose onto a universal curve of M 
versus H/T [1]. 
 
Figure 1.5. Domain structures observed in magnetic particles:  (a) superparamagnetic; 
(b) single domain particle; (c) multi-domain particle [9].  
 
1.2.3. Magnetic Relaxation 
Considering particles in a carrier liquid under the influence of an external magnetic field, 
it can be shown that when the applied magnetic field is removed the magnetization of the 
particles is reversed. There are two main mechanisms for the magnetization reversal: spin 
rotation or particle rotation, which describe whether the change in direction of the 
magnetic moment of the particle is due to the reversal of the magnetic spin of the particle 
or the actual physical rotation of the particle. The time required for the reversal of the 
b c a 
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magnetic moment of the particle (spin rotation) is related to the magnetic anisotropy of 
the material, Néel relaxation time, τN. The mathematical expression of Néel relaxation 
time is shown by Equation 1.3 [4].  
9









The characteristic time for the randomization of the magnetization due mainly to the 
thermal motion of the particle is known as Brown relaxation time, τB, expressed 







τ = --------------- (1.4) 
For a superparamagnetic material τN << τB, which means that the magnetization reversal 
occurs by rotation of the magnetic axis. Alternatively, when the magnetic moment of the 
particle is locked to a given crystallographic direction (easy axis), the particle is 
thermally blocked and τB << τN. 
If the particle magnetic moment reverses at times shorter than the experimental time 
scales, the system is in a superparamagnetic state, if not, it is in the so-called blocked 
state. The critical temperature, which separates these two regimes, is called blocking 
temperature, TB. Thus, beside the dependence of the magnetization on the particle size 
and composition, the magnetic properties depend greatly on the temperature. Above TB 
ferro- or ferrimagnetic particle will behave as superparamagnetic. It is possible to 
calculate TB using Equation 1.5. The blocking temperature depends on the anisotropy 
constant, the size of the particles, the applied magnetic field, and the experimental 
measuring time.  





=  -------------------- (1.5) 
Thus under certain circumstances of particle size and temperature, ferro- or ferrimagnetic 
particles may be considered superparamagnetic. The criterion of superparamagnetism is 
regularly assumed considering particles with a relaxation time lower than 100 s. In the 
case of Fe3O4 with an anisotropy constant, K = 4.4 ×104 Jm−3, the critical 
superparamagnetic particle size at room temperature, T = 290 K, is between 9 and 17 nm 
[10]. 
A simple and rapid way to estimate the blocking temperature (TB) is provided by DC 
magnetometry (SQUID) measurements, in which a zero-field-cooling (ZFC) and field-
cooling (FC) procedure is employed. Briefly, the sample is cooled from room 
temperature in zero magnetic field (ZFC) and in a magnetic field (FC). Then a small 
magnetic field is applied (about 100 Oe) and the magnetization is recorded on warming. 
As temperature increases, the thermal energy disturbs the system and more moments 
acquire the energy to be aligned with the external field direction. The number of 
unblocked, aligned moments (i.e. the ZFC magnetization curves) reaches a maximum at 
the blocking temperature (TB). Above the TB the thermal energy is strong enough to 
randomize the magnetic moments leading to a decrease in magnetization. In the case of 
FC procedure, magnetization monotonically increases as the temperature decreases. For a 
single magnetic domain, the FC and ZFC curves diverge below TB due to the existence of 
magnetic anisotropy barriers. Above TB the sample is superparamagnetic and below is 
ferro- or ferrimagnetic. At TB the thermal energy becomes comparable to the energy 
barrier gained in external magnetic field.  
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1.2.4. Dependence of Magnetization on Particle Size  
The magnetization of bulk magnetic materials is inherently larger than for nanoparticles 
of the respective materials. Experimental values for the saturation magnetization of 
magnetite (Fe3O4) nanoparticles have been reported in the range of 30-60 emu/g which is 
lower than theoretical saturation magnetization (92 emu/g) of bulk magnetite [11-13]. 
Several researchers using a variety of techniques have  investigated  the  causes  for  the  
observed  reduction  in magnetization  in  fine  magnetic particles. In 1968 Berkowitz et 
al observed that the saturation magnetization, MS (293K) depends upon the average 
crystallite size (Figure 1.6) [14].  The values of MS (293K) for the samples (γ-Fe2O3 
particles) with the largest crystallite sizes were very close to the theoretical saturation 
magnetization (74 emu/g) of bulk maghemite (γ-Fe2O3) while a sharp decrease of MS 
occurred for the samples with the smallest crystallite sizes. They gave several reasons for 
the decreasing of MS: 
(1) the presence of either α-Fe2O3 or γ-Fe2O3.H2O 
(2) the magnetostatic interactions among all the crystallites in a particle, as well as 
the interactions between the particles 
(3) the magnetocrystalline anisotropy of γ-Fe2O3 and 
(4) the consequence of crystallite sizes that depart from the critical size of 400Å.  
Many other researchers also observed the decrease in saturation magnetization (MS) of 
Fe3O4 and γ -Fe2O3 nanoparticles from the corresponding MS value of bulk material. The 
reported possible reasons for the decreasing of MS of particles are [12, 15-16]:  
(a) existence of noncollinear spin and magnetically dead layer (about ~1 nm thick) 
which formed by asymmetric environment effect of the surface atoms.        
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(b) high effective anisotropy fields in the surface, nonmagnetic grain boundaries and 
hydrogen in the lattice.  
(c)  particle surface defects and order-disorder structural characteristics because of 
their amorphous nature  












Figure 1.6. Saturation magnetization as a function of the crystallite size of acicular γ-
Fe2O3 particles [14]. 
 
1.3. Magnetic Nanoparticles for Biomedical Applications 
Nano-science and nanotechnology have generated tremendous opportunities in many 
biological and technical fields of applications because of the unique chemical and 
physical properties of nanomaterials in comparison to the bulk materials. Magnetic 
nanoparticles have been attracted in the bio-medical field to a large extent in recent years. 
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This is due to a number of beneficial factors: First, they have sizes that place them at 
dimensions comparable to those of a virus (20–500 nm), a protein (5–50 nm) or a gene (2 
nm wide and 10–100 nm long) [17]. Second, the nanoparticles are magnetic, which 
means that they can be manipulated by an external magnetic field. As for example, 
magnetic nanoparticles can be guided to a chosen site using a localized magnetic field 
gradient, hold them there until the therapy is complete and then remove them. Third, 
nanoparticles have a large surface area that can be properly modified to attach biological 
agents. Finally, since the particles are very small, there is a possibility of ubiquitous 
tissue accessibility.  
Applications in biotechnology impose strict requirements on the particles’ physical, 
chemical, thermal, mechanical, and pharmacological properties, including chemical 
composition, granulometric uniformity, crystal structure, magnetic behavior, surface 
structure, adsorption properties, solubility and low toxicity [17]. Based on their unique 
properties, magnetic nanoparticles offer a high potential for several biomedical 
applications, such as [18-22]: 
(a) cellular labelling/call separation; 
(b) tissue repair; 
(c) targeted drug delivery; 
(d) magnetic resonance imaging (MRI); 
(e) hyperthermia; 
(f) magnetofection; etc. 
For all of these applications, the effectiveness of the magnetic particles depends upon 
their (a) magnetic susceptibility; (b) magnetic saturation; (c) superparamagnetic 
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behaviour; (d) size and monodispersity; (e) biocompatibility and toxicity; (f) chemical 
stability and (g) tailored surface chemistry such as availability of interactive functions at 
their surface of  bio-molecules like antibody; protein; drug; gene etc.  
 
Magnetic hyperthermia is promising therapy for cancer treatment in which the cancerous 
organs or tissues are preferentially heated to temperatures between 42°C and 46°C [18-
20]. The heating helps to shrink tumors by damaging cells or depriving them of 
substances they need to live. Moreover, magnetic resonance imaging (MRI) has been 
recognized as one of the best noninvasive imaging modalities in both clinical and 
research fields. In this thesis, we have focused the magnetic hyperthermia and MRI 
imaging of the magnetic nanoparticles for the diagnostic and therapeutic (theronestic) 
application.  
 
1.4.  Hyperthermia 
Cancer is a group of diseases characterized by abnormal regulation of cellular growth and 
reproduction [23]. Cancer cells can be characterized by some basic features that include 
uncontrolled cell proliferation, decreased cellular differentiation, ability to invade the 
surrounding tissue and ability to establish new growth at ectopic sites [24]. Cancer cells 
are characterized by essential alterations in cell physiology that collectively dictate 
malignant growth. These are:  i) self-sufficiency in growth signals, ii) insensitivity to 
growth-inhibitory (antigrowth) signals, iii) evasion of programmed cell death and 
metastasis [25]. As per the National Center for Health Statistics, cancer is one of the 
second leading (second only to heart diseases) cause of death in the U.S. and many other 
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industrialized countries [26]. It kills approximately 500,000 people each year in the 
United States and costs our society more than 100 billion dollars annually. The American 
Cancer Society estimates 1,437,180 new cancer cases and 565,650 deaths (at a rate of 
1500 people a day) related to cancer in 2008 [27].  
Up to date, the best known methods for curing cancer are surgery, radiotherapy 
and chemotherapy. Although radiation and surgical interventions have increased the five-
year survival rate in cancer patients, it has been suggested that neither may be able to kill 
or remove all cancerous tissue due to the irregular shape of the tumor. Not to mention the 
very invasive nature of a surgery and the collateral damage that is inevitable in 
radiotherapy. In chemotherapy, drugs that are injected either systematically or locally 
stop the reproduction of cancerous cells [28]. However, chemotherapy attacks all sorts of 
cells without discerning between cancerous and normal cells. Therefore, many side 
effects are attributed to chemotherapy. Hair, skin, mouth, stomach and intestines cells are 
attacked by this method resulting in hair loss, sores in mouth and throat, dry skin, nausea, 
vomiting, and diarrhea [27]. Moreover, both radiation therapy and chemotherapy are 
known to cause “the second cancers”. For instance, chemotherapy is a high risk in 
causing leukemia.  
Within the past decade, hyperthermia has been widely used in a variety of 
therapeutic procedures, either as a singular therapy or as an adjuvant therapy with 
radiation and drugs in cancer treatments. Since it is associated with few complications 
[27], hyperthermia is preferable for patients suffering from inoperable or surgically 
complex tumors, or for patients who are looking for an alternative to the costly and risky 
surgical procedures [29].  
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1.4.1. Types, Methods and Principles of Hyperthermia 
Hyperthermia (HT) is a minimally invasive method for selective heat treatment in which 
the target tissues are heated to about 42-46°C [30-36]. HT is usually applied as one of 
three different treatment strategies: local hyperthermia (LH), which restricts the 
application of heat to the tumor site, regional hyperthermia (RH) which is applied to treat 
an entire organ or limb and whole body hyperthermia (WBH), which applies heat to the 
entire body [37]. Since its inception, different methods have been used in hyperthermia to 
generate thermal energy or heat in tumors including microwaves, high-frequency 
radiowaves, special radiant-heat systems, temperature controlled water baths, high energy 
magnets, ultrasound, capacitive heating using RF electric field, as well as interstitial and 
intracavitary probes [37-39]. 
Cancer cells are more susceptible to effects of heat at temperatures above 41°C as 
compared to normal cells [40]. Therefore, in a hyperthermia treatment, thermal energy is 
delivered to tumors to raises the intratumoral temperature above 42°C for duration of 
more than 60 minutes, while maintaining the temperatures in the surrounding normal 
tissue below 42°C [41]. Death of the tumor cells occur due to a heat-induced cytotoxic 
response and/or increased cytotoxic effects of radiation and drugs at such an elevated 
temperatures. Both the direct cell-killing effects of heat and the sensitization of other 
agents by heat are phenomena strongly dependent on the achieved distribution of the 
temperature increase and duration of heating.  
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1.4.2. Magnetic Nanoparticles for Hyperthermia 
Magnetic nanoparticle hyperthermia has attracted growing research interests in malignant 
tumor treatment due to its simple implementation, low cost, and reduced complication. A 
major concern with the hyperthermia treatments is difficulty in heating the local tumor 
region to the intended temperature without causing harm to the normal tissues [42-43]. 
To overcome this, the idea of magnetic particles based intracellular hyperthermia was 
first proposed for the treatment of deep-seated tumors more than fifty years ago. In this 
method, micron sized magnetic particles were delivered to the tumor tissue or blood 
vessels induce localized heating when exposed to an alternating magnetic field, leading to 
irreversible thermal damage to the tumor [44]. This method enables adequate heat to be 
generated within tumor tissue without necessitating heat penetration through the skin 
surface, thus eliminating the consequent side effects of excessive collateral thermal 
damage. Magnetic nanoparticles have been exploited as miniature heat generators in 
tissue to address the limitations of conventional hyperthermia approaches. It is an 
effective and clinically safe therapeutic alternative for cancer treatment because of its 
ability to provide sufficient and localized heating in tumors, its versatility in treating 
tumors of irregular shapes that are unsurpassed by traditional non-invasive heating 
approaches, and its maneuverability to be incorporated into other treatment routes to 
achieve optimized therapeutic effect. The critical properties of magnetic nanoparticles 
which are used for heat generation include non-toxicity, biocompatibility, injectability, 
high-level accumulation in the target tumor and effective absorption of the energy of the 
AC magnetic field [42]. To date, the magnetite (Fe3O4) and maghemite (γ-Fe2O3) 
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nanoparticles are most frequently studied in hyperthermia due to their excellent 
biocompatibilty [45-46]. 
Nanoparticles have undergone rapid growth as site-specific carriers for the 
delivery of therapeutic, imaging, and sensing agents [28]. Nanoparticles loaded with anti-
cancer agents are used to target tumor cells selectively to reduce drug intake by healthy 
tissue. The multifunctional nanoparticles have been developed by encapsulating the 
magnetic nanoparticles (MNPs) and anticancer drugs (Ads) to combine the magnetic 
hyperthermia with the chemotherapy [47]. The site-specific targeting of the nanoparticles 
enhance selective uptake of the MNPs and Ads by the target cells and thereby potentially 
restrict the hyperthermic and chemotherapeutic effects to a particular diseased areas 
avoiding various side effects to the surrounding normal tissues [48]. Thus, the combined 
therapy of magnetic hyperthermia and chemotherapy using the nanoparticles offer better 
therapeutic efficacy for cancer treatment. 
 
1.4.3. Mechanism of Heat Generation by Magnetic Nanoparticles  
Ferromagnetic materials are commonly known to dissipate heat by hysteresis when 
exposed to an alternating (AC) magnetic field [35]. The heating by hysteresis is enhanced 
as the size of the ferromagnetic particles decreases to nanoscale. Ferrofluid consisting of 
extremely fine particles with diameter around 10 nm have superparamagnetic properties. 
The magnetization of a superparamagnetic ferrofluid relaxes back to zero when it is 
removed from a magnetic field, due to the ambient thermal energy of its environment 
[49]. This relaxation either corresponds to the physical rotation of the particles 
themselves within the fluid (known as Brownian rotation), or rotation of the atomic 
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magnetic moments across an effective anisotropy barrier within each particle (known as 
Néel relaxation) [40,49]. The relaxation phenomena strongly depend on the size of the 
particles. For the smaller particles the Néel relaxation process dominates, while large 
particles relax following Brownian rotation [40]. For magnetite the critical size for the 
transition from Neel to Brown relaxation is about 13 nm [40]. When ferrofluid is exposed 
to an external AC magnetic field, magnetic particles generate heat mainly due to the Néel 
relaxation mechanism and/or Brownian rotation of the particles [35,50]. The heat induced 
by the ferrofluid is termed magnetic fluid hyperthermia. In Neel relaxation mechanism, 
thermal energy is released when the initial permanent magnetic moment of magnetic 
nanoparticles changes with the alternating magnetic field [51]. In this case, the Eddy 
current heating is negligible [50]. On the other hand, the heat is generated in Brown 
relaxation mechanism due to friction between the moving particles and liquid. One of the 
main advantages of fine superparamagnetic nanoparticles is that they are able to produce 
an impressive level of heating at relatively low magnetic fields and frequencies (less than 
1 MHz) [51]. At such small frequency levels, the induced electric fields are negligible 
[52]. The specific amount of heat known as the specific loss power (SLP) generated by 
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where H and f are the magnetic field strength and frequency respectively, φ is the 
concentration (volume of nanoparticles per unit volume of tissue), η is the liquid 
viscosity, Kb is Boltzmann constant, Md and K are two parameters that depend on the 
nanoparticles material, T is the temperature, Rp is the nanoparticle radius and Vp is the 
nanoparticle volume. 
 
1.5. Magnetic Resonance Imaging Contrast Agents 
Magnetic resonance imaging (MRI) has been recognized as a powerful noninvasive 
diagnostic technique to visualize the fine structure of a human body in a high spatial 
resolution [53]. MR images of biological tissue are constructed by applying a static 
magnetic field to the tissue, exciting the magnetic moments of protons in the tissue with a 
radio frequency pulse, and spatially resolving the density and/or relaxation times of the 
excited protons. Compared to other medical imaging modalities, MR images possesses 
high spatial resolution but have limited sensitivity (poor contrast) with anatomical or 
pathological features that possess similar proton relaxation times, such as small liver 
metastases [54]. In such poor contrast features, the sensitivity of MRI can be effectively 
increased by the use of MRI contrast agents, which locally increases image contrast by 
shortening proton relaxation times. The use of MR contrast agents enables achievement 
of clear images for accurate diagnosis, by exerting an influence on the longitudinal (T1) 
or transverse (T2) relaxation time of the surrounding tissue. For example, paramagnetic 
complexes containing gadolinium (Gd3+) or manganese (Mn2+) ions induce the local 
relaxation change of the nearby water protons and mainly reduce T1, providing positive 
contrast (bright signal) on T1-weighted MR image [55-56]. On the other hand, the 
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superparamagnetic iron oxide (SPIO) nanoparticles function as MRI contrast agents by 
shortening the spin-spin proton relaxation (T2 relaxation) of nearby water protons. The 
shortened T2 relaxation is manifested as negative contrast (darkening) in the MR image, 
thus increasing the contrast of the tissue containing SPIO nanoparticles [57]. Iron oxide is 
an attractive material as a biocompatible contrast agent as it is readily sequestered and 
metabolized by the body [58]. Superparamagnetic magnetite nanoparticles have been 
widely utilized as ultrasensitive dark negative contrast for stem cell tracking and early 
detection of cancers due to their strong T2 shortening effect [59-61].  
The ability of magnetite nanoparticles to generate MR contrast is influenced by 
the particles size, crystallographic structure and presence of contaminants. While 
maghemite (γ-Fe2O3) nanoparticles are sometimes used as MRI contrast agents, 
magnetite is preferred due to a higher saturation magnetization (mass normalized 
maximum magnetic moment) compared to maghemite. The influence of the size and 
composition of magnetite nanoparticles and other Fe-based spinels on the MR contrast 
has been studied recently [62-63]. These studies demonstrated that with increasing size of 
the nanoparticles within the size range of 6 to 12 nm the MR contrasts increases as shown 
in Figure 1.7. A higher MR contrast of larger magnetite nanoparticles is reasonable, 
because faster spin-spin relaxation processes of the water molecules are induced by 
materials with a larger magnetization [64]. Nevertheless, superparamagnetism is an 
important property of SPIO MRI contrast agents due to the inherent absence of remnant 
magnetization in the nanoparticle after applying an external magnetic field, as remnant 
magnetization would lead to undesirable magnetic aggregation of the nanoparticles. The 
small size of the magnetite nanoparticles is important for MRI contrast applications 
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because the iron oxide particles become superparamagnetic at diameters <30 nm, the 
maximum size for a single magnetic domain particle [65]. Therefore, it has yet to be 
determined what size range is optimum for highest MR contrast without losing the 
















Figure 1.7. Nanoscale size effect of Fe3O4 nanocrystals on magnetism and induced MR 
signals. (a) TEM images of Fe3O4 nanocrystals of 4 to 6, 9, and 12 nm. (b) Size-
dependent T2-weighted MR images of Fe3O4 nanocrystals in aqueous solution at 1.5 T. 
(c) Size-dependent changes from red to blue in color-coded MR images based on T2 
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values. (d) Graph of T2 value versus Fe3O4 nanocrystal size. (e) Magnetization of Fe3O4 
nanocrystals measured by a SQUID magnetometer [62]. 
 
The commercial T2 contrast agents are synthesized by coprecipitation and coated by 
different polymers or molecules [66]. The hydrodynamic size and coating determine the 
nanoparticle biodistribution and the desired organ or tissue to be imaged [67-68]. For 
example, iron oxide nanoparticles coated by dextran (Feridex, Guerbet) or carboxidextran 
(Resovist, Schering) with a high hydrodynamic size have been used to image the liver 
[69-70]. However, magnetic nanoparticles coated by the same polymers but with a low 
hydrodynamic size (Sinerem, Guerbet and Supravist, Schering) have been used as blood 
pool agents to image macrophages or lymph nodes [71]. 
There are two different strategies to improve the quality of the contrast agents. 
One is related to the nanoparticle synthesis method, and the other is related to the coating 
and the hydrodynamic size. The coprecipitation method presents several problems, such 
as the poor control of the size and size distribution and the lack of crystallinity of these 
particles due to the presence of defects in the structure and the lack of symmetry of the 
iron ions at the surface [66]. As a consequence of that, these nanoparticles present poor 
magnetic properties which are in detriment of the contrast in the MR images. Uniform 
and high crystalline magnetite nanoparticles would be highly desirable for this 
application. In relation to the coating and the hydrodynamic size, an important effort 
should be done to developed contrast agents with covalently bonded ligands and small 
hydrodynamic sizes to enhance the blood half-life time. Polymers or small molecules are 
usually bonded to the nanoparticle surface by adsorption forces, and when the particles 
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are introduced to the body, they are desorbed due to dilution, facilitating its aggregation 
and uptake by the macrophages [66].  
The use of magnetic nanoparticles as MRI contrast agents can be divided into 
molecularly targeted approaches, which rely on equipping the nanoparticles with specific 
ligands to recognize specifically the target markers and the passive approaches. The 
passive approaches are based on the non-specific accumulation of the nanoparticles into 
the tissues to be imaged, for instance the organs of the RES system such as liver and 
spleen following intravenous injection of the nanoparticles. Dextran-coated magnetite 
nanoparticles have been clinically used as MRI contrast agents for more than a decade 
and commercially available products are available with different sizes and surface 
chemistry. Imaging of the lymph node system has also been achieved through either 
intravenous or subcutaneous injection of dextran-coated nanoparticles.  
Currently, there is wide interest in using targeted SPIO nanoparticles in diagnostic 
imaging applications, with a number of recent studies demonstrating the clinical potential 
for cancer diagnosis and tumor detection. Molecularly targeted approaches are more 
challenging but promising in vivo results have been reported, enabling MR imaging of 
rare molecular events at the cellular and subcellular level. For this, the SPIO 
nanoparticles are conjugated with targeting vectors or biomarkers (i.e. antibodies, small 
molecular ligands, aptamers), to target them at a specific site. Monoclonal antibody and 
peptide sequences have been conjugated to magnetite nanoparticles and used to target 
them to pathologic areas such as tumors, myocardial infarction, or beta-amyloid plaques 
[66, 72]. Magnetite nanoparticles conjugated with the synaptotagmin I protein that bind 
to anionic phospholipids expressed in apoptotic cells have for instance been used to 
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detect with MRI apoptotic tumor cells following treatment with chemotherapeutics in a 
murine lymphoma model [73]. Herceptin-conjugated nanoparticles could also be used to 
detect cancer cells implanted in mice in vivo in T2 weighted MRI sequences [74]. Recent 
years have witnessed an explosion of work in molecular imaging by MRI and interested 
readers are referred to recent reviews [72, 75-77]. 
In addition to bioconjugation, SPIO nanoparticle material properties can be 
manipulated by changes in size and surface chemistry. These approaches enable “tuning” 
of the colloidal magnetic properties [74]. Specifically, the local T2 proton relaxivity of 
SPIO nanoparticles can be modified via interfacial surface chemistry to induce 
aggregation or dispersion in the colloid, thus providing control of the ultimate 
nanoparticle aggregate size and magnetic properties, with the end goal being the 
optimization of the colloid for a specific imaging application. 
 
1.6. Biocompatibility, Biodistribution and Clearance of Magnetic 
Nanoparticles 
The important properties which determine the biocompatibility and toxicity of magnetic 
nanoparticles are the nature of the magnetically responsive component, such as iron, 
nickel or cobalt [78-79]. But, cobalt and nickel are highly toxic and susceptible to 
oxidation, and thereby they are of little interest [79]. Iron oxide nanoparticles such as 
magnetite (Fe3O4) or maghemite (γ-Fe2O3) are most commonly used in biomedical 
applications. The biocompatibility of iron oxide nanoparticles has been proven in 
previous studies on the humans [66] through toxicological and pharmacological tests. 
Iron oxides in a human body can be degraded in blood pools rich in iron such as 
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hemoglobin after 7 days and thereby it is considered as nontoxic. However, excessive 
amounts of iron are harmful to the function of liver; the upper limit of the iron 
concentration is 4 mg/g of wet liver tissue [80]. 
Magnetic nanoparticles are small enough to be considered as biological entities 
and can cross vascular barriers and migrate in the extracellular space without causing 
embolic phenomena [28, 81]. Due to their small size, nanoparticles cause no blood 
coagulation on their surface but they are likely to be consumed through phagocytosis 
[82]. However, the blood vessels in tumors are very "leaky" relative to normal blood 
vessels and the endothelial barriers are diminished; therefore nanoparticles have a better 
chance to enter the local tumor cells rather than being drained to the lymphatic glands. 
The phenomenon is known as EPR, for "Enhanced Permeability and Retention" and it is 
enhanced through coating the nanoparticles with a protein layer [83]. Not everything in 
the blood stream will invade a tumor by this route, but on the whole it is a fairly non-
specific mechanism that works for a wide range of nanoparticles, as long as the 
nanoparticle of interest is able to circulate long enough. A more specific method to target 
a tumor is to attach molecules to the surface of the nanoparticle that improves its ability 
to attach to the surface of a tumor or to penetrate into the cancerous cells. These 
molecules can be sugars, small molecules, antibodies, or small peptides; folic acid is one 
of the most commonly employed small molecules, which targets the folate receptor 
present on the surface of many tumor cells [47, 84].  
Probably the most important factor in the design of any nanoparticle for in-vivo 
application is the biocompatibility of the device. The term “biocompatibility” has many 
meanings. In some cases the mere demonstration of water solubility is cited as evidence 
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of biocompatibility. In other cases “biocompatible” means that the nanoparticle must 
display limited toxicity to the organism at its effective dose, it must be able to perform its 
function without interference from the organism’s healthy mechanisms, and it must be 
able to circulate long enough to accomplish its intended task. Shape, size, and charge are 
all factors in determining how long a given nanoparticle will circulate before being 
eliminated by the liver, kidneys, or spleen. A key requirement for intravenously 
administered nanoparticles is that they have an ability to circulate in the bloodstream for 
> 2 hours; if it is filtered out by the liver or the kidneys it can't make it to the tumor. 
 
What happens to Nanoparticles after Intravenous Injection? 
One of the most important pathways for clearance of nanoparticles in vivo is the 
mononuclear phagocytic system (MPS), alternatively known as reticulo-endothelial 
system (RES). After particles are injected into the bloodstream they are rapidly coated by 
components (opsonins) of the circulation, such as plasma proteins (immunoglobulins, 
complement proteins, fibronectin, etc.) [21,33]. This process is known as opsonisation. 
Body’s major defence system, the RES is a diffuse system of specialized cells that are 
phagocytic (i.e. engulf inert material) associated with the connective tissue framework of 
the liver (Kupffer cells), spleen and lymph nodes [21]. These macrophages easily 
recognize the opsonized particles and rapidly clear them from the blood circulation.  The 
fate of nanoparticles following intravenous (iv) administration, is indicated in Figure 1.8. 
Therefore, the first step for achieving long circulation of the nanoparticle is development 
of a strategy to minimize or delay the nanoparticle uptake by the MPS or RES or 
phagocytes.  















Figure 1.8. Biodistribution of nanoparticles following intravenous injection [21].  
 
 
The size, morphology, charge, and surface chemistry of magnetic particles could strongly 
influence their biodistribution. The smaller, more neutral and more hydrophilic particle 
surface are responsible for the longer its plasma half-life i.e. longer circulation time [33]. 
Particles that have a largely hydrophobic surface are efficiently coated with plasma 
components and thus rapidly removed from the circulation, whereas particles that are 
more hydrophilic can resist the opsonisation process and are cleared more slowly [85]. 
This has been used to the advantage when attempting to synthesize RES evading particles 
by sterically stabilizing the particles with a layer of hydrophilic polymer chains [86]. In 
the literature the most common coatings are derivatives of dextran, polyethylene glycol 
(PEG), polyethylene oxide (PEO), poloxamers and polyoxamines [87]. The role of the 
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dense brushes of polymers is to inhibit opsonization, thereby permitting longer 
circulation times [88-90]. A further strategy in avoiding the RES is by reducing the 
particle size [91-92]. Particles below 100 nm are small enough both to overcome the RES 
uptake of the body as well as penetrate the very small capillaries within the body tissues 
[91]. Despite all efforts, however, complete evasion of the RES by these coated 
nanoparticles has not yet been possible [85]. Thus, a pre-requisite to the widespread use 
of nanoparticles in vivo is their ability to resist non-specific adsorption of opsonins i.e. to 
avoid the RES uptake. In this thesis, the in vivo biodistribution of nanoparticles are 
studied using mice and rat to evaluate their bold circulation time.  
 
1.7. Iron Oxide Nanoparticles: Building Block of Ferrofluids 
Magnetic nanoparticles are comprised of metals and metal oxides including Ni, Co, Fe, 
iron oxide (γ-Fe2O3, Fe3O4 etc) and other ferrites (MnO·Fe2O3, CoO·Fe2O3 NiO·Fe2O3). 
Although, the ferromagnetic transition metal (Fe, Co and Ni) particles have high 
saturation magnetization value but it is very difficult to produce their nanoparticles in 
stable form due to rapid oxidation on their surface. For example, nanoscale Fe particles 
are so unstable that they will spontaneously burst into flames when exposed to air. Ni and 
Co particles are less reactive but an oxide coating will still form if exposed to air. Also, 
cobalt and nickel are toxic, making them unsuitable for in vivo applications [22]. In 
contrast, iron oxide nanoparticles are easily fabricated due their chemical stability. Iron 
oxide consist of iron (Fe2+ or Fe3+) ions which are the component of blood hemoglobin 
and essential for metabolism of red blood cells and thereby it is considered as nontoxic 
(toxicity can arise when overdose). Iron oxide nanoparticles are superparamagnetic; that 
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is, they do not show any magnetism in the absence of an external magnet, but develop a 
magnetic moment when an external magnet is applied. In addition, they have relatively 
high saturation magnetization and high initial susceptibility. Therefore, iron oxide 
particles such as magnetite (Fe3O4) or maghemite (γ-Fe2O3) are most commonly 
employed in the biomedical applications for past decades. In biomedical applications, the 
iron oxide nanoparticles are generally used in ferrofluid form. A ferrofluid (also known 
as magnetic fluid or magnetic colloid or magnetic liquid) is a stable and homogeneous 
colloidal suspensions of single-domain magnetic particles dispersed in appropriate carrier 
liquid which is either polar (e.g. water) or non-polar (e.g. hydrocarbon) [93-94]. The 
advantage of the ferrofluid is that it is possible to control its flow using an external 






Figure 1.9. Flow of ferrofluid in presence of a permanent magnet. 
 
Ferrofluid contains colloidal ferro- or ferrimagnetic particles with a typical size of 10 nm 
dispersed in a carrier liquid. Because of their small size, these magnetic colloid particles 
contain a single magnetic domain, and therefore have a permanent magnetic moment 
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proportional to their volume. In the absence of an external magnetic field, the magnetic 
moments of each single particle are randomized and the materials are not magnetized and 
hence magnetic fluids are paramagnetic in behavior. On the other hand, since the particle 
sizes are so small, their magnetic moments can freely rotate essentially instantaneously 
along an applied magnetic field gradient and this can significantly enhance the strength of 
the applied field. Thus like ferromagnets magnetic fluids can easily approach their 
saturation magnetization. Hence magnetic fluids are called superparamagnetic that 
means although they are ferromagnetic on the molecular scale, they resemble a 
paramagnet on the colloidal scale, with the major difference that the magnetic moments 
of magnetic colloids are much larger than the moments in a paramagnet (typical values 
are 10-19 Am2 for magnetic colloids and 10-23 Am2 for paramagnets). A schematic drawing 
of the properties of a superparamagnetic fluid is shown in Figure 1.6. Further, 
superparamagnetic fluids differ from ordinary paramagnetic fluids in that they have high 
magnetic susceptibility ( χ ) and are able to be saturated in moderate fields. In addition, 
they also differ from typical ferromagnetic materials in that they do not exhibit magnetic 
hysteresis (zero coercive force). 
 
Figure 1.10. A schematic diagram of the properties of superparamagnetic fluids [95]. 
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In ferrofluid, the sizes of colloidal magnetic particles are so small (~10 nm) that particles 
are subject to Brownian motion (Figure 1.11). Collision of particles would eventually 
lead to coagulation and sedimentation due to the van der Waal’s forces (Figure 1.12). 
This process is also speeded up due to magnetic dipole-dipole interactions. Due to the 
van der Waals force of attraction and magnetic dipole-dipole attractive interactions, the 
magnetic nanoparticles tend to coagulate irreversibly. Hence a suspension of bare 
















Figure 1.12. van der Waal’s interaction between particles in a colloidal suspension. 
Chapter 1: Background 
 33
1.8. Stability of Ferrofluids 
For technical and biomedical uses and scientific studies, the most important property of 
magnetic colloid is its stability i.e. stability against sedimentation and agglomeration of 
the particles. Such sedimentation and agglomeration is due to gravitational and magnetic 
forces. The particles do not sediment and the suspension remains well dispersed if the 
thermal energy due to Brownian motion of the particles ET= kBT (kB: Boltzmann’s 
constant, T: absolute temperature) is high enough to provide sufficient mixing of the 
suspensions [93-94].  Therefore it needs to be higher than the energy of the particles in 
the gravitational field or in a magnetic field respectively. 
 
1.8.1.   Stability in a Magnetic-Field Gradient  
Sedimentation of particles due to an external magnetic field can be avoided if thermal 
energy (ET) of the particles is greater than the magnetic energy (EH) i.e. 











>1 ------------------- (1.7) 
where m (= M0V) is the magnetic moment of the particle, M0 is the spontaneous 
magnetization of the magnetic material of the particles, µ0 is the permeability of free 
space, and volume V = 3
6
dpi  for a spherical particle of diameter d.  
Thus the expression for the maximum size of the particles is: 















        ------------------------- (1.8) 
For stability of magnetite particles in a magnetic field, actual size of the particles is in the 
order of 10 nm [93-94]. 
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1.8.2.    Stability against Settling in a Gravitational Field 
Due to gravitational energy (Eg), particles tend to settle down while thermal energy (ET) 
counteracts the gravitational force and prevents the sedimentation of the particles. 
Gravitational energy of the particles in the gravitational field is 
                                             Eg = ∆ρghpid3/6 ---------- (1.9) 
where ∆ρ is the density difference between the particles and the carrier liquid, g is the 
gravitational acceleration and h the height of particle of diameter d from the bottom of a 
container. For gravitational stability of magnetite particles, maximum size of particles is 
in the order of 10 nm [93-94].  
 
1.8.3.    Stability against Magnetic Agglomeration 
Due to magnetic dipole-dipole interaction, particles tend to agglomerate while thermal 
energy provides motion which prevents agglomeration of particles. Expression for the 
magnetic dipole interaction energy (Edd) is   










  -------------------- (1.10) 
where dl /2δ= , with δ the surface-to-surface separation distance of particles. 
For particles to escape agglomeration, the thermal energy of the two interacting particles 
should be greater than the magnetic dipole interaction energy i.e. 







 -------------------- (1.11)            
The interaction energy reaches its maximum when the particles come into contact ( l = 0) 
and thus the expression for the maximum size of the particles is 
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To avoid the agglomeration due to magnetic dipole-dipole interaction, size of the 
magnetite particles should be in the order of 10 nm [93-94]. Thus the thermal energy of 
magnetite particles with 10 nm diameter is efficient to avoid sedimentation or 
agglomeration due to gravity or magnetic dipole interaction respectively. However, there 
is an additional problem as discussed later. 
 
1.8.4.   Stability against the van der Waals Attractive Force 
Always there is van der Waals force of attraction between the particles and this van der 
Waal’s interaction energy for spherical particles of diameter d with the surface-to-surface 
separation distance δ is expressed as below [93] 
































    ---------------- (1.13) 
where l (= 2δ/d) is the normalized distance and A is the Hamaker constant. 
 
In order to achieve colloidal stability in the system, the van der Waals attractive force 
between the particles has to be avoided. The stabilization of the suspension can be 
achieved by incorporating steric repulsion into the system and for that the particles are 
coated with a layer of surfactant of long chained molecules (Figure 1.13). The steric 
repulsive energy, comes out from the interaction of the long tails of surfactant molecules, 
can be expressed as below [93] 
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where ξ  is the surface concentration of the surfactant molecules, t (= 2s/d) is the 















Figure 1.13. Schematic sketch of the surfactant coated colloidal magnetic particles in a 
ferrofluid [94].  
 
 
1.8.5.   Net Interaction Curve 
For magnetite particles with diameter, d = 10 nm and a surface density ς  = 1 nm-2 with 2 
nm surfactant layer thickness different interaction energies are plotted as a function of the 
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interparticle (surface-to-surface separation) distance, δ (Figure 1.14). Thus a surfactant 
thickness of 2 nm provides an energy barrier of about 20 kBT between the particles, being 
sufficient to avoid their agglomeration due to van der Waals attraction and magnetic 












Figure 1.14. Potential energy versus interparticle distance between the surfacted 
magnetite particles of 10 nm diameter [94].  
 
The iron oxide nanoparticles are usually stabilized in an organic solvent (e.g. hexane, 
toluene etc) or in polar solvent like water using the hydrophobic (e.g. oleic acid, oleyl 
amine) or hydrophilic (e.g. dextran, ethylene glycol) coating to their surface, respectively. 
A schematic drawing of a ferrofluid, seen on three length scales, is shown in Figure 1.15. 
Iron oxides exist in a variety of chemical compositions and with different 
magnetic properties (Table 1.3) [96]. However, the magnetite (Fe3O4) nanoparticles are 
commonly used as building blocks of ferrofluid due to their biocompatibility, high 
saturation magnetization and high chemical stability [18, 97]. Moreover, magnetite 
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nanoparticles have been considered an ideal candidate for biological applications, both as 
a tag for sensing and imaging, and as an activity agent for antitumor therapy [98-102]. 
 
 
Figure 1.15. Schematic drawing of a ferrofluid on three length scales. On the 
macroscopic length scale (left), it resembles an ordinary liquid. On the colloidal length 
scale (middle), the fluid is appears to consist of small solid particles dispersed in a liquid. 
Each particle consists of a single domain iron oxide core, and a surface grafted with 
surfactant or polymer chains (right) [95]. 
 
Table 1.3. Iron oxyhydroxide and iron oxide species [96] 
Mineral Formula Magnetic response 
Goethite α - FeOOH antiferromagnetic 
Akaganeite β - FeOOH antiferromagnetic 
Lepidocrocite γ - FeOOH antiferromagnetic 
Feroxyhyte δ - FeOOH ferrimagnetic 
Ferrihydrite Fe3HO8 4H2O antiferromagnetic 
Hematite α Fe2O3 ferrimagnetic 
Maghemite γ – Fe2O3 weakly ferrimagnetic 
Magnetite Fe3O4 ferrimagnetic 
 
Chapter 1: Background 
 39
1.9. Crystal Structure of Iron Oxide 
Magnetite (Fe3O4) has an inverse spinel crystal structure with face centered cubic unit 
cell where oxygen ions are located regularly in cubic close packed positions along the 
[111] axis [96]. Figure 1.16 shows the unit cell of magnetite, typical inverse spinel 
ferrites. The unit cell is comprised of 56 atoms: 32 O2- anions, 16 Fe3+ cations and 8 Fe2+ 
cations, respectively [8]. The chemical formula of magnetite is Fe3O4, however more 
appropriately it is defined as FeO·Fe2O3 (molar ratio of Fe2+:Fe3+ = 1:2). The inverse 
spinel structure is arranged such that half of the Fe3+ ions are occupying interstitial 8 
tetrahedral (A-sites) positions and the remaining half of Fe3+ and all of the Fe2+ are 










Figure 1.16. Representation of the inverse spinel structure of magnetite. 
 
 
Maghemite (γ-Fe2O3) has a structure similar to that of magnetite, only differs in that all of 
the Fe is in the trivalent state (Fe3+). Cation vacancies (□) compensate for the oxidation of 
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Fe2+ to Fe3+ cations (Equation 1.17). Due to the small difference in crystal structure, 





                                                                                        ---------------------- (1.15) 
 
 
Table 1.4. Physical properties of magnetite and maghemite [93,96,103] 
Mineral Crystal Cell Density Color Magnetic Curie 
 system Dimensions (g/cm3)  saturation Temperature 
  (Å)   (emu/g) (K) 
Fe3O4 cubic a0= 8.39 5.26 black 90-98 850 
γ-Fe2O3 cubic or a0= 8.34 4.87 reddish- 76-81 820-986 
 tetragonal   brown   
 
 
1.10. Synthesis of Iron Oxide Nanoparticles 
It has long been of scientific and technological challenge to synthesize controlled size, 
phase pure, controlled shaped magnetic nanoparticles with narrow size distribution. Wet 
chemical methods have been widely used to produce iron oxide nanoparticles because 
they are very straightforward, tractable and very efficient methods for producing large 
quantities of the final product with appreciable control over size, composition and 
sometimes even the shape of the nanoparticles [18]. A brief revision of some of the most 
frequently used wet chemical routes is described below. 
 
Oxidation
2 3 2 3
3+ 2+ 3+ 3+ 3+ 3+
8 A 8 8 B 32 8 A 5.3 2.7 8 B 32
Magnetite (FeO.Fe O ) Maghemite (γ-Fe O )
(Fe ) [Fe Fe ] O         (Fe ) [(Fe )Fe ] O
→
⇒ 
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1.10.1. Co-Precipitation 
Co-precipitation has been widely used to synthesize the iron oxides (either Fe3O4 or γ-
Fe2O3) due to its ease and large volume capability. Conventionally, magnetite is prepared 
by adding a base (NH4OH or NaOH) to an aqueous mixture of Fe2+ and Fe3+ salts (e.g. 
chlorides, sulphates, nitrates etc.) at a 1:2 molar ratio under inert atmosphere at 
temperature range of 60-95°C [104-106]. The precipitated magnetite is black in color. 
The chemical reaction may be written as follows [107-108]: 
                         Fe2+ + 2Fe3+ + 8OH− → Fe3O4 + 4H2O ---------------------- (1.16) 
The precipitation of Fe3O4 is carried out between pH = 9-14 while maintaining a molar 
ratio of Fe3+:Fe2+ = 2:1 under an inert environment [108-109]. The non-oxidizing 
oxygen-free inert (N2 or Ar) environment is necessary to avoid the oxidation as shown in 
Equation 1.16 and Equation 1.17 [4, 16].   
                         Fe3O4 + 0.25 O2 + 4.5 H2O → 3Fe(OH)3 --------- (1.17) 
                         4 Fe3O4 + O2→ 6 γ-Fe2O3 ----------------------- (1.18) 
In order to prevent the possible oxidation in air as well as from agglomeration, Fe3O4 
nanoparticles are usually coated with organic or inorganic molecules during the 
precipitation process [109-110].  
 
Genesis of the particles in the solution under optimum synthetic conditions takes place by 
the formation of tiny crystalline nuclei in a supersaturated medium, followed by crystal 
growth [111]. The latter process is controlled by mass transport and by the surface 
equilibrium of addition and removal of individual monomers, i.e., atoms, ions, or 
molecules. Hereby, the driving force for monomer removal (dissolution) increases with 
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decreasing particle size. Thus, within an ensemble of particles with slightly different 
sizes, the large particles will grow at the cost of the small ones. This mechanism is called 
Ostwald ripening and is generally believed to be the main path of crystal growth. The 
major disadvantage of the precipitation route is that the control of size, shape and 
composition of nanoparticles very much depends on the type of salts used, Fe2+ and Fe3+ 
ratio, precipitation temperature, pH and ionic strength of the precipitation medium [104-
107]. As a matter of fact, the magnetite nanoparticles synthesized using this method are 
usually polydisperse in size and heavily aggregated, leading to a poor colloidal stability. 
As a result, the production of significant quantities of controlled sized nanoparticles with 
narrow size distribution remains a significant challenge using this method.  
 
1.10.2. Microemulsion 
A microemulsion can be defined as a thermodynamically stable isotropic dispersion of 
two immiscible liquids consisting of nanosized domains of one or both liquids in the 
other, stabilized by an interfacial film of surface-active molecules [17-18]. In water-in-oil 
microemulsions, the aqueous phase is dispersed as microdroplets or microcavities 
(typically 1–50 nm in diameter) surrounded by a monolayer of surfactant molecules in 
the continuous hydrocarbon phase (Figure 1.17) [18]. This surfactant-stabilized 
microcavity provides a confinement effect that limits particle nucleation, growth, and 
agglomeration [17]. The size of the reverse micelle is determined by the molar ratio of 
water to surfactant [112]. By mixing two identical water-in-oil microemulsions 
containing the desired reactants, the microdroplets will continuously collide, coalesce, 
and break again, and finally a precipitate forms in the micelles [18]. By the addition of 
solvent, such as acetone or ethanol, to the microemulsions, the precipitate can be 
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extracted by filtering or centrifuging the mixture. Recent developments have been 
focused in the use of microemulsions for the preparation of highly monodispersed 
magnetic nanoparticles useful in biomedical applications. The principle advantage of 
utilizing this type of microemulsion system for nanoparticle formation is that the size of 
nanoparticles can be controlled by modulating the size of aqueous micellar core [18]. 
Although many types of magnetic nanoparticles have been synthesized in a controlled 
manner using the microemulsion method, the particle size and shapes usually vary over a 
relative wide range [10]. Moreover, the working window for the synthesis in 
microemulsions is usually quite narrow and the yield of nanoparticles is low compared to 
other methods, such as thermal decomposition and coprecipitation. Large amounts of 
solvent are necessary to synthesize appreciable amounts of material. It is thus not a very 









Figure 1.17. Structure of reverse micelles formed by dissolving, a surfactant, in a 
hydrocarbon. [18]. 
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1.10.3. Thermal Decomposition 
Thermal decomposition method have been widely used to synthesize high-quality (single-
crystalline, monodisperse, well-shaped, and phase pure) quantum dot and rare earth oxide 
nanocrystals [113-117].  In the similar way, monodisperse iron oxide nanocrystals with 
smaller size can essentially be synthesized through the thermal decomposition of 
organometallic compounds in high-boiling organic (non-aqueous) solvents containing 
stabilizing surfactants. The organometallic precursors e.g. iron(III) acetyleacetonate 
(Fe(AcAc)3), iron(II) acetate (Fe(Ac)2), iron pentacarbonyl (Fe(CO)5) and iron oleate 
(Fe(OA)3), surfactants such as oleic acid (OA, RCOOH), lauric acid (LA), oleyl amine 
(OM, RNH2), tri-octyl phospine oxide (TOPO) and hexadecylamine (HDA) and organic 
solvents like diphenyl ether (Ph2O, bp 265ºC), 1-hexadecene (bp 274°C), dioctyl ether 
(bp 287ºC), benzyl ether (bp 300ºC), 1-octadecene (bp 330ºC), 1-eicosene (bp 330°C) 
and trioctylamine (bp 365°C), are widely used for the synthesis of iron oxide 
nanoparticles using this technique [118-125]. Typical thermal decomposition synthesis of 







Figure 1.18. Schematic representation of thermal decomposition synthesis of Fe3O4 
nanoparticles (Ph2O is diphenyl ether) [123]. 
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In principle, the ratios of the starting reagents including organometallic compounds, 
surfactant and solvent are the decisive parameters for the control of the size and 
morphology of magnetic nanoparticles. The reaction temperature, reaction time, as well 
as aging period may also be crucial for the precise control of size and morphology. The 
size and shape of the nanocrystals can also be controlled by variation of the reactivity and 
concentration of the precursors. The reactivity can be tuned by changing the chain length 
and concentration of the fatty acids. Generally, the shorter the chain length, the faster the 
reaction rate is. Alcohols or primary amines could be used to accelerate the reaction rate 
and lower the reaction temperature.  
If the metal in the precursor is zero valent, such as in carbonyls, thermal 
decomposition initially leads to formation of the metal, but two-step procedures can be 
used to produce oxide nanoparticles as well. For instance, iron pentacarbonyl can be 
decomposed in a mixture of octyl ether/trioctyl amine and oleic acid at 100-300ºC, 
subsequent addition of trimethylamine oxide (CH3)3NO or Pyridine N-Oxide (C5H5)NO 
as a mild oxidant at elevated temperature, results in formation of monodisperse γ-Fe2O3 
nanocrystals with a size of approximately 5-16 nm [118-121]. Decomposition of 
precursors with cationic metal centers leads directly to the oxides, that is, to Fe3O4, if the 
Fe(acac)3 is decomposed  in the presence of 1,2-hexadecanediol, oleylamine, and oleic 
acid in phenol ether [121-124]. A 4-6 nm-sized magnetite particles can be directly 
obtained through the decomposition of Fe(acac)3 while larger ones can be synthesized 
through subsequent seed-mediated growth [123]. Direct thermal decomposition of iron-
surfactant complex has also been demonstrated to fabricate monodisperse 5-22 nm 
magnetite nanoparticles successfully depending upon the decomposition temperature and 
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aging period [121, 125]. In this method, iron(III) chloride and sodium oleate are reacted 
in situ to generate an iron oleate complex which was then decomposed at temperatures 
between 274 to 365ºC in different solvents, such as 1-hexadecene, octyl ether, 1-
octadecene, 1-eicosene, or trioctylamine. The thermal decomposition of iron 
pentacarbonyl at relatively low temperature induces nucleation while the decomposition 
of the iron oleate complex at a higher temperature leads to growth. Peng and co-workers 
reported a general decomposition approach for the synthesis of size- and shape-controlled 
magnetic oxide nanocrystals based on the pyrolysis of metal fatty acid salts in non-
aqueous solution [126]. The reaction system was generally composed of the metal fatty 
acid salts, the corresponding fatty acids (decanoic acid, lauric acid, myristic acid, palmitic 
acid, oleic acid, stearic acid), a hydrocarbon solvent (octadecene (ODE), n-eicosane, 
tetracosane, or a mixture of ODE and tetracosane), and activation reagents. Nearly 
monodisperse Fe3O4 nanocrystals, with sizes adjustable over a wide size range (3–50 nm) 
could be synthesized, with controlled shapes, including dots and cubes. This method can 
be explained by the classical LaMer mechanism. That is, a short burst of nucleation from 
a supersaturated solution is followed by the slow growth of particles without any 
significant additional nucleation, thereby achieving a complete separation of nucleation 
and growth [127]. 
The above-mentioned nanoparticles are dispersible in organic solvents. However, 
water soluble magnetic nanoparticles are more desirable for biomedical applications. In 
addition, the use of toxic solvents and surfactants may reduce the biocompatibility of the 
produced nanoparticles, although iron oxide itself is considered a biocompatible material. 
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Therefore, several groups have been tried to modify the thermal decomposition method to 
synthesize water soluble magnetite nanoparticles without sacrificing their 
biocompatibility. Gao et al have reported one step synthesis of water-soluble 5 nm iron 
oxide nanocrystals by thermal decomposition of Fe(acac)3 or FeCl3·6H2O in 2-
pyrrolidone at 245 ºC [128-129]. In this method, 2-pyrrolidone is used both as solvent 
and stabilizer since it has strong polarity, high boiling point, and coordination capacity 








Figure 1.19. Coordination of 2-pyrrolidone with the Fe ions of Fe3O4 nanoparticles 
[128]. 
 
Kim et al have also reported one-pot synthesis of water-soluble 5 nm magnetite 
nanoparticles by the thermal decomposition of Fe(acac)3 in presence of  
polyvinylpyrrolidone polymeric surfactant [130]. Recently, synthesis of water soluble 6-
25 nm magnetite nanoparticles by  the  decomposition of Fe(acac)3 in liquid polyols e.g. 
benzyl alcohol (bp 205ºC), diethylene glycol (bp 245ºC), tri ethylene glycol (bp 280ºC) 
and tetra ethylene glycol (bp 300ºC) have been reported [131-133]. The advantage of this 
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approach is the possibility to kinetically control of experimental conditions and easily to 
scale-up.  
 
1.10.4. Hydrothermal Synthesis 
Li et al. reported a generalized hydrothermal method for synthesizing a variety of 
different nanocrystals by a liquid–solid–solution (LSS) reaction [134]. This strategy is 
based on a general phase transfer and separation mechanism occurring at the interfaces of 
the liquid, solid, and solution phases present during the synthesis (Figure 1.20). The 
system consists of metal linoleate (solid), an ethanol–linoleic acid liquid phase (liquid), 
and a water–ethanol solution (solution) at different reaction temperatures under 
hydrothermal conditions.  
After the aqueous solution of noble metal ions, sodium linoleate (or another sodium 
stearate) and the mixture of linoleic acid (or another fatty acid) and ethanol were added 
into the vessel in order. Three phases formed in this system: sodium linoleate (solid), the 
liquid phase of ethanol and linoleic acid (liquid), and the water–ethanol solution 
containing noble metal ions (solution). A phase transfer process of the noble metal ions 
occurred spontaneously across the interface of sodium linoleate (solid) and the water–
ethanol solution (solution) based on ion exchange, which led to the formation of noble 
metal linoleate and the entering of the sodium ions into the aqueous phases. Then at a 
designated temperature, the ethanol in the liquid and solution phases reduced the noble 
metal ions at the liquid–solid or solution–solid interfaces. Along with the reduction 
process, the in-situ generated linoleic acid absorbed on the surface of the noble metal 
nanocrystals with the alkyl chains on the outside, through which the produced metal 
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nanocrystals will gain hydrophobic surfaces. A spontaneous phase-separation process 
then occurred because of the weight of the metal nanocrystals and the incompatibility 
between the hydrophobic surfaces and their hydrophilic surroundings, and the noble 











Figure 1.20. Scheme of liquid–solid–solution (LSS) phase transfer synthetic strategy 
[134]. 
 
This LSS phase transfer and separation process can generate nanocrystals with a large 
variety of nanocrystals such as noble metal, magnetic/dielectric, semiconducting, rare-
earth fluorescent, and polymer nanoparticles with different chemistries and properties and 
with low dispersity [134]. The phase transfer process can occur for nearly all the 
transitional or main group metal ions, which gives flexibility to the reactions at the 
interfaces. After the phase transfer process of the metal ions from aqueous solution to the 
solid phase of (RCOO)nM, under designated reaction conditions, the Mn+ dehydrates into 
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oxides (to yield for example, TiO2, CuO, ZrO2, SnO2 or ZnO) and/or composite oxides 
(to yield for example, MFe2O4 (M represents Fe, Co, Mg, Zn or Mn) and MTiO3 (M 
represents Ba or Sr) through co-precipitation). Li et al. have synthesized ~ 10 nm sized 
nanocrystals of magnetic spinel MFe2O4 through the coprecipitation reactions of Fe2+ 
ions and Fe3+, Co2+, Mg2+, Mn2+ and Zn2+ ions following this LSS phase transfer and 
separation method. Li et al. also reported a synthesis of monodisperse, hydrophilic, 
singlecrystalline ferrite microspheres by hydrothermal reduction [135]. A mixture, 
consisting of FeCl3, ethylene glycol, sodium acetate, and polyethylene glycol, was stirred 
vigorously to form a clear solution, then sealed in a Teflon-lined stainless-steel autoclave, 
and heated to and maintained at 200 ºC for 8–72 h. In this way, monodisperse ferrite 
spheres were obtained with tunable sizes in the range of 200–800 nm. In this method, 
ethylene glycol was used as a high-boiling-point reducing agent, which is known from 
the polyol process to produce monodisperse metal or metal oxide nanoparticles; sodium 
acetate as electrostatic stabilizer to prevent particle agglomeration, and polyethylene 
glycol as a surfactant against particle agglomeration.  
 
The advantages and disadvantages of the four above mentioned synthetic methods are 
briefly summarized in Table 1.5. In terms of simplicity of the synthesis, co-precipitation 
is the preferred route. In terms of size and morphology control of the nanoparticles, 
thermal decomposition seems the best method developed to date. As an alternative, 
microemulsions can also be used to synthesize monodispersed nanoparticles with various 
morphologies. However, this method requires a large amount of solvent. Hydrothermal 
synthesis is a relatively little explored method for the synthesis of magnetic 
nanoparticles, although it allows the synthesis of high-quality nanoparticles. To date, 
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thermal decomposition is the best method to prepare high quality magnetic nanoparticles 
on a large scale.  
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There are huge demands in biomedical field for the high quality magnetic nanoparticles 
consisting of following properties:  
1. water soluble 
2. monodisperse 
4. biocompatible 
5. superparamagnetic and 
6. high saturation magnetization, MS 
Although, ferromagnetic (Fe, Co and Ni) have high MS however, unstable Fe 
nanoparticles can be spontaneously oxidized and less reactive Ni and Co nanoparticles 
are very toxic. And as a consequence Fe, Co and Ni nanoparticles are not suitable for bio-
applications. Therefore, iron oxide particularly magnetite (Fe3O4) and maghemite (γ-
Fe2O3) nanoparticles have been commonly used in biomedicine because of their low 
toxicity and high chemical stability. The major difficulty in the synthesis of ultrafine iron 
oxide particles is to control the particle size and its distribution at the nanosized scale. 
This difficulty arises from the fact that the nanoparticles form aggregates and 
continuously grow to minimize the overall surface free energy. Therefore, the search for 
facile and flexible synthetic routes which are able to produce iron oxide nanoparticles 
with the desired size, acceptable size distribution without particle aggregation is of 
extremely importance to realize the full potential of these materials in biomedicine.  
Several synthesis methods including co-precipitation, microemulsion and thermal 
decomposition methods have been employed to synthesize iron oxide nanoparticles. 
Among these methods, the thermal decomposition of organometallic compounds has 
been well accepted as a promising technique which is able to produce high quality 
monodispersed superparamagnetic iron oxide nanoparticles. The size distribution of iron 
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oxide nanoparticles should be monodisperse for their better performance in biomedical 
applications. High quality (high crystallinity, monodispersed, high Ms and phase pure) 
magnetite nanoparticles can be synthesized by the high temperature thermal 
decomposition of iron (III) acetylacetonate, Fe(acac)3 in presence of oleic acid and/or 
oleylamine. However, the obtained magnetite nanoparticles are only suspendable in non-
polar (organic) solvent which makes them inappropriate for biomedical applications. 
Therefore, further surface modifications on these hydrophobic nanoparticles are 
necessary to optimize their water suspensibility and biocompatibility for in vivo 
applications. Various surface coating materials such as lipids, surfactants, polymers, 
silica and Au have been attempted to convert the hydrophobic magnetite nanoparticles to 
be hydrophilic. However, it has been noted that these surface modification procedures are 
usually very complicated, tedious and time consuming. Moreover, the surface modified 
magnetite nanoparticles are not preferred for long term applications due to the risk of 
dissociation of the coating layers, which leads to agglomeration of the nanoparticles. In 
addition, the use of toxic solvents and chemicals during the surface modifications may 
reduce the biocompatibility of the surface modified nanoparticles, although iron oxide 
itself is considered a biocompatible material. Thus, direct one pot synthesis of 
hydrophilic magnetite nanoparticles is extremely important to realize the full potential of 
these materials in biomedicine.  
In recent years, magnetite nanoparticles have been focused on the simultaneous 
therapeutic and diagnostic (i.e. theronestic) applications on a large extend. Magnetic 
hyperthermia based on the magnetite nanoparticles is promising therapy for cancer 
treatment in which the cancerous organs or tissues are preferentially heated to 
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temperatures between 42°C and 46°C. The heating helps to shrink tumors by damaging 
cells or depriving them of substances they need to live. Magnetic resonance imaging 
(MRI) based on the magnetite nanoparticles has been recognized as one of the best 
noninvasive imaging modalities in both clinical and research fields. The strong 
superparamagnetism of magnetite nanoparticles allows the visualization of the target 
diseased tissue in any plane of body using T2- weighted magnetic resonance imaging. 
 
Magnetite (Fe3O4) nanoparticles have received a great deal of attention in the biomedical 
field in past two decades due to their superparamagnetic behavior, relatively high 
saturation magnetization (MS, 92 emu/g for bulk Fe3O4), nontoxicity, good chemical 
stability and excellent biocompatibility. Moreover, thermal decomposition technique has 
been recognized as one of the best method to prepare high quality monodispersed 
nanoparticles on a large scale. Therefore, the objective of this project is to develop size 
controlled hydrophilic magnetite nanoparticles with well controlled sizes and size 
distributions using the thermal decomposition technique and then characterization of their 
structure and properties relevant to magnetic hyperthermia and magnetic resonance 




2.2.    Plan of Work 
In this thesis, we have planned to develop high quality superparamagnetic magnetite 
nanoparticles by thermal decomposition of organometallic precursors and then to explore 
Chapter 2: Motivation and Work Plan 
66 
 
the feasibility of their use in magnetic hyperthermia and as MRI contrast agent. We had 
planned our work in the following approaches: 
 
A. Preparation and characterizations of hydrophobic magnetite nanoparticles using 
thermal decomposition technique and study of time, temperature, surfactant and 
solvent effect to optimize the reaction parameter for obtaining monodispersed 
superparamagnetic nanoparticles with high saturation magnetization (Ms).  
B. Conversion of hydrophobic to hydrophilic nanoparticles and characterization of 
their structure and properties.  
C. Direct one step synthesis of hydrophilic magnetite nanoparticles using polyol 
based synthesis technique and optimization of the reaction parameter to develop 
monodispersed superparamagnetic nanoparticles with high saturation 
magnetization (Ms).  
D. Direct one step synthesis of hydrophilic magnetite nanoclusters with high 
saturation magnetization (Ms) and then characterizations of their structure and 
properties. 
E. Evaluation of in vitro biocompatibility using normal and cancer cell lines. 
F. Evaluation of in vitro cellular uptake efficacy using cancer cell lines. 
G. Magnetic hyperthermia (Ac magnetic field heating) and MRI relaxivity studies of 
hydrophilic magnetite nanoparticles in vitro. 
H. Evaluation of in vitro therapeutic efficacy using cancer cell lines. 
I. Evaluation of in vivo MRI imaging efficacy in animal surface tumor models. 
J. Evaluation of localization, retention and bioavailability of hydrophilic 
nanoparticles in vivo. 
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Preparation and optimization of monodispersed and controlled size 
hydrophobic magnetite nanoparticles 
Conversion of hydrophobic to 
hydrophilic Fe3O4 nanoparticles 
One step synthesis of hydrophilic 
Fe3O4 nanoparticles & nanoclusters 
Hydrophilic Fe3O4 
Nanoparticles & Nanoclusters 
 Preparation and optimization 
 Characterization 
 In vitro biocompatibility study 
 In vitro cellular uptake study  
 Ac magnetic field heating  measurement 





Evaluation of imaging efficacy 
  





Evaluation of therapeutic efficacy 
 
 In vitro magnetic hyperthermia 






Evaluation of biodistribution efficacy 
 
 In vivo biodistribution kinetics 
using mice and rat animal model 
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3.1. Characterization Techniques 
The as-synthesized magnetite particles were either dispersed in a carrier liquid to 
obtain ferrofluid suspension (liquid) or dried at 40°C in an oven for overnight to 
obtain dry powders. Both the powder and ferrofluid samples were characterized using 
a series of characterization tools or methods to study their structure, morphology, 
magnetic properties. All the characterization tools are listed in Table 3.1. Cytotoxicity, 
cellular uptake, AC field induced magnetic hyperthermia and magnetic resonance 
imaging (MRI) studies of the ferrofluid samples were carried out to evaluate efficacy 
of the as-prepared nanoparticles for diagnostic and therapeutic applications. 
 
Table 3.1. Instruments used for characterizations 
Characterization Tool Company and Model 
X- ray diffraction (XRD) Bruker D8 Advance 
Fourier transform infrared spectroscopy (FTIR) Varian 3100 
X-ray photoelectron spectroscopy (XPS) Kratos AXIS Ultra DLD 
Transmission electron microscopy (TEM) JEOL 2010 and 3010 
Thermogravimetric analysis (TGA) DMSE SDTQ600 
Zetasizer Malvern Nano-ZS 
Vibrating sample magnetometer (VSM) Lakeshore, Model 665  
Superconducting quantum interference device (SQUID) Quantum Design, MPMS XL 
Inductively coupled plasma mass spectrometry (ICP-MS) Agilent ICP-MS 7500 Series 
 
 
3.1.1. X-ray Diffraction (XRD) 
When a beam of monochromated X-ray impinges on a crystal composed of atoms 
arranged periodically in three dimensions, it will be scattered by the atoms within the 
crystal. The coherently scattered X-rays, having the same frequency and definite 
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phase difference, interfere with each other either constructively or destructively. A 
diffraction pattern is generated when the scattered rays mutually reinforce one another 
[1]. 
The principle of X-ray diffraction is governed by the well-known Bragg’s Law 
[2]:  
 
                                                            nλ =2d sinθ ------------- (3.1) 
 Where n = order of reflection i.e. an integer corresponding to the order of diffraction 
plane (n =1 for first order of reflection),  λ = wavelength of incident X-ray, d = 
interplanar spacing i.e. the distance between two diffraction plane and θ = diffraction 
















Figure 3.1. Bragg X-ray diffraction. 
 
In this work, X-ray diffraction experiments were performed to identify the 
crystallographic structure of nanoparticles. XRD patterns of the powder samples were 
taken using a diffractometer (Bruker AXS Powder, D8 Advance) with Cu-Kα 
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(λ=1.5418Å) radiation source. The powders of the requisite sample were packed on a 
glass plate to make the specimens and the surface of the powder was smoothened by 
pressing another glass plate over it.   The x-ray diffraction plot of the samples was 
taken between 2θ = 100 and 2θ = 800.  
 
 A computer recorded all intensity versus angle data via an interface and produced a 
plot. The position of peak, corresponding relative intensities and the interplanar 
spacing (d) were obtained from the computer. The phase analysis and indexing of the 
peaks were done by matching the peak positions and relative intensities with standard 
powder diffraction files (PDF) compiled by the Joined Committee of Powder 
Diffraction Standards (JCPDS) [3]. 
The average crystallite size of the powder was determined using Scherrer formula [2]: 







= ……………. (3.2) 
where Dc = mean crystallite size, κ = particle shape factor (for spherical particles, κ = 
0.9), λ= X-ray wavelength (Å),  B
 
= peak width measured at half intensity, FWHM 
(radian) and θ = diffraction angle (degree). 
The relative intensity and corresponding two theta values, which were retrieved for 
each plot from the computer, were replotted and analyzed using graphical (origin) 
software. The uncorrected FWHM (B) measured from the plot has several 
components other than broadening due to crystallite size. They were instrumental 
broadening and broadening due to stress in the crystal. Therefore, the corrected 
FWHM (BC) was calculated using the Warren’s formula [2]: 
2 2 2
C M SB B B= − …………… (3.2) 
Where BM = measured full width at half-maximum intensity, and BS = peal width of 
the standard silicon material. 
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3.1.2. Fourier Transform Infrared Spectroscopy (FTIR) 
Molecular bonds vibrate at various frequencies depending upon the elements and the 
type of bonds. For any given bond, there are several specific frequencies at which it 
can vibrate. According to quantum mechanics, these frequencies correspond to the 
ground state (lowest frequencies) and several excited states (higher frequencies). One 
way to cause the frequency of a molecular vibration to increase is to excite the bond 
by absorbing light energy. For any given transition between two states the light energy 
(determined by the wavelength) must exactly equal the energy difference between the 
two states (usually ground state (E0) and the first excited state (E1)), as shown in the 
following equation:  
 
1 0
hcE E λ− = ……………..(3.3) 
Where h = Plank’s constant, c = speed of light, and λ = the wavelength of light. 
 
The energy corresponding to these transitions between molecular vibration states is 
generally 1-10 kilocalories/mole that corresponds to the infrared portion of the 
electromagnetic spectrum. FTIR is a powerful tool for identifying types of chemical 
bonds (functional groups). The wavelength of light absorbed is characteristic for the 
chemical bond. By interpreting the infrared absorption spectrum, the chemical bonds 
in a molecule can be determined.  
In infrared spectroscopy, IR radiation is passed through a sample (Figure 3.2). Some 
of the infrared radiation is absorbed by the sample and some of it is passed through 
(transmitted). The resulting spectrum represents the molecular absorption and 
transmission, creating a molecular fingerprint of the sample. Like a fingerprint no two 
unique molecular structures produce the same infrared spectrum. 
Chapter 3: Characterization Techniques  
73 
 
In this work, powder samples were characterized FTIR (Varian 3100) to investigate 
structure of the particles especially to indentify adsorbed coating molecules onto their 
surface.  Samples were prepared by following steps: 
(1) First less than 0.1 mg particles were mixed with 25 mg KBr powder (highly 
transparent substance in IR range) using spatula. 
(2) Then the resulting mixture was pounded with a pestle. 
(3) Finally a thin pallet was formed under a press. 
IR spectra of the samples were recorded on a computerized spectrophotometer (FTIR, 
















Figure 3.2. A simple FTIR spectrometer layout. 
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3.1.3. X-ray Photoelectron Spectroscopy (XPS) 
X-ray photoelectron spectroscopy (XPS) is a quantitative spectroscopic technique that 
measures the elemental composition, empirical formula, chemical state and electronic 
state of the elements that exist within a material. A sample maintained under ultra 
high vacuum (UHV) is bombarded with X-rays. The X-rays penetrate a substantial 
distance into the sample and excites electron (referred to as photoelectrons). A small 
fraction of these photoelectrons (from the top 1 to 10 nm on the surface) escape from 
the sample. The kinetic energy of these photoelectrons is measured by an analyzer 
(Figure 3.1).  
Because the energy of a particular X-ray wavelength is known, the electron binding 
energy of each of the emitted electrons can be determined by using an equation: 
                            Ebinding = Ephoton – Ekinetic – Φ………………(3.4) 
 
where where Ebinding is the binding energy of the electron, Ephoton is the energy of the 
X-ray photons being used, Ekinetic is the kinetic energy of the electron as measured by 
the instrument and Φ is the work function of the spectrometer (not the material).  
 
A typical XPS spectrum is a plot of the number of electrons detected (intensity) (Y-
axis, ordinate) versus the binding energy of the electrons detected (X-axis, abscissa). 
Each element produces a characteristic set of XPS peaks at characteristic binding 
energy values that directly identify each element that exist in or on the surface of the 
material being analyzed. These characteristic peaks correspond to the electron 
configuration of the electrons within the atoms, e.g., 1s, 2s, 2p, 3s, etc. The number of 
detected electrons in each of the characteristic peaks is directly related to the amount 
of element within the area (volume) irradiated. To generate atomic percentage values, 
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each raw XPS signal must be corrected by dividing its signal intensity (number of 
electrons detected) by a "relative sensitivity factor" (RSF) and normalized over all of 
the elements detected. 
 
In this work, powder samples were analyzed using XPS (Kratos AXIS Ultra DLD) to 














Figure 3.3. Basic components of a monochromatic XPS system. 
 
 
3.1.4. Transmission Electron Microscopy (TEM) 
Transmission electron microscopy (TEM) is a very powerful tool for obtaining 
morphology and crystallographic information of materials. The main components of a 
TEM include an electron gun, a condenser lens system, a specimen chamber, 
objective and intermediate lenses, projector systems for producing images and 
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diffraction patterns, and vacuum/computer systems. Electron beams with high energy 
transmitted through the specimen, and an image formed, further magnified and 
detected by an camera. For the most common types of TEM, the electron energy 
employed is in the range of 60-300 kV. The appropriate electron energy depends on 
the nature of the specimen and the information required. Much higher electron energy 
is suggested if the specimen is relatively thick or very high resolution is required. To 
satisfy different research interests, three basic appearances of TEM image are taken.  
 
A. Bright field image 
In bright field image, only the undeflected electrons contribute to the formation of 
image. In the absence of a specimen, a bright background is observed. Regions of the 
specimen that are thicker or of higher density will scatter more strongly (i.e. more 
electrons will be deflected) and will appear darker image. This technique is suitable 
for all specimens (amorphous or crystalline, biological or metallic), provided the 
specimen is thin enough. 
 
B. Dark field image 
In dark field image, only the part of the specimen that diffracts electrons contributes 
to the image. It has the reverse contrast to the bright field image. The background 
appears dark in the absence of a specimen. To obtain a dark field image with better 
resolution, the primary electron beam has to be tilted so that the chosen diffracted 
beam travels along the optical axis and pass through the centered aperture. This 
technique is suitable to detect the crystalline grains and defects in specimen, which 
cannot be clearly observed in bright field image. 
 
 
Chapter 3: Characterization Techniques  
77 
 
C. Diffraction image 
In diffraction image, only the diffracted rays contribute to the formation of a 
diffraction pattern in the back focal plane of the objective lens. After applying a 
selected area only a small area enclosed by the aperture contributes to the diffraction 
pattern. If a single crystal specimen is oriented such that several sets of planes are 
parallel to the beam, this will give rise to a diffraction pattern consisting of a regular 
array of spots. If the specimen contains many crystals of random orientation as in a 
polycrystalline specimen, then the diffraction pattern is the sum of the individual 
patterns forming a ring patterns. This technique provides information about the crystal 
structure and lattice spacing of the samples. 
 
In this work, TEM (JEOL 2010 and 3010, LaB6) was used to investigate structure, 
size, morphology, and size distribution of nanoparticles. The microstructure of a 
single particle was characterized using HRTEM. Samples for TEM were prepared by 
diluting ferrofluid sample with the additional corresponding carrier fluids (hexane, 
water etc) to obtain the color of “weak tea.” The solutions were cast onto a carbon-
coated grid and the carrier fluid was evaporated.  
 
3.1.5. Thermogravimetric Analysis (TGA) 
Themogravimetric analysis (TGA) is an analytical method by means of thermal 
energy to measure the amount and rate of weight change in a material, either as a 
function of increasing temperature, or isothermally as a function of time, in a 
controlled atmosphere. This technique can be used to characterize any material that 
exhibits a weight change due to decomposition, oxidation or dehydration. TGA curves 
can provide information concerning the thermal stability and the composition of the 
initial sample, any intermediate compounds formed and the residue. 
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In this work, TGA (DMSE SDTQ600) was used to determine amount of organic 
coating adsorbed on to the surface of the nanoparticles and amount of magnetic core 
(Fe3O4) of the nanoparticles. TGA experiments were carried by placing 5-25 mg dry 
powder samples in a standard alumina pan under N2 atmosphere and then scanning 
from room temperature to 800 °C with a heating rate of 20 °C min-1. 
 
3.1.6. Zeta Potential Measurements 
A charged particle will move in an applied electric field. The mobility of the particle 
is related to some exterior factors, such as dielectric constant and viscosity of the 
suspending liquid. It also depends on the electrical potential at the boundary between 
the moving particle and the liquid. This boundary is called slip plane and is usually 
defined as the point where Stern layer and diffuse layer meet. Stern layer consists of 
ions tightly bound to the particle (Figure 3.4). Diffuse layer consists of free ions that 
rapidly exchange with ions in Stern layer and it can be visualized as a charged 
atmosphere surrounding the particle. Stern layer and diffuse layer together are called 
double layer. The electrical potential at the slip plane is related to the mobility of the 
particle and is called Zeta potential. It is the measurable potential of a solid surface 
and is a function of particle surface charge density. 
The magnitude of the zeta potential gives an indication of the potential stability of the 
colloidal system. If all the particles in suspension have a large negative or positive 
zeta potential then they will tend to repel each other and there will be no tendency for 
the particles to come together (flocculate). However, if the particles have low zeta 
potential values then there will be no force to prevent the particles coming together 
and flocculating. The general dividing line between stable and unstable suspensions is 
generally taken at either +30 or -30 mV. Particles with zeta potentials more positive 
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than +30 mV or more negative than -30 mV are normally considered stable. The most 
important factor that affects zeta potential is pH. A zeta potential value on its own 
without a quoted pH is a virtually meaningless number. A typical plot of zeta 
potential versus pH is shown in Figure 3.5.  The point where the plot passes through 
zero zeta potential is called the Isoelectric point and is very important from a 
















Figure 3.4. Schematic representation of zeta potential. 
 
 
Zeta potential is derived from measuring the mobility distribution of a colloidal 
dispersion of charged particles as they are subjected to an electric field. Thus, it is the 
electrophoretic mobility that we measure directly with the conversion to zeta potential 
being inferred from theoretical considerations. The technique used to measure the 
electrophoretic mobility in Malvern’s Zetasizer Nano series of instruments is Laser 
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Doppler Velocimetry. The essence of a classical micro-electrophoresis system is a 
cell with electrodes at either end to which a potential is applied (Figure 3.6). Particles 
move towards the electrode of opposite charge, their velocity is measured and 





















Figure 3.6. Schematic diagram of a sample holder (electrophoretic cell) which is used 
measure the Zeta potential by Malvern Zetasizer instrument. 















Figure 3.7. Basic components of a Malvern zetasizer instrument. 
 
A zeta potential measurement system comprises of six main components (Figure 3.7). 
First of all a laser (1) is used to provide a light source to illuminate the particles 
within the sample; for zeta potential measurements this light source is split to provide 
an incident and reference beam. The reference beam is also ‘modulated’ to provide 
the doppler effect necessary. The laser beam passes through the centre of the sample 
cell (2), and the scattering at an angle of 17° is detected. On insertion of the cell into 
the cell holder, the cell terminals allow the system to recognise the type of zeta 
potential cell fitted, and configures the software to use the correct measurement 
sequence. When an electric field is applied to the cell, any particles moving through 
the measurement volume will cause the intensity of light detected to fluctuate with a 
frequency proportional to the particle speed. A detector (3) sends this information to 
a digital signal processor (4). This information is then passed to a computer (5), 
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where the Zetasizer Nano software produces a frequency spectrum from which the 
electrophoretic mobility and hence the zeta potential information is calculated. 
In this work, Zeta potential of diluted ferrofluid samples were measured Zetasizer 
(Malvern Nano-ZS) to determine surface charge adsorbed on to the surface of the 
nanoparticles. The samples were prepared by diluting ferrofluid sample with the 
additional corresponding carrier fluids to obtain the color of “weak tea.”  
 
3.1.7. Vibrating Sample Magnetometer (VSM) 
Vibrating sample magnetometer (VSM) was used to characterize the magnetic 
properties of the material. It is based on vibrating a sample in a magnetic field to 
produce an alternating electromagnetic field in the pickup coils. A schematic diagram 
of VSM is shown in Figure 3.8. Sample is placed between two electromagnet poles 
which are attached to pickup coils. The electromagnets produce a high magnetic field 
(~90 kOe) to saturate the sample. The sample vibrates vertically and the oscillation 
induces an AC signal (i.e. e.m.f. according to the Faraday’s law) in the pickup coils. 
The amplitude of this signal is proportional to the magnetic moment of the sample. A 
M-H hysteresis loop is obtained by slowly sweeping the applied field from a 
maximum positive field, through zero, to a maximum negative field and reversing to 
the maximum positive field.  
 
In this work, VSM (Lakeshore, Model 665) was used to determine the saturation 
magnetization (MS) of the nanoparticles. VSM experiments were carried by placing 
10-20 mg dry powder samples (wrapped with aluminum foil) in a VSM sample holder 
and then scanned from 2T to -2T (Tesla, 1 T = 104 Gauss) at the room temperature. A 
small piece of nickel was used as a standard sample to calibrate the VSM before all 



















Figure 3.8. Schematic diagram of a VSM. 
 
 
3.1.8. Superconducting Quantum Interference Devices (SQUID) 
Superconducting Quantum Interference Devices (SQUID) is an instrument which 
converts magnetic flux (which is difficult to measure) into voltage (which is easy to 
measure). As a result, SQUID magnetometer can be used to detect and measure small 
magnetic fields. The magnetization can be measured over wide temperature range 
from that of liquid helium (~4K) up to four hundred degrees. 
In this work, SQUID (Quantum Design, MPMS XL) was used to get magnetic 
information at low temperature. Superparamagnetic characteristics of the 
nanoparticles were investigated by the zero field cooling (ZFC) and field cooling (FC) 
procedures. Temperature dependence of magnetization was measured using SQUID 
between 5 K and 300 K in the applied field of 50-100 Oe.  
 
3.1.9. ICP-MS Analysis 
The Fe concentration of the ferrofluid samples (water suspension of Fe3O4 
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nanoparticles) was determined by ICP-MS analysis. A known volume of ferrofluid 
samples were put in a glass test tube and dried in oven. Then 1-2 ml of concentrated 
nitric acid was added. The tube was then heated to 110°C for 45 min and the samples 
were analyzed using ICP-MS (Agilent ICP-MS 7500 Series) after sufficient dilution 
with milli-Q water. The analysis of sample was done in comparison with the ICP-MS 
standard (Sigma).  
 
3.1.10. In vitro Cytotoxicity Studies 
In vitro biocompatibility of the nanoparticles was evaluated by cytocompatilibility 
studies with MCF-7 mammalian breast cancer cells (Michigan Cancer Foundation-7) 
and NIH-3T3 mouse fibroblast cell lines (3-day transfer, inoculum 3 x 105 cells) using 
MTT assay (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). The 
MCF-7 and NIH-3T3 cells were seeded in 96-well plates (Costar, IL, USA) at the 
density of 5000 viable cells/well and incubated 24 hours (48 hours in case of NIH-
3T3) to allow cell attachment. The MCF-7 and NIH-3T3 cells were incubated for 24 h 
with media containing nanoparticles at different concentrations. Wells without the 
nanoparticles treatment were used as control. 10µl of MTT was added into the 96 well 
plates at five hours prior to the time point. The cells were incubated till the time point. 
After incubation, the media solution was removed from the wells, leaving the 
precipitate. Dimethylsulphoxide (100 µl) was added to the wells to dissolve the 
formazan crystals which were formed. Finally, the absorbance in each well was 
measured using a microplate reader (GENios, Tecan, Switzerland) at 550 nm. The cell 




Absorbance of sample well% Cell viability = 100 
Absorbance of control well
×
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3.1.11. In vitro Cellular Uptake Studies 
3.1.11.1. Qualitative Analysis of In Vitro Cellular Uptake 
To assess the cellular uptake qualitatively, the MCF-7 cancer cells were grown in 175 
cm2 culture flask at a cell density of 1 x 106 cells/ml. After 24 hours, the media was 
replaced by fresh media containing the nanoparticles with 2 mmol of Fe/L 
concentration. After 24 hours of incubation, the media was removed; the cells were 
washed 4 times with PBS (Phosphate buffered saline, Table 3.2), and fixed with 2.5% 
glutaraldehyde at 37oC. After 2 hours, the glutaraldehyde solution was removed and 
the cells were washed with PBS. The cells were then scraped and pelleted at 3500 rpm 
for 10 minutes. The pellet was post-fixed using 1% Osmium tetroxide at PH 7.4 for 1 
hour, followed by washing with PBS two times. The cell pellet was then fixed in 6% 
gelatin followed by a series of dehydration process using ethanol and acetone. Finally, 
the cell pellet was embedded in araldite resin. The embedded cell samples were then 
sectioned into thin films of 100 nm thickness. The sections were stained using lead 
citrate prior to the observation of the samples using Transmission Electron 
Microscope (JEOL, JEM- 1220). 
 
Table 3.2: PBS contains the following constituents 
Salt Concentration (mmol/L) Concentration (g/L) 
NaCl 137 8.00 
KCl 2.7 0.20 
Na2HPO4 • 2 H2O 8.1 1.44 
KH2PO4 1.76 0.24 
pH 7.4 7.4 
 
3.1.11.2. Quantitative Evaluation of In Vitro Cell Uptake 
 
MCF-7 cancer cells were seeded in 24 well plates (Costar, IL, USA) at a density of 
5000 viable cells/well (n = 3). The cells were allowed to grow for 24 hours. The 
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media in the plates were then replaced by fresh media. To the fresh media 100 µl of 
the nanoparticles with 43-142 mg of Fe/L concentrations (final concentrations of 4-14 
µg of Fe/well) was added. Cancer cells with 100 µl of PBS were used as control. After 
24 hours, the media was removed and the plates were washed 4 times with 500µl each 
of fresh PBS. The cells were then trypsinized and 10 µl of the solution was used to 
count the number of cells. The cell suspension was centrifuged at 2000 rpm for 5 
minutes. 2 ml of concentrated nitric acid was added to the cell pellet followed by 
heating at 80oC for 1 hour to dissolve the cell pellet and eventually to convert the iron 
oxide nanoparticles taken up by the cell into the corresponding Fe ions. The resulting 
solution was diluted using MilliQ water, and then filtered using a 0.45 µm PTFE 
filter. Finally the filtered solution was analyzed by Inductively Coupled Plasma-Mass 
Spectrometer (Agilent ICP MS 7500). The cell uptake at different Fe loading was 
represented in terms of Fe uptake in picogram (pg) per cell. 
 
 
3.1.12. Magnetic Hyperthermia Studies 
AC magnetic field induced heating ability of the as prepared magnetite nanoparticles 
was determined from the time-dependent calorimetric measurements using a RF 
generator (EASYHEAT-5060, Ameritherm, Figure 3.9) operating at different 
frequency (240 & ~400 kHz). Samples were placed in the centre of the water cooled 
copper tubing coil (Figure 3.9). One milliliter of ferrofluid samples (aqueous 
suspension of magnetite nanoparticles) with the Fe concentration in the range of 0.5 – 
10 mg/ml were subjected to 89 kA/m AC field and time dependent temperature rise 
was monitored for different times using an optical fibre based temperature probe 
(FLUOTEMP Series, FTP-LN2). The specific absorption rate (SAR) was calculated 
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where C is the specific heat of solvent (here Cwater= 4.18 J/g °C), ∆T/∆t is the initial 
slope of the time-dependent temperature curve and mFe is weight fraction of magnetic 










Figure 3.9. Instrument for generating hyperthermia: EasyHeat-5060 (Source: 
Ameritherm Inc., NY). 
 
In magnetic hyperthermia application, the alternative magnetic field (AMF) causes 
the heating of magnetic nanoparticles to provide therapeutic effect.  However, the 
AMF could act for non-selective heating of both, cancerous as well as healthy tissue 
due to generation of eddy currents. The energy (E) absorbed due to eddy current is 
proportional to the area (piD2/4) of the exposed tissue i.e. E ~ D2. Therefore, a strict 
limitation H×f < C (f = frequency, H = field amplitude and C = constant) are followed 
for a particular induced current loop diameter. Hergt and Dutz (2007) have used a coil 
with a diameter of 0.1 m and found a limit of H×f = 5 × 109 Am-1S-1 [90]. In this 
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work, we have used a coil with a diameter of 0.034 m (for 240 kHz) and 0.032 m (for 
~400 kHz) which is about 1/3 of the diameter of the coil of Hertz and Dutz and thus 
we could use a limit of 9 times of that reported by Hertz and Dutz (5 × 109 Am-1S-1) 
i.e. H×f = 4.5 × 1010 Am-1S-1. Therefore, the potentiality of the nanoparticles for the 
magnetic hyperthermia applications has been evaluated using the combinations of 
either H = 18 - 134 kA/m & f = 240 or H = 17 - 104 kA/m & f = ~400 kHz i.e. H×f = 
0.4 – 4.2 × 1010 Am-1S-1.  
 
3.1.13. In vitro Hyperthermia 
For in vitro cellular hyperthermia, 1 × 106 exponentially growing MCF-7 cancer cells 
in DMEM cell culture medium (Dulbecco's Modified Eagle Medium) containing 10% 
FBS (Fetal bovine serum) and 1 % antibiotic antimycotic solution were taken in 15 ml 
sterile polypropylene tubes and centrifuged at 1000 rpm for 5 minutes to get cell 
pellet. Then, the cells were re-suspended in 1 ml DMEM medium containing iron 
oxide (IO) nanoparticles having 1 mg of total iron (i.e. 1 mg/ml Fe concentration) in 
15 ml polypropylene tubes. The tubes were subjected to an initial AC field of 89 
kA/m field using the RF generator operating at 240 kHz frequency and temperature 
rise of the cell suspension was monitored using the optical fibre based temperature 
probe. After the temperature reached to 45°C, the field was adjusted (by decreasing 
the field) to maintain about 45°C temperature of the cell suspension for 1 hr magnetic 
hyperthermia treatment. For comparison, same numbers of cells as above were treated 
using only the magnetic field (without using nanoparticles) and another with only the 
IO nanoparticles (without using magnetic field) with 1 mg of Fe/ml concentration. 
Cells without any treatment were used as control. 
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After the treatment, the cells were centrifuged and washed with PBS for 2 times. 
Then, 2 × 104 cells were placed in a 96 well plate in 16 replicates and following 48 hrs 
of incubation in 5% CO2 incubator. MTT assay was performed to evaluate the cell 
viability. For this purpose, the cell culture supernatants were replaced with 100 µl 
each of fresh medium containing 10 µl of 5 mg/ml MTT each. The plates were then 
incubated for 5 hours at 37°C. The purple formazan crystals were dissolved in 50% 
DMF in water solution containing 20% SDS (sodium dodecyl sulphate). Thereafter, 
the absorbance was measured at 550 nm wavelength in a plate reader. The percentage 
of cell viability was calculated using the following equation: 
 
  Absorbance from the well treated with IO or magnetic filed or bothCell viability (%) = ×100




3.1.14. MRI Relaxivity Studies  
The longitudinal (T1) and transverse (T2
 
and T2*) relaxation times of ferrofluid 
samples containing various Fe concentrations were measured at 20°C using a Siemens 
Symphony 1.5T MRI and a Varian 9.4T MRI scanner with a head coil. Gradient echo 
images for calculation of T2* were acquired at 4 to 5 echo times (TE) for individual 
bottles as single 2D coronal slices (FOV: 6.4cm; Matrix: 64x64; Voxel dimensions 
(VD): 1mm x 1mm x 5mm; repetition time (TR): 1.6s; TE: 5ms to 60ms/; flip angle: 
90°). T2 relaxation times were determined from a multi-echo spin-echo sequence of 
all bottles (32 echoes; TR: 1600 ms; TE: 15–480 ms; FOV: 18cm; Matrix: 256x256; 
VD: 0.7mm x 0.7mm x 5mm). T1 relaxation times were determined from a saturation 
recovery experiment using spin-echo images obtained with a number of TRs (7 TRs; 
TR: 100–6400 ms; TE: 15 ms; FOV: 18cm; Matrix: 256x256; VD: 0.7mm x 0.7mm x 
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5mm). The T1, T2 and T2* relaxation time was computed using in-house software 
(MATLAB V7) by fitting appropriate exponential functions. Based on the T1, T2 and 
T2* values, the specific relaxivities (r1, r2, and r2*), which are a measure of the 
induced change of the spin-lattice relaxation rate (T1–1), spin-spin relaxation rate (T2–
1and T2*–1) per unit concentration of Fe, were calculated. The T1, T2
 
and T2* 
relaxation times of ferrofluid samples containing various Fe concentrations were also 
measured using a Varian 9.4T MRI scanner (Palo Alto, CA, USA). The T2 and T2* 
were measured using multiple spin echo sequence at TR=10000 ms and TE=5.69 ms 
while the T1 was measured by using inversion recovery spin echo sequence.  
 
3.1.15. In vivo MRI Imaging  
In vivo animal studies were approved by the A*STAR Institutional Animal Care and 
Use Committee (IACUC). The contrast agent kinetics were studied on healthy Wistar 
rats (male, weight 320-340 g) under 2% isoflurane anaesthesia using a Varian 9.4T 
MRI and a 72 mm volume coil. The magnetite nanoparticles were injected at a dosage 
of 5 mg [Fe]/kg body weight through tail vein. T2-weighted images were acquired 
every 48 s for 32 min with a fast spin echo sequence (TR/TE = 1000/28 ms, field of 
view = 8 cm, thickness = 2 mm, intersection gap = 0.3 mm, matrix = 256 x 192, under 
fat saturation and respiratory trigger; respiration rate = 60 /min). The coronal and 
axial sections of the whole body of the rat were imaged at different time periods. The 
SNR (signal to noise ratio) from the liver and kidney and the normalized contrast (%) 
were calculated and plotted against time. 
 
  Mean signal from the region of interest SNR = 
Background standard deviation
 




  SNR change at any time tNormalized contrast (%) = 100
SNR at time zero before contrast
 ×  
 
Xenograft tumor model was developed using severe combined immune deficiency 
(SCID) mice (female, weight 20 g). MCF-7 cancer cells were injected into the 
subcutaneous part of the mice near the right flank. The tumor was allowed to develop 
to a volume of 150-200 mm3. The tumor-bearing SCID mice were imaged using a 
Bruker 7T Clinscan MRI. Contrast agent was injected (dosage: 5 mg of [Fe]/ Kg body 
weight) through tail veins of the mice under 1% isoflurane anesthesia. T2-weighted 
images were acquired at various time points within 12 hours after injection using fast 
spin-echo sequence (TR/TE = 1500/36 ms, resolution=100 µm, thickness = 1 mm). 
ROI (region of interest) was taken from the tumor and the signals were normalized by 
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To meet the increasing demand of high quality magnetite nanoparticles for various 
applications, synthesis of magnetite nanoparticles with fine size and uniform size 
distribution, high crystallinity and precise composition control has been intensively 
studied in the last decade. The major difficulty in the synthesis of ultrafine magnetite 
particles is to control the particle size and its distribution at the nanometric scale. This 
difficulty arises because during the synthesis, the magnetic nanoparticles form aggregates 
and continuously grow to minimize the overall surface free energy. Moreover, the 
saturation magnetization (MS) value of the nanosized magnetic particles significantly 
decreases from that of the bulk materials (briefly explained in Chapter 1, Section 1.6.4). 
Therefore, the search for facile and flexible synthetic routes which are able to produce 
magnetic nanoparticles with the desired size, acceptable size distribution with high MS 
value is of extremely importance to realize the full potential of magnetite nanoparticles 
for their biomedical applications. Several synthesis procedures like chemical 
coprecipitation, microemulsion and thermal decomposition method (described in Chapter 
1, Section 1.7) have been adopted to achieve this goal. Among these methods, the thermal 
decomposition of organometallic compounds in a high boiling point organic solvent 
containing stabilizing surfactant is a very promising technique to produce monodispersed 
magnetite nanoparticles without particle aggregation [1-5].  
The MS of the magnetic particles depends upon their size and crystallinity which are 
linearly varied with the reaction temperature and reaction time of the thermal 
decomposition.  Thus, the MS of the magnetite particles could be are improved using 
higher reaction temperature and reaction time; however, the size and distribution of the 
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particles would be affected with the reaction time and temperature. Therefore, 
synthesizing nanosized magnetite particles with high MS using higher reaction time and 
temperature without affecting their size and size distribution is still a big challenge. In 
this work, we have studied the time, temperature, surfactant and solvent effects on the 
size, distribution and magnetic properties of Fe3O4 nanoparticles prepared by thermal 
decomposition method. The surfactant or solvent effect has been adopted over the 
temperature and time effect to produce magnetite nanoparticles with high MS value while 
maintaining their size smaller with an acceptable size distribution. 
 
4.2. Experimental  
Absolute ethanol, hexane, toluene and tetrahydrofuran (THF) were used without 
purification. oleylamine (OM, ≥70%), oleic acid (OA, 90%), phenyl ether (PET, 99%), 
benzyl ether (BET, ≥98%), 1-octadecene (ODE, 90%) and iron(III) acetylacetonate 
(Fe(acac)3, 97%) were purchased from Sigma-Aldrich. Chemical structure of Fe(acac)3, 
OM and OA are shown in Figure 4.1. 
 
4.2.1. Synthesis of Hydrophobic Magnetite Nanoparticles  
Magnetite nanoparticles were prepared by thermal decomposition of Fe(acac)3 precursor 
in presence of solvent and surfactant (OA+OM) mixture [6-7]. Our experimental reaction 
setup for the synthesis of magnetite nanoparticles are shown in Figure 4.2. The magnetite 
particles are immediately coated with OA and OM surfactant as soon as they nucleated 
from the decomposition of Fe(acac)3 precursor. The OA and OM are amphiphilic 
molecules which consist of hydrophilic polar head (–COOH or –NH2) and hydrophobic 
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nonpolar (CH3-(CH2)7-CH=CH-(CH2)7–) tail (Figure 4.3). The hydrophilic head part 
reacts with the surface OH groups of Fe3O4 particles and thus chemically bonded to the 
Fe3O4 particles while the hydrophobic tail help them to be stabilized in a nonpolar carrier 
liquids like hydrocarbons (hexane, dodecane etc) to produce oil based ferrofluid 











Figure 4.1. Chemical structure of iron(III) acetylacetonate (Fe(acac)3), oleic acid (OA),  
























Figure 4.3. Schematic sketch of OA and OM surfactant molecules.  






Figure 4.4. Schematic representation of synthesis of hydrophobic magnetite 
nanoparticles and their ferrofluid suspension. 
 
The flow chart of the synthesis procedure is shown in Figure 4.5. Typically, a 2 mmol 
(~0.7 g) of Fe(acac)3 was dissolved in a 20 ml solvent and/or surfactant mixture (SSM in 
Table 4.1) into a three necked round bottom flask (RBF) and the resulting mixture 
solution was magnetically stirred under a flow of argon. The solution was dehydrated at 
120 °C for 1 h, and then quickly heated to a certain temperature (220-330ºC) and kept at 
this temperature for a certain time (1/2 - 24 h). The resulting black supernatant solution 
was cooled to room temperature by removing the heat source. A 20 mL of ethanol was 
added into the supernatant solution and the precipitated particles were collected by 
centrifugation at 10000 rpm. The precipitated particles were three times washed with 
ethanol (to remove excess surfactants) followed by the centrifugation. Finally, one half of 
the washed hydrophobic particles were dispersed in an organic solvent (e.g. hexane, THF, 
toluene etc) to fabricate ferrofluid and the other half was dried overnight in oven (at 
40°C) to obtain dry magnetite powder.  
 
 





















Figure 4.5. Flow chart for synthesis of magnetite nanoparticles by thermal 
decomposition. 
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The stability of the as prepared ferrofluid samples were tested by exposing the ferrofluid 
to a strong permanent magnet and no phase separations of particles were observed on 
exposure the magnet indicating the formation of stable ferrofluid suspension. The flow of 
the ferrofluid in presence of a magnet is shown in shown in Figure 4.6. All of the samples 









Figure 4.6. Photo of hydrophobic ferrofluid (Right) and flow of the ferrofluid in presence 
of a permanent magnet (Left). 
4.2.2. Characterization of Nanoparticles  
The ferrofluid (nanoparticles suspended in hexane) samples were characterized by 
transmission electron microscopy (TEM, JEOL 2010) while dry powder samples were 
characterized by X-ray diffraction (XRD, Bruker D8 Advance), Fourier transform 
infrared spectroscopy (FTIR, Varian 3100), X-ray photoelectron spectra (XPS, Kratos 
AXIS Ultra DLD), thermogravimetric analysis (TGA, DMSE SDTQ600). 
superconducting quantum interference device (SQUID, Quantum Design, MPMS XL) 
  Chapter 4: Synthesis of Hydrophobic Magnetite Nanoparticles 
100 
 
and vibrating sample magnetometer (VSM, Lakeshore, Model 665) measurement. Crystal 
structure of the as-synthesized nanoparticles was identified by XRD while their size and 
morphology were investigated by TEM. The organic coating adsorbed to the particle 
surface was determined by FTIR, XPS and TGA measurements. Magnetic properties of 
the particles were studied using VSM and SQUID measurement. 
 
Table 4.1. Hydrophobic magnetite nanoparticles samples and corresponding results. 
Sample 
code 

















A1 220 2 BET + OM 4.9 3 narrow 46 Temp. effect 
A2 265 2 PET + OM 5.8 5 narrow 51 
A3 300 2 BET + OM 9.4 9 relatively wide 60 
A4 330 2 ODE +OM 14.3 24 very wide 74 
B1 300 1/2 BET + OM ---- 7 relatively narrow 57 Time effect 
B2 300 4 BET + OM ---- 12 very wide 65 
C1 300 1/2 BET + OM 
+ OA 




C2 300 2 ---- 8 very narrow ---- 
C3 300 4 ---- 14 very narrow 67 




D2 2 ---- 6 narrow 58 
D3 4 ---- 7 narrow ---- 
D4 24 ---- 11 relatively narrow 71 
D5 330 1/2 OM + OA ---- 6 narrow ---- 
D6 2 ---- 7 relatively narrow ---- 
D7 4 ---- 9 relatively narrow 76 
D8 300 1/2 OM ---- 8 narrow ---- 
D9 2 ---- 10 relatively narrow ---- 
D10 4 ---- 10 relatively narrow 65 
 
4.3. Results and Discussion 
4.3.1. Effect of Temperature 
To study the effect of reaction temperature, the samples A1, A2, A3 and A4 were 
prepared using different reaction temperature (220, 265, 300 and 330ºC respectively) at 
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2h of reaction time (Table 4.1). Figure 4.7 (a), (b), (c) and (d) are the XRD patterns of the 
A1, A2, A3 and A4 samples, respectively. Position of the diffraction peaks which are 
assigned to the (111),  (220), (311),  (222), (400), (422), (511), (440) and (533), match well 
with the standard XRD data for bulk magnetite (JCPDS file No. 19-0629) and 
corresponding which indicating the formation of Fe3O4 phase. It can be seen that 
broadness of the peaks decrease with increasing the reaction temperature which could be 
due to the increase of either the particle size or the crystallinity of the particles. The 
average crystallite sizes are calculated using Scherrer’s equation [8] as 4.9, 5.8, 9.4 and 
14.3 nm (Table 4.1). This result demonstrates that the particle size increases with 
increasing the reaction temperature and the reason for this could be the increase of 











Figure 4.7. XRD patterns of the samples (a) A1, (b) A2, (c) A3 and (d) A4. 

















Figure 4.8. TEM images of the samples (a) A1, (b) A2, (c) A3 and (d) A4 (scale bar - 20 
nm). 
Figure 4.8 (a), (b), (c) and (d) show the TEM images of the A1, A2, A3 and A4 samples, 
respectively. It can be seen that the size distribution of the magnetite particles prepared at 
lower reaction temperature such as 220 and 265ºC are quite narrow (Figure 4.8 (a) and 
(b)). However, the particle size distribution becomes very wide when they prepared at 
higher reaction temperature such as 300 and 330ºC. The wider particle size distribution 
indicates that the crystal growth of the nanoparticles at the higher reaction temperature is 
very much uncontrolled. The average particle sizes are measured from the TEM images 
are about 3, 5, 9 and 24 nm for the particles prepared using the reaction temperature 220, 
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265, 300 and 330ºC respectively which further demonstrates that size of the particle 
increases with the reaction temperature.  
 
Figure 4.9 (a), (b), (c) and (d) depict the magnetization (M-H) curves of the A1, A2, A3 
and A4 samples, respectively. It can be seen that the MS increases from 46 to 74 emu/g 
with increasing the reaction temperature from 220 to 330ºC. The increase of MS with 
increasing the reaction temperature could be due to the increase of either particle size or 














Figure 4.9. Magnetization (M-H) curves of the samples (a) A1, (b) A2, (c) A3 and (d) 
A4. 
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4.3.2. Effect of Time 
To study the effect of reaction time, the samples B1 and B2 were prepared using different 
reaction time intervals (1/2 and 4 h respectively) at 300ºC (Table 4.1). Figure 4.10 (a) and 
(b) show the TEM images of B1 and B2 samples, respectively. It can be seen that average 
size of the particles again increase from 7 to 12 nm and size distribution of the particles 
becomes wider with increasing the reaction time from 1/2 to 4 h. This is simply because 
of the “Ostwald ripening” i.e. small particles becomes smaller and large particle becomes 










Figure 4.10. TEM images of the samples (a) B1 and (b) B2 (scale bar - 20 nm). 
 
Figure 4.11 (a) and (b) are the M-H curves of the B1 and B2 samples, respectively. The 
MS value again increases from 57 to 65 emu/g with increasing the reaction time from 0.5 
to 4h. The increase of MS with increasing the reaction time also could be due to the 
increase of either particle size or crystallinity of the particles.  















Figure 4.11. Magnetization curves of the samples (a) B1 and (b) B2. 
 
In summary, The MS of the particles can be increased using higher reaction temperature 
and longer reaction time during the thermal decomposition of Fe(acac)3. However, the 
increase in reaction temperature and/or reaction time resulted in unwanted particle size 
increase and undesirable particle size distribution. Therefore, the surfactant and solvent 
effect is adopted for controlling the above time and temperature dependent size and 
dispersity to obtain narrow size distribution magnetite nanoparticles with the desired size 
and higher MS value. 
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4.3.3. Effect of Surfactant  
To study the surfactant effect, the samples C1, C2 and C3 were prepared using different 
reaction time intervals (1/2, 2 and 4 h respectively) at 300ºC mixing one additional 
surfactant OA to the previous solvent surfactant mixture (SSM) (Table 4.1). Figure 4.12 
(a), (b) and (c) depict the TEM images of the C1, C2 and C3 samples, respectively. It can 
be seen that the particle size distribution is very narrow in presence of OA even at the 
higher reaction temperature of 300ºC using longer reaction time interval (4h). The narrow 
size distribution in presence of OA is due to the selective adsorption of coordinating OA 
surfactant to the particle surface which controls the particles to grow very uniformly 
(Figure 4.13) [9]. However, average size of the particles increases from 6 to 14 nm with 
increasing the reaction time from 1/2 to 4h. This indicates that although the size 
distribution of particles improved in presence of OA but the particles continuously grow 
with the reaction time.  Therefore, the solvent effect is adopted to confine the particles 








Figure 4.12. TEM images for the samples (a) C1, (b) C2 and (c) C3 (scale bar - 20 nm). 











Figure 4.13. Schemetic mechanism for the formation of particle in presence of OA and 
OM [9]. 
 
4.3.4. Effect of Solvent 
To study the solvent effect, D1 to D10 samples are prepared varying the reaction 
temperature (300 to 330ºC) and reaction time interval (1/2 to 24h) removing the solvent 
from the previous solvent surfactant mixture (SSM) (Table 4.1). Figure 4.14 (a), (b), (c) 
and (d) show the TEM images of D1, D2, D3 and D4 samples and Figure 4.15 (a), (b) 
and (c) depict the TEM images of D5, D5 and D7 samples, respectively. It can be seen 
that the particle size increases from 5 to 11 nm and 6 to 9 nm with increasing the reaction 
time from 1/2 to 24h  and 1/2 to 4h at two different reaction temperature 300 and 330ºC 
respectively. Thus, the size of the particles increases very slowly with increasing the reaction time 
if they are decomposed in absence of solvent. The TEM image shown in Figure 4.14 (d), 
indicates that there is no obvious abnormal crystal growth even when the reaction period 
is 24 h, suggesting that ‘‘Ostwald ripening’’ does not happen in the reaction system 
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which does not have solvent. Moreover, the particles prepared in absence of solvent have 
relatively narrow size distribution even at higher reaction temperature (300 and 330ºC). 
This indicates that the growth of the particles has been confined in absence of the solvent. 
The possible reason is that in absence of solvent, the particles are surrounded with very 





























Figure 4.15. TEM images for the samples (a) D5, (b) D6 and (c) D7 (scale bar - 20 nm). 
 
To confirm the solvent effect, we have prepared particles using single OM surfactant. 
Figure 4.16 (a), (b) and (c) show the TEM images for the samples D8, D9 and D10 which 
are prepared at 330ºC varying the reaction time interval (1/2 to 4h) removing the OA 
surfactant from the previous surfactants mixture (OA+OM) (Table 4.1). The particle size 
increase very slowly from 8 to 10 nm with increasing the reaction time from 1/2 to 4h 








Figure 4.16. TEM images for the samples (a) D8, (b) D9 and (c) D10 (scale bar - 20 nm). 
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Figure 4.17 A and B show the high resolution TEM (HRTEM) and selected area electron 
diffraction (SAED) pattern of the D8 samples which was prepared in absence of solvent 
(in presence of only OM surfactant). It can be seen from the HRTEM image (Figure 4.17 
A) that the magnetite nanoparticles prepared by the solvent-free thermal decomposition 
technique are highly monodispersed. Moreover, the clear lattice fringes and clear 
diffraction rings which are shown in HRTEM (Figure 4.17A) and SAED (Figure 4.17B) 
respectively indicate that the as-prepared magnetite nanoparticles are highly crystalline.  
Each ring represents a set of (hkl) planes which contributes to the electron diffraction. 
The diffraction rings are attributed to the (220), (311), (400), (422), (511) and (440) 











Figure 4.17. A. HRTEM image and B. SAED pattern of D8 samples prepared in 
presence of only OM surfactant. 
 
  Chapter 4: Synthesis of Hydrophobic Magnetite Nanoparticles 
111 
 
Figure 4.18 (a), (b), (c), (d) and (e) show the magnetization (M-H) curves for the samples 
C3, D2, D4, D7 and D10, respectively. It can be seen that in absence of solvent, the MS 
value significantly increases with the increase of the reaction temperature and reaction 
time although the change in particle size is not so significant (Table 4.1). The increase in 
MS value could be due to the increase in crystallinity of the magnetite particles which 
increases with the reaction time and temperature. Zero coercivity (Hc) and zero 
remanance (Mr) on the M-H curves indicate that the samples prepared in absence of 
















Figure 4.18. M-H curves for the samples (a) C3, (b) D2, (c) D4, (d) D7 and (e) D10. 
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In summary, the growth of particles is well controlled relatively at lower reaction 
temperature and for shorter reaction time which results in formation of the smaller size 
particles with narrow size distribution and lower value of MS. The MS of the particles is 
significantly improved with increasing the reaction time and temperature, however, size 
distribution of those particles is found to be very wide. The uniform size particles can be 
synthesized at higher reaction temperature using longer reaction time by adopting the 
surfactant or solvent effect. The growth of the particles is restricted if the reaction is 
carried out in absence of the solvent that that carried in presence of OA surfactant. 
Therefore, magnetite nanoparticles with enhanced MS can be synthesized by solvent free 
thermal decomposition reaction using higher reaction temperature and longer reaction 
time while keeping size of the particles smaller with narrow distribution. 
 
Temperature dependence of magnetization was measured using SQUID between 10 and 
300 K in the applied field of 100 Oe. Figure 4.19 shows the zero field cooling (ZFC) and 
field cooling (FC) curves for the sample D7 with the size of 9nm.  The similar feature of 
the ZFC and FC curves are observed for all the samples (D1 to D10) which also confirms 
that the particles prepared in absence of solvent are SPM in nature [11]. The ZFC curve 
reached the maximum at about 100 K, which corresponded to the blocking temperature 
(TB) of the sample. Above TB the sample is superparamagnetic and below is 
ferromagnetic. The M-H curves of the sample at 300 and 10 K are shown in Figure 4.20. 
Again, the Zero coercivity and zero remanence indicating that  the particles are 
superparamagnetic at the room temperature (300 K) while the particles exhibit 
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ferromagnetic behavior at 10K and the observed values of the coercivity and saturation 












Figure 4.19. ZFC and FC magnetization curves for the sample D7 under an applied field 






















Figure 4.20. SQUID magnetization (M-H) curves measured at 10 and 300 K. 
 
 
4.3.5. Identification of Organic Coating 
The chemically adsorbed organic coating on the particle surfaces were recognized by FT-
IR, XPS and TGA measurements. Figure 4.21 (a) and (b) show the FTIR spectra of the 
D10 and D7 samples which are prepared in OM and OA+OM surfactant media (Table 
4.1). The similar FT-IR spectra are observed for the particles prepared in presence of OM 
and OA+OM surfactant(s) media. The peaks below 800 cm-1 belong to the Fe3O4 particles 
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while the peaks (with star marked) above 800 cm-1 are due to the OA and OM coating 














Figure 4.21. FT-IR spectra of (a) OM and (b) OA+OM coated magnetite particles.  
 
The broad band between 3600 and 3000 cm-1 centered at 3400 cm-1 is assigned for the O–
H stretching vibration arises due to the water which is physically adsorbed onto the 
particle surface. The peaks at about 2924; 2852 cm-1 are assigned to the C–H stretching 
vibration which arises from the particle surface adsorbed OA and/or OM coatings. The 
peaks at about 1599; 1500 and 1411; 1047 cm−1 are attributed for N–H bending and C–
N stretching vibration due to the surface adsorbed OM coating while the peaks at 1562 
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and 1440 cm-1 are assigned to COO- stretching vibration due to  the surface adsorbed OA 
coating. In addition, the strong absorption peaks at about 585 cm−1 is due to the Fe–O 
stretching vibration of Fe3O4 nanoparticles. 
 
Table 4.2. Analysis of FTIR absorption frequencies of the organic coated magnetite 
nanoparticles [10, 12-13]. 
Absorption frequencies (cm-1) for Remarks (υ: stretching vibration; 
δ: bending vibration) OM coated OM+OA coated 
3600-3000 3600-3000 υ(O-H) for H2O 
2924 and 2852 2924 and 2852 υ(C-H) for OM and OA 
~1599 and ~1500 ~1599 δ(N-H) for OM 
--- 1560 and ~1440 υ(COO¯ ) for OA 
~1411 and ~1047 ~1411 and ~1047 υ(C-N) for OM 
881 843 δ(C=C) for OM and OA 
585, 451 585, 451 υ(Fe–O) for Fe3O4 
 
Figure 4.22 A (a) and (b) depict the wide scan XPS spectrum of the D10 and D7 samples 
which are prepared in OM and OA+OM surfactant media (Table 4.1). The corresponding 
deconvoluted O(1s) and C(1s) spectrum are shown in Figure 4.22 B and C, respectively. 
The position of the O(1s) and C(1s) peaks component are shown in Table 4.3. The O(1s) 
peak at about 531.4, 532.4 and 533.9 eV are assigned for the O–H, C=O and C–O bond, 
while the C(1s) peak components at about  285.3, 286.6, 288.9 and 289.4 eV are assigned 
for the C–C/C–H, C-N, C=O and C–O bond, respectively, arising from surface adsorbed 
OA and OM coatings and water [13-18]. In addition, the Fe(3p3/2), O(1s), Fe(2p3/2) and 
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Fe(2p1/2) peaks components at around 55.2, 530.2, 710.8 and 724.4 eV are attributed to 














Figure 4.22. A. Wide scan XPS spectra of (a) OM and (b) OM+OA coated magnetite 
particles. B.  convoluted O(1s) XPS spectra and C. convoluted C(1s) XPS spectra of D7 
sample. 
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The similar XPS spectra are observed for all the particles prepared in presence of OM 
and OA+OM media. Thus, the XPS results further confirm the chemically adsorbed OA 
and OM coatings onto surface of the Fe3O4 nanoparticles. 
 
Table 4.3. Analysis of O(1s) and C(1s) XPS spectra of the organic coated magnetite 
nanoparticles [13-18]. 
Peaks B.E. (eV) Remarks 
O(1s) 530.2 Fe–O in Fe3O4 
531.4 O-H in physically adsorbed H2O 
532.4 C=O from the (–COOH) of  OA 
533.9 C–O from the (–COOH) of  OA 
C(1s) 285.3 C–C/C–H in OM and/or OA 
286.6 C–N in OM 
288.9 C=O from the (–COOH) of  OA 
289.4 C–O from the (–COOH) of  OA 
 
 
The adsorbed organic coating on the particle surfaces can be furthered recognized by 
TGA measurements. Figure 4.23 (a) and (b) show the TGA curves of D10 and D7 
samples which are prepared in OM and OA+OM surfactant media (Table 4.1).  TGA 
curves represent a two-stage weight loss in the temperature ranges of 25 – 200ºC and 
200–800ºC. The first slight amount of weight loss is due to the evaporation of physically 
adsorbed water and the second major weight loss is due to the decomposition of 
chemically adsorbed organic coating from the particle surface. It is estimated from the 
TGA result that the total amount of weight losses are 12 and 16 wt % for the OM and 
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OA+OM coated magnetite particles. The similar pattern of TGA curves are observed for 










Figure 4.23. TGA curves of (a) OM and (b) OM+OA coated magnetite particles. 
 
Thus the FTIR, XPS and TGA analysis indicate that OA and OM molecules are 










The growth of particles is well controlled relatively at lower reaction temperature and for 
shorter reaction time which results in formation of the smaller size particles with narrow 
size distribution and lower value of MS. The MS of the particles is significantly improved 
with increasing the reaction time and temperature, however, size distribution of those 
particles is found to be very wide. The uniform size particles can be synthesized at higher 
reaction temperature using longer reaction time by adopting the surfactant or solvent 
effect. The growth of the particles is slower if the reaction is carried out in absence of the 
solvent than that carried in presence of OA surfactant. Therefore, magnetite nanoparticles 
with enhanced MS can be synthesized by solvent free thermal decomposition reaction 
using higher reaction temperature and longer reaction time while keeping size of the 
particles smaller with narrow distribution. 
 
In summary, a novel solvent free thermal decomposition method has been developed to 
synthesize high quality magnetite nanoparticles. Reaction temperature of this method can 
be easily adjusted due to the absence of solvent. By using this method, the Ms value of 
the synthesized Fe3O4 nanoparticles can reach 76 emu/g, while the superparamagnetic 
property of the Fe3O4 nanoparticles is well retained. The obtained Fe3O4 nanoparticles 
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Conversion of Hydrophobic 












The hydrophobic magnetite nanoparticles prepared from the thermal decomposition 
technique are coated with a layer of oleate and/or oleylamine and cannot immediately be 
used in biological applications because they are only soluble in hexane and other 
nonpolar or weakly polar organic solvents. For such particles to be useful in biology, they 
must be soluble in water in a pH range of about 5 to 9, at salt concentrations up to a few 
hundred mM, and temperatures up to 95 °C for various biological reactions [1]. To meet 
these biocompatibility requirements, the hydrophobic nanoparticles need to be modified. 
There are two general approaches in nanoparticle surface modifications: surface 
functionalization and encapsulation.  
 
5.1.1. Surface Functionalization 
Surface functionalization can be achieved by surfactant addition (i.e. bi-layer surfactant 
stabilization) and surface surfactant exchange (i.e. ligand exchange) [2-3]. The surfactant 
addition uses the hydrophobic interaction of the incoming long-chain hydrocarbon with 
that from the surfactant to form a cell-membrane-like double-layer structure, as shown in 
Figure 5.1 A [1]. In this approach, the nanoparticles are surrounded by the double-layer 
structure and the surface of the particles is functionalized with the functional group “F”. 
Depending on the chemical property of “F”, such modified nanoparticles can be 
dispersed in various liquid media, including water and PBS. Surface surfactant exchange, 
as shown in Figure 5.1 B, refers to the replacement of original surfactant on the surface of 
the particles by a bi-functional surfactant (single layer) with one functional group capable 
of binding to the particle surface via strong chemical bond and the other functional group 
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“F” having the polar character so that the particles can be dispersed in water or be further 
conjugated with bio-molecules like monoclonal antibody or folate receptor for in vivo 










Figure 5.1. Schematic representation of surface functionalization of hydrophobic 
magnetite nanoparticles: A. double layer and B. single layer [1]. 
  
5.1.2. Encapsulation 
Encapsulation can be achieved by entrapping the hydrophobic nanoparticles into a 
polymer matrix [4]. In this approach, the magnetite nanoparticles are confined 
(encapsulated) to a core surrounded by a hydrophilic polymeric membrane and thus 
obtain a biocompatible encapsulated polymeric nanoparticle, as shown in Figure 5.2. The 
polymeric nanoparticles can be freeze-dried for long-term storage and are more 
chemically and physically stable in vivo.  




Figure 5.2. Schematic representation of surface encapsulation of hydrophobic magnetite 
nanoparticles. 
A number of different polymers have been used in formulating polymeric nanoparticles, 
but those receiving the most attention are the biodegradable polymers because they have 
the advantage of not requiring surgical removal after they serve their intended purposes. 
Moreover, biodegradable matrices can provide a further control of release rates, by 
joining the typical diffusive mechanism with tunable polymer degradation. Therefore, 
biodegradable polymers especially poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) 
(PLGA) and poly (ε-caprolactone) (PCL) have been commonly used over the past two 
decades for the development of polymeric nanoparticles in cancer and other biomedical 
applications [5-6]. However, these polymers are highly hydrophobic and there by the 
encapsulated nanoparticles made of these polymers are not water soluble. Moreover, 
nanoparticles composed of those polymers are difficult to conjugate directly hydrophilic 
molecular probes for targeting, for which amphiphilic linker molecules are needed, 
resulting in complications in the technology. To solve this problem, amphiphilic 
copolymers (with one hydrophobic and one hydrophilic end) have been developed 
inserting hydrophilic elements into the hydrophobic chains of the polymers. Recently, 
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Feng S-S groups have synthesized various biodegradable copolymers such as PLA- 
methoxy poly(ethylene glycol) (PLA-mPEG) [7-8] and PLA-d-α-tocopherol polyethylene 
glycol 1000 succinate (PLA-TPGS) [9-10]. Among these, they have significantly used PLA-
TPGS copolymers for the formulation of the polymeric nanoparticle due to its controllable 
biodegradability, high encapsulation efficiency, high emulsification efficiency, high 
cellular uptake, excellent biocompatibility and non-toxicity. Polymeric nanoparticles can 
be prepared by several techniques such as emulsification-solvent evaporation method 
(single and double emulsion method) [11-12], solvent displacement method 
(nanoprecipitation method) [13-14], and the micelle formation [15-17]; depending on the 
nature of the polymeric material and the characteristics of the therapeutic agents to be 
loaded [18].  
 
In this work, we have tried to covert functionalize the hydrophobic nanoparticles into 
hydrophilic by following three approaches: 
1. Bi-Layer surfactant stabilization using lauric acid (LA).  
2. Ligand exchange with the polyethylene glycol diacid (PEGDA), poly(acrylic 
acid) (PAA) and 3-aminopropyltriethoxysilane (APTES). 
3. Encapsulation within a copolymer of poly(lactide) (PLA) and D-α-tocopherol 
polyethylene glycol 1000 succinate (TPGS). 
The structure, morphology and properties of the converted nanoparticles are 
characterized to evaluate their potentiality in hyperthermia therapy and MRI imaging 
applications. 




Oleylamine (OM), lauric acid (LA), polyethylene glycol diacid (PEGDA, Mw = 600), 
dopamine (DPA) hydrochloride, sodium carbonate, N-hydroxysuccinimide (NHS), N,N′-
dicyclohexylcarbodiimide (DCC), dimethylformamide (DMF), poly(acrylic acid) (PAA, 
Mw = 1800), diethylene glycol (DEG), 3-aminopropyltriethoxysilane (APTES), 
poly(lactide) (PLA), stannous octoate  and organic solvents used in the syntheses were 
purchased from Sigma Aldrich. Vitamin E D-α-tocopherol polyethylene glycol 1000 
succinate (TPGS) was from Eastman chemical company (USA), which was freeze dried 
for two days before use. Chemical structure of OM, LA, PEGDA, DPA, PAA, APTES, 
PLA and TPGS are shown in Figure 5.3.  
The OM coated hydrophobic magnetite nanoparticles are synthesized using the solvent-
free thermal decomposition technique as described in the previous chapter. Typically, 2 
mmol of Fe(acac)3 was dissolved in a 20 mL oleylamine and magnetically stirred under a 
flow of argon. The solution was dehydrated at 120 °C for 30 min, and then quickly 
heated to 320 °C and kept at this temperature for 1h. The black solution was cooled to 
room temperature by removing the heat source. 20 mL of ethanol was added into the 
solution and the precipitated particles were collected by centrifugation at 10000 rpm 
followed by three times washing with ethanol. The resulting OM coated hydrophobic 
nanoparticles are then converted into hydrophilic nanoparticles either by 
functionalization with hydrophilic molecules or encapsulation within hydrophilic 
polymeric matrix.   
 













Figure 5.3. Chemical structure of oleylamine (OM), lauric acid (LA), polyethylene 
glycol diacid (PEGDA), dopamine (DPA), poly(acrylic acid) (PAA), 3-
aminopropyltriethoxysilane (APTES), poly(lactide) (PLA) and D-α-tocopherol 
polyethylene glycol 1000 succinate (TPGS) molecules. 
 
5.2.1. Synthesis of Bi-Layer Surfactant Stabilized Nanoparticles 
Bi-layer stabilized hydrophilic Fe3O4 nanoparticles were prepared following the method 
reported in my previous paper [19], except that the lauric acid (dodecanoic acid) was 
used for the outer layer coating (Figure 5.4) of the Fe3O4 nanoparticles. Typically, ~1g of 
the washed OM coated Fe3O4 nanoparticles obtained by thermolysis (as described in 
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Chapter 4, Section 4.2.1) was combined with 20 ml deionized water and the slurry was 
heated to 60°C under vigorous stirring. A solution of 10% (w/v) ammonium salt of lauric 
acid (LA) was prepared separately by mixing 30 mL water, 3 g lauric acid and 30-40 
drops of a solution of NH4OH (pH = 10). This solution was added to the slurry dropwise 
using a 1 mL plastic syringe under constant stirring at 60°C until the slurry changed into 
a stable suspension. To confirm the stability of the aqueous suspension of the Fe3O4 
nanoparticles was exposed to a permanent magnet for 10 min, and no phase separation 
was observed. Thus, the hydrophobic Fe3O4 nanoparticles was coated with double 
surfactant layers to stabilize them in water medium to obtain stable water-based magnetic 
fluid. The first inner layer of OM molecules are chemically adsorbed surfactant and the 
second layer of LA molecules are physically absorbed onto the surface of the Fe3O4 









Figure 5.4. Schematic representation for the synthesis of bi-layer surfactant modified 
nanoparticles [19]. 
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5.2.2. Synthesis by Ligand Exchange 
5.2.2.1. Synthesis of PEGylated Nanoparticles 
PEGylated hydrophilic magnetite nanoparticles were prepared using the method reported 
by Xie et al [21]. In this method, dopamine (DPA) was first linked with one of the 
carboxylic groups in the PEG diacid (PDA) via the EDC/NHS chemistry and then the 
resulting PEG-dopamine-acid (PDA) was covalently anchored on the surface of the 










Figure 5.5. Schematic representation for the synthesis of PEG-dopamine-acid (PDA) 
modified nanoparticles [21]. 
Typically, 4 mL PEG diacid, 2 mg NHS (N-hydroxysuccinimide), 3 mg DCC 
(dicyclohexylcarbodiimide) and 1.27 mg dopamine hydrochloride were dissolved in a 
mixture solvent containing 2 mL CHCl3, 1 mL DMF (dimethylformamide) and 
anhydrous 10 mg Na2CO3. The solution was stirred at room temperature for 2 h. Then 5 
mg OM coated Fe3O4 nanoparticles were added, and the resulting solution was stirred 
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overnight at room temperature under Ar flow. The PDA modified Fe3O4 nanoparticles 
were precipitated by adding hexane, collected by a permanent magnet and dried 
overnight in oven. The particles were then dispersed in water.  
 
5.2.2.2. Synthesis of PAA Modified Nanoparticles 
Hydrophobic nanoparticles can be transferred into water medium by the ligand exchange 
approach using polyelectrolyte molecules such as poly(acrylic acid) (PAA) as reported by 








Figure 5.6. Schematic representation for the synthesis of PAA modified nanoparticles 
[22]. 
 
Typically, 8.0 mL DEG solution containing 0.5 g PAA was heated to 110°C with 
vigorous stirring under Ar flow. A toluene solution of OM coated Fe3O4 nanocrystals 
with 5 mg/mL Fe concentration was injected to the hot solution which became turbid 
immediately. The system was heated to 240°C and kept at this temperature for 1 h until 
the solution became clear. The hydrophobic OM coating was replaced by PAA molecules 
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due to the strong coordination of their functional groups to the nanocrystal surface as 
shown in Figure 5.6. After the solution was cooled down to room temperature, excess 
dilute hydrochloric aqueous solution was added, and a brown-black magnetic powder was 
obtained by centrifuging. The powder was washed three times with pure water. Finally, 
the washed powders are dispersed in water.  
 
5.2.2.3. Synthesis of APTES Modified Nanoparticles 
The 3-aminopropyltriethoxysilane (APTES) molecule consists of three alkoxy groups and 
amino (NH2) group at two opposite ends of its chemical structure (Figure 5.3) and thus it 
can covalently bond to the nanoparticles through the alkoxy groups while keeping the 
NH2 functional groups available for further bio-conjugation (Figure 5.7). Moreover, 
APTES can provide very good biocompatibility to the nanoparticles for their applications 
in biology [23]. Therefore, the method of surface functionalization with APTES could be 
promising for converting hydrophobic nanoparticles into hydrophilic nanoparticles to 
transfer them in an aqueous medium. Several groups have been tried to functionalize the 
magnetite nanoparticles with APTES [24-26]. However, the APTES functionalized 
nanoparticles have been found to be heavily agglomerated in all these previous results. 
Thus, here we have tried to synthesize non-agglomerated APTES functionalized 
magnetite nanoparticles using the modified aqueous/organic solvent deposition method 
[27]. Typically, OM coated magnetite nanoparticles were suspended in 30 ml 1:1 ethanol-
water mixture (5% wt/v) and pH of the solution was adjusted to 5 by addition of acetic 
acid. Then, 10 ml of APTES was added to the solution and the resulting mixture solution 
was magnetically stirred at room temperature for 3 days under a flow of argon. Then, the 
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resulting APTES functionalized nanoparticles were precipitated from the supernatant by 
centrifugation at 8000 rpm for 15 min followed by three times washing with ethanol. 
Finally, one half of the functionalized nanoparticles were dispersed in water after 
washing and the other half was dried overnight in oven to obtain dry functionalized 
nanoparticles. 
 
In the aqueous/organic solvent deposition method, the APTES molecules are adsorbed to 
the surface of the magnetite nanoparticles by two step reaction procedures (Figure 5.8). 
In the hydrolysis-condensation reaction (step 1), alkoxide groups (–OC2H5) of APTES 
molecules are replaced by hydroxyl groups (OH) to form reactive silanol groups, which 
condense with other silanol groups to form silane polymer producing siloxane bonds (Si–
O–Si). In the second step, the silane polymers are chemically adsorbed to the magnetite 








Figure 5.7. Schematic representation for the synthesis of APTES modified nanoparticles 
[23]. 













Figure 5.8. Deposition of APTES on the surface of the magnetite core through 
hydrolysis-condensation (Step 1) and silanization (Step 2) reactions [26].  
 
 
5.2.3. Synthesis by Polymeric Encapsulation 
5.2.3.1. Synthesis of PLA-TPGS Polymer 
The PLA-TPGS copolymer (90:10 w/w ratio) was synthesized by the ring opening 
polymerization procedure reported elsewhere [9]. In brief, 9 g of PLA, 1 g of TPGS and 
0.05 g stannous octate (in distilled toluene, 1%) were taken in an ampoule. The ampoule 
was evacuated in liquid nitrogen for 45 min. After that the ampoule was sealed by butane 
burner and reacted in silicone oil bath at 145oC. After 12 h, the reaction product was 
dissolved in dichloromethane (DCM) and then precipitated in excess cold methanol to 
remove unreacted lactide monomers and TPGS. The final product was collected by 
filtration and vacuum dried at 45oC for two days.  
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5.2.3.2. Preparation of Fe3O4 Encapsulated Polymeric Nanoparticles  
 
Fe3O4 encapsulated PLA-TPGS nanoparticles (IO-PNPs) were prepared by both the 
single emulsion and nanoprecipitation method.  
A. Single Emulsion Method 
A schematic representation of formation of the encapsulated polymeric nanoparticles 
(PNPs) using the single emulsion method is shown in Figure 5.9. Typically, 100 mg 
of the polymer and 2 mg OM coated Fe3O4 were added to 8 ml of 
dichloromethane (DCM) and the resulting solution was vortexed till the polymer 
was completely dissolved in the organic solvent and a clear solution was obtained. 
The organic phase was then added into 120 ml of aqueous phase containing the 
emulsifier at a given concentration (15% w/v TPGS) and sonicated (at 25 W 
output) for 90 seconds to disperse the emulsion using a probe sonicator. The 
resulting emulsion was allowed to stir overnight to evaporate the organic solvent 
completely. Finally, the polymeric nanoparticles were obtained by centrifugation at 
10,000 rpm for 30 minutes followed by removal of the emulsifier by several times 
washing with water. 
 
In this preparation method, the organic phase consisting of water insoluble solvent (DCM), 
polymer (PLA-TPGS) and magnetic nanoparticles (MNPs) occupy the hydrophobic core of the 
micelle which is initially formed in the aqueous phase as shown in Figure 5.10.  Due to 
immiscibility of solvent (DCM), the non-solvent (water) does not diffuse into the organic phase 
however, the solvent diffuse into the non-solvent (water) or evaporates due to its low boiling 
point. Thus, the solvent carry the MNPs and deposit them at the interface between the 
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solvent/non-solvent. Therefore, the MNPs are dispersed near the periphery of the polymeric 




































Figure 5.10. Structure of micelle formed by dissolving, an emulsifier (TPGS) in water. 
The inner hydrophobic core of the micelle can dissolve organic-soluble compounds.  
 
B. Nanoprecipitation Method  
 A schematic representation of formation of the encapsulated polymeric nanoparticles 
(PNPs) using the nanoprecipitation method is shown in Figure 5.11. Typically, 100 
mg of the polymer and 2 mg of OM coated Fe3O4 were added to 8 ml of 
tetrahydrofuran (THF) and the resulting solution was vortexed till the polymer 
was completely dissolved in the organic solvent and a clear solution was obtained. 
A 30 ml of aqueous phase containing a known concentration of the emulsifier 
(15% w/v TPGS) was well dispersed using a probe sonicator for 30 seconds. The 
organic phase was then added into the aqueous phase. The solution was 
vigorously stirred still uniformity and finally diluted with large volume of water. 
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The resulting solution was then allowed to be stirred overnight to eliminate the 
organic solvent. Finally, the polymeric nanoparticles were obtained by 
centrifugation at 10,000 rpm for 30 minutes followed by removal of the emulsifier 














Figure 5.11. Schematic representation of synthesis of the polymeric nanoparticles (IO@PLA-
TPGS) by nanoprecipitation method. 
 
In this preparation method, the organic phase consisting of partially water soluble solvent 
(THF), polymer (PLA-TPGS) and magnetic nanoparticles (MNPs) occupy the 
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hydrophobic core of the micelle which is initially formed in the aqueous phase as shown 
in Figure 5.9.  However due to the partial water miscibility of the solvent (THF), the non-
solvent (water) diffuse into the core and co-exist with the organic phase bringing 
interaction of the emulsifier with the polymer. Thus, the emulsifier influences the 
distribution of the MNPs within the polymer matrix to develop uniformly MNP dispersed 
polymeric nanoparticles (IO@PLA-TPGS) as shown in Figure 5.11.  
 
5.2.4. Characterization of Nanoparticles  
The size and morphology of the functionalized magnetite nanoparticles were determined 
by transmission electron microscopy (TEM, JEOL 2010) while their structure was 
identified Fourier transform infrared spectroscopy (FTIR, Varian 3100) and  
thermogravimetric analysis (TGA, DMSE SDTQ600). Magnetic properties were 
measured using vibrating sample magnetometer (VSM, Lakeshore, Model 665). Iron (Fe) 
content within the polymeric nanoparticles (PNPs) was measured by ICP MS (Agilent 
ICP MS 7500 Series). For this, a known amount of PNPs were dissolved in 2 ml of 
concentrated nitric acid and the resulting solutions were analyzed using ICP-MS after 
sufficient dilution with milli-Q water. The analysis of sample was done in comparison 
with the ICP-MS standard (Sigma Aldrich).The encapsulation efficiency (EE %) and iron 




Amount of Fe O  present in the polymeric nanoparticles  EE% = 100
Amount of Fe O  used in the preparation of polymeric nanoparticles
×  
 Weight of Fe present in X g of polymeric nanoparticles  % Fe content = 100
X g of polymeric nanoparticles
×  
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Cell viability studies were performed by MTT assay using MCF-7 mammalian breast 
cancer cells. For this, the MCF-7 cancer cells were incubated for 24 h with media 
containing APTES coated (IO@APTES) and PLA-TPGS encapsulated (IO@PLA-TPGS) 
nanoparticles at concentrations ranging from 0.625 – 10 mg/ml Fe. AC magnetic field 
induced heating ability of the IO@APTES nanoparticles was determined from the time-
dependent calorimetric measurements using a RF generator operating at 240 kHz. The 
T1, T2
 
and T2* relaxation times of aqueous suspensions of IO@APTES and IO@PLA-
TPGS nanoparticles with the Fe concentration of 0.0066 – 0.4 mM was measured at 9.4T 
using a Varian MRI scanner. The IO@PLA-TPGS nanoparticles were injected into a 
Wistar rat body at a dosage of 0.8 mg [Fe]/kg body through tail vein and then in vivo 
MRI images of rats were obtained by using a fast spin echo sequence (TR/TE 
=1000/28.24 ms, flip angle = 90°, field of view = 8 cm, thickness = 2 mm, intersection 
gap = 0.3 mm, matrix = 256 x 192, under fat saturation and external trigger). 
 
5.3. Results and Discussion 
5.3.1. Structure Identification 
Figure 5.12 A, B, C and D shows the FTIR spectra of the bi-layer surfactant, PDA, PAA 
and APTES modified nanoparticles, respectively. The peaks below 700 cm-1 are due to 
Fe–O stretching vibration for the iron oxide nanoparticles [29] while the peaks above 700 
cm-1 are due to the organic coating adsorbed onto the surface of the nanoparticles. The 
broad band between 3600 and 3000 cm−1 are due to the O–H stretching vibration 
attributed for water molecules adsorbed to the particle surface [30]. 
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The peaks in Figure 5.12 A at about ~3400, 3130-3030, 2962-2809, ~1670, 1501-1602 
and ~1435 are due to N–H stretching, NH4+ bending, C–H stretching, O–H stretching, N–
H bending and O-C=O stretching vibration respectively (Table 5.1), which are attributed 
to adsorbed OM (inner layer) and LA (outer layer) molecules onto the particle surface 
[19, 21, 30-31]. The band at 1100-1250 cm-1 are assigned due to the bridging between 
COOH groups of the outer layer lauric acid molecules and the excess (free) lauric acids 
molecules through H-bonding [33].  
The peaks in Figure 5.12 B at about ~3400, 2962-2809, ~1670, ~1643, 1501-1602, ~1435 
and 1100-1250 cm-1 are due to N–H stretching, C–H stretching, O–H stretching, C=O 
stretching, N–H bending, O-C=O stretching and C–O–C stretching vibration respectively 
(Table 5.1), which are attributed to adsorbed PDA molecules onto the particle surface 
[19, 21, 29-31].  
The peaks in Figure 5.12 C at about 2962-2809, ~1710, ~1670, 1550-1610 and 1396, and 
~1060 cm-1 are due to C–H stretching, C=O stretching, O–H stretching, COO- stretching 
and O-H bending vibration respectively (Table 5.1), which are attributed to adsorbed 
PAA molecules onto the particle surface [19, 22, 29-31].  
The peaks in Figure 5.12 D at about 3429, 2962-2809, 1625, 1385, 1120-1048 and ~ 935 
cm-1 are due to N–H stretching, C–H stretching, N–H bending, C–N stretching, Si-O–Si 
stretching and Si–O–Et bending vibration respectively (Table 5.1), which are attributed to 
adsorbed APTES molecules onto the Fe3O4 nanoparticle surface [26, 33-34].  
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Table 5.1. FT-IR absorption frequencies (4000-400 cm-1) of bi-layer surfactant, PDA, 
PAA and APTES modified nanoparticles [19, 21-22, 26-27, 30-34]. 
Samples Absorption frequencies 
(cm-1) 









~3400 and 1501-1602 
~1435 
1100-1250 
δ(NH4+) for ammonium salts of LA 
υ(C-H) for –CH2 of OM and LA 
υ(O-H) for –CO2H of LA 
υ(N-H) and δ(N-H) for -NH2 of OM  
υ(O-C=O) for –CO2H of LA 
The couple between –COOH of LA (outer layer) 







~3400 and 1501-1602 
~1435 
1100-1250 
υ(C-H) for –CH2 of PDA 
υ(O-H) for –CO2H of PDA 
υ(C=O) for amide of PDA 
υ(N-H) and δ(N-H) for amide of PDA 
υ(O-C=O) for –CO2H of PDA 








1550-1610 and 1396 
~1060 
υ(O-H) for H2O 
υ(C-H) for –CH2 of PAA 
υ(C=O) for –CO2H of PAA 
υ(O-H) for –CO2H of PAA 
υ(COO-) for –CO2H of PAA 






~3400  and 1625 
1385 cm−1 
1120-1048 and ~ 935 
υ(O-H) for H2O 
υ(C-H) for propyl group of APTES 
υ(N-H) and δ(N-H) for NH2 group of APTES 
υ(C-N) for CH2-NH2 of APTES 
Si-O–Si and Si–O–Et bonds of silanized APTES 
 















Figure 5.12. FTIR patterns of the A. bi-layer surfactant, B. PDA, C. PAA and D. APTES 
modified nanoparticles. 
 
The surface adsorbed organic coatings were further identified by TGA analysis. Figure 
5.13 A, B, C and D depict TGA curves the bi-layer surfactant, PDA, PAA and APTES 
modified nanoparticles, respectively. The minor weight loss in the temperature range of 
25–200ºC is due to the evaporation of water while the major weight loss in the 
temperature range of 200–800ºC is due to the decomposition of the adsorbed organic 
coating from the particle surface. The total amount of weight losses were 32 wt%, 25 
wt%, 11 wt% and 14 wt% for the  bi-layer, PDA, PAA and APTES modified 
nanoparticles, respectively. Two different type of weight loss occurs between 200-800°C 
                                 Chapter 5: Conversion of Hydrophobic to Hydrophilic Nanoparticles 
145 
 
for the bi-layer coated nanoparticles:  the first weight loss occurs rapidly in the 
temperature range of 200-350°C due to thermal degradation of outer (secondary) layer 
which is physically adsorbed (reversibly and weakly bonded) onto the particle surface 
while the second weight loss occurs in the temperature range of 350-800°C due to the 
thermal degradation of inner (primary) layer which is chemically adsorbed (irreversibly 














Figure 5.13. TGA curves of the A. bi-layer surfactant, B. PDA, C. PAA and D. APTES 
modified nanoparticles. 
Thus, the FTIR and TGA results indicate that the LA molecules are physically adsorbed 
forming an outer layer of the bi-layer (inner OM layer) modified nanoparticles while the 
PDA, PAA and APTES molecules are chemically adsorbed on to surface of the magnetite 
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nanoparticles replacing the OM coating of the hydrophobic nanoparticles through the 
ligand exchange procedure. The free -CO2H and NH2 functional groups of the bi-layer 
surfactant, PDA, PAA and APTES modified nanoparticles are further required to be 
conjugated with the bio-molecules (antibody, folate receptor etc.) so that they can be used 
in the site-specific targeting applications.  
 
Figure 5.14 A and B show the FTIR spectra of the encapsulated PLA-TPGS (IOs-PNPs) 
nanoparticles prepared by single emulsion and nanoprecipitation method, respectively. 
The peaks at about 2962-2809, ~1755, 1501-1602, ~1435 and 1100-1250 cm-1 are due to 
C–H stretching, C=O stretching and C–O–C stretching vibration respectively, which are 
attributed to encapsulating PLA-TPGS polymer  molecules onto the Fe3O4 particle 
surface [19, 21, 29-31].  The peaks in Figure 5.14 B are broader than the peaks in 5.14 A 
indicating that the size of the PNPs prepared by nanoprecipitation method is smaller than 
those prepared by the single emulsion method [29-31].  
Figure 5.15 shows the TGA curve the IOs-PNPs nanoparticles. The major weight loss in 
the temperature range of 200–500ºC is due to the evaporation the complete 
decomposition of the PLA-TPGS matrix of IOs-PNPs nanoparticles. After 500ºC, the 


















Figure 5.14. FTIR spectra of the encapsulated PLA-TPGS nanoparticles (IOs-PNPs) 












Figure 5.15. TGA curve of the encapsulated PLA-TPGS (IOs-PNPs) nanoparticles. 




Figure 5.16 A, B, C and D shows the TEM images of the bi-layer surfactant, PDA, PAA 
and APTES modified nanoparticles suspended in an aqueous medium, respectively. It can 
be seen that the bi-layer surfactant and PAA modified nanoparticles are are very much 
agglomerated in an aqueous medium while, the PDA and APTES modified nanoparticles 
are very well dispersed in aqueous media.  
The TEM results indicate that the procedure of converting the hydrophobic nanoparticles 
either by adding a second layer of LA onto them or replacing the OM layer with PAA are 
not as effective to prevent the agglomeration in their aqueous suspension. However, the 
ligand exchange via PEGylation or APTES functionalization is very effective to transfer 
the nanoparticles in aqueous media without any agglomeration. The clear lattice fringes 
and electron diffraction rings of HRTEM and SADP image which are shown in the 
Figure 5.16 E and F respectively indicate that the nanoparticles are still consisting of 
highly crystalline magnetite phase even after their surface functionalization.    
Figure 5.17 A and B show the TEM images of Fe3O4 encapsulated polymeric (PLA-
TPGS) nanoparticles (IOs-PNPs) prepared by the single emulsion and nanoprecipitation 
method, respectively. It can be seen that the magnetite nanoparticles distributed more 
towards the periphery (PDI = 0.153) of the PNPs prepared using the single emulsion 
method while the magnetite nanoparticles are distributed homogeneously (PDI = 0.093) 
within the matrix of the PNPs prepared using the nanoprecipitation method. Moreover, 
size of the PNPs prepared by single emulsion method (D = 282 nm) is larger than those 
prepared by nanoprecipitation method (D = 249 nm).  
























Figure 5.16. TEM images of the A. bi-layer surfactant, B. PDA, C. PAA and D. APTES 
modified nanoparticles. E. HRTEM and F. SADP of APTES modified nanoparticles. 
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Hence, the encapsulation efficiency of the PNPs prepared by single emulsion method is 
lower than those prepared by nanoprecipitation method (Table 5.2). Polydispersity index 
of size distribution (as determined by the Zetasizer Nano-ZS) of the NPs are 0.153 and 
0.093 respectively. We can thus conclude that the preparation of the PNPs by the 
nanoprecipitation method is more efficient to control the particle size and the distribution 










Figure 5.17. TEM images of Fe3O4 encapsulated PLA-TPGS (IOs-PNPs) nanoparticles 
prepared by A. single emulsion and B. nanoprecipitation method, respectively (scale bar = 
100 nm).  
 




MNP (wt %) 
Encapsulation 





Single emulsion  
2 
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5.3.3. Magnetic properties 
Figure 5.18 A, B, C and D show the magnetization (M-H) curves (measured at 2 T) of the 
bi-layer surfactant, PDA, PAA and APTES modified nanoparticles suspended in an 
aqueous medium, respectively. Their saturation magnetization (MS) values were 
estimated as 54, 60, 65 and 63 emu/g respectively. The MS values are different because of 
the different amount of nonmagnetic (surfactant or polymer) coating on to the Fe3O4 
nanoparticle surface. The zero coercivity and zero remanance on all of the M-H curves 
indicate that the surface modified magnetite nanoparticles are superparamagnetic in 













Figure 5.18. Room temperature M-H curves of the A. bi-layer surfactant, B. PDA, C. 
PAA and D. APTES modified magnetite nanoparticles.  
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Figure 5.19 shows the temperature dependence of the zero-field cooled/field cooled 
(ZFC-FC) magnetization of the APTES functionalized nanoparticles measured by 
SQUID under an applied field of 50 Oe. The ZFC curve reached the maximum at about 
129 K, which corresponded to the blocking temperature (TB) of the nanoparticles. The 
similar feature of ZFC-FC curves are observed for all the surface functionalized 
magnetite nanoparticles which also confirms that the functionalized nanoparticles are 












Figure 5.19. ZFC and FC magnetization curves of the APTES functionalized magnetite 
nanoparticles under an applied field of 50 Oe. 
Figure 5.20 A and B depict the M-H curves (measured at 0.5 T) of the IOs-PNPs prepared 
by single emulsion and nanoprecipitation method, respectively. The MS values were 
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estimated as 5 and 25 emu/g indicating that the MS value of the former IOs-PNPs is lower 
than latter IOs-PNPs. The higher MS value of the IOs-PNPs prepared by nanoprecipitation is 











Figure 5.20. Room temperature M-H curves of the Fe3O4 encapsulated PLA-TPGS 
nanoparticles (IOs-PNPs) prepared by A. single emulsion and B. nanoprecipitation 
method, respectively. 
 
5.3.4. In vitro Cytotoxicity Studies 
Figure 5.21 shows the cytotoxicity profile of the APTES coated (IO@APTES) and PLA-
TPGS encapsulated (IO@PLA-TPGS) nanoparticles using the MCF-7 breast cancer cells. 
It can be seen that MCF-7 cells do not show any cytotoxicity with the magnetite 
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nanoparticles in the range of 0.625 – 10 mg Fe/ml concentrations. Thus, both the APTES 
coated and PLA-TPGS encapsulated magnetite nanoparticles are biocompatible up to the 










Figure 5.21. Cytotoxicity profile of the APTES coated (IO@APTES) and PLA-TPGS 
encapsulated (IO@PLA-TPGS) nanoparticles on MCF-7 breast cancer cells.  
 
5.3.5. Magnetic Hyperthermia Studies 
Figure 5.22 shows the time dependent temperature rise of 1 ml aqueous suspension of the 
APTES coated magnetite nanoparticles (IO@APTES) with the iron concentrations of 0.5, 
1, 2.5, 5 and 10 mg/ml upon exposure to 89 kA/m AC magnetic field at 240 kHz 
frequency. The time required to raise the temperature up to 42ºC for the IO@APTES 
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nanoparticles with different iron concentration (0.5-10 mg/ml) are given in Table 5.3. 
The results indicate that the rate of temperature rise systematically increases with the iron 
concentration of both the IO@APTES nanoparticles (Figure 5.33).  The heating of the 
IO@APTES nanoparticles under AC magnetic field could be due to Neel and Brownian 
loss which arise from rotation of the magnetization vector and the nanoparticles itself, 
respectively [35]. Inset of Figure 5.22 depicts the AC magnetic field (H) dependent SAR 
(specific absorption rate) values of the IO@APTES nanoparticles with 1 mg/ml iron 
concentration at 240 kHz frequency, indicating that the SAR values varies nearly with H2 










Figure 5.22. Time dependent temperature rise of 1 ml IO@APTES sample with different 
iron concentration. Inset shows field dependent SAR values of 1 ml IO@APTES sample. 











Figure 5.23. The time required time to raise the temperature up to 42 ºC for the IO@250 
and IO@APTES nanoparticles with different Fe concentrations.  
 
Table 5.3. The time required to raise the temperature up to 42 ºC for the IO@APTES 
nanoparticles with different Fe concentrations. 
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5.3.6. MRI Relaxivity Studies 
Figure 5.24 A and B show the transverse relaxation rates (1/T2
 
and 1/T2* at 9.4 T) of the 
IO@APTES and IO@PLA-TPGS nanoparticles with different Fe concentration. The 
corresponding relaxivities (r1, r2, and r2*) values of the IO@APTES are estimated as 
0.4543, 168.3 and 275.2 mM-1s-1 and those values for the IO@PLA-TPGS nanoparticles 
are estimated as 0.3772, 104.9 and 224.4 mM-1s-1respectively which indicates both the 
IO@APTES and IO@PLA-TPGS nanoparticles could be used as a T2 MRI contrast 
agent. Moreover, the r2, and r2* relaxivity values of the IO@APTES nanoparticles are 
relatively greater than that of the IO@PLA-TPGS nanoparticles due to the greater 
magnetization of IO@APTES nanoparticles (Ms = 63 emu/g) than that of IO@PLA-
TPGS (Ms = 25 emu/g). 
 
 











Figure 5.24. Transverse relaxation rates (1/T2
 
and 1/T2*) vs Fe concentration of A. 
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5.3.7. In vivo MRI Imaging 
Figure 5.25 show the coronol image of the rat liver before injection (A) and after 
injection (B) of the IO@PLA-TPGS nanoparticles. The postcontrast image (Figure 5.25 
B) shows a darker liver image compared to the precontrast image (Figure 5.25 A) 
indicating accumulation of the IO@PLA-TPGS nanoparticles in the liver. Hence, signal 
reduction is occurred due to the change of brightness i.e. darkness in MRI image due to 
accumulation of IO@PLA-TPGS nanoparticles in the liver. This signal reduction after 
administration of the IO@PLA-TPGS nanoparticles indicating that the IO@PLA-TPGS 








Figure 5.25. Shows the coronol image of the rat liver before injection (A) and after 
injection (B) of the IO@PLA-TPGS nanoparticles. Arrows indicate liver of the rat. 




The hydrophobic nanoparticles are successfully converted into the hydrophilic 
nanoparticles either by functionalization or polymeric encapsulation. The MS values of 
the PDA, PAA and APTES modified nanoparticles are found to be different (54, 60, 65 
and 63 emu/g respectively) because of the different amount of nonmagnetic (surfactant or 
polymer) coating on to the Fe3O4 nanoparticle surface. The surface modified magnetite 
nanoparticles are superparamagnetic in nature at the room temperature. The preparation 
of the encapsulated PLA-TPGS nanoparticles by the nanoprecipitation method is more 
efficient over the single emulsion method with respect to higher encapsulation efficiency, 
controlled particle size, higher Ms and the uniformity of the distribution of magnetic 
nanoparticle within the polymeric matrix.  
In vitro cell viability studies indicate that both the IO@APTES and IO@PLA-TPGS 
nanoparticles are cytocompatible up to the iron concentration of 10 mg/ml. The 
significant temperature rise of the IO@APTES nanoparticles upon exposure of AC 
magnetic field upto 89 kA/m at 240 kHz frequency confirm their potential applicability 
for magnetic hyperthermia applications. The r2* relaxivity values of the IO@APTES 
nanoparticles (r2*= 275.2 mM-1s-1) are found to be relatively greater than that of the 
IO@PLA-TPGS nanoparticles (r2*= 224.4 mM-1s-1) due to the greater magnetization of 
IO@APTES nanoparticles (Ms = 63 emu/g) than that of IO@PLA-TPGS (Ms = 25 
emu/g). Thus, both the IO@APTES and IO@PLA-TPGS nanoparticles could be used as 
a MRI T2 contrast agent and the IO@PLA-TPGS nanoparticles demonstrated promising 
contrast in vivo MR imaging. 
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Magnetite (Fe3O4) nanoparticles have been extensively used in magnetic separation [1-3], 
targeted drug delivery [4-8], as contrast agents magnetic resonance imaging (MRI) [9-
14], and hyperthermia for cancer treatment [14-20] due to their superparamagnetic 
behavior, relatively high saturation magnetization (MS), low toxicity, good chemical 
stability and excellent biocompatibility [1,11, 20-23]. The superparamagnetic behavior of 
the magnetite nanoparticles is highly dependent on their size, shape and crystallinity. 
Besides the superparamagnetic behaviors and biocompatibility, water suspensibility of 
the magnetite nanoparticles is another key factor for their successful use in biomedical 
applications [22-23]. The magnetite nanoparticles synthesized from the co-precipitation 
method are usually polydisperse in size and heavily aggregated, leading to a poor 
suspensibility in water.  Moreover, due to the limitation of the reaction temperature (<90 
oC), the magnetite nanoparticle obtained by this method are semi-crystalline (or semi-
amorphous) and weekly bonded with the surface capping agents and hence easily 
oxidized into maghemite structure resulting significant reduction of their MS value. 
Therefore, we have demonstrated (in Chapter 3) the synthesis of high quality (i.e. high 
crystallinity, monodispersed, high Ms and phase pure) magnetite nanoparticles by the 
high temperature (>200 oC) thermal decomposition of iron (III) acetylacetonate, Fe(acac)3 
in presence of oleic acid and/or oleylamine [24-27]. However, the obtained magnetite 
nanoparticles are hydrophobic in nature i.e. they are only suspendable in non-polar 
(organic) solvent which makes them inappropriate for biomedical applications. 
Therefore, further surface modifications on these hydrophobic nanoparticles are 
necessary to optimize their water suspensibility and biocompatibility for in vivo 
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applications. Various surface coating materials such as lipids [28-30], surfactants [31-33], 
polymers [34-37], silica [38-40] and Au [41-43] have been attempted to convert the 
hydrophobic magnetite nanoparticles to be hydrophilic.  
However, it has been noted that these surface modification procedures are usually very 
complicated, tedious and time consuming. Moreover, the surface modified magnetite 
nanoparticles are not preferred for long term applications due to the risk of dissociation of 
the coating layers, which leads to agglomeration of the nanoparticles. In addition, the use 
of toxic solvents and chemicals during the surface modifications may reduce the 
biocompatibility of the surface modified nanoparticles, although iron oxide itself is 
considered a biocompatible material. 
 
Thus, direct one pot synthesis of hydrophilic magnetite nanoparticles is extremely 
important to realize the full potential of these materials in biomedicine. Thus, several 
groups have further modified the thermal decomposition technique to synthesize 
hydrophilic magnetite nanoparticles by a single step method [44-47]. Thermolysis of 
Fe(acac)3 in liquid polyol is a very facile technique for synthesizing hydrophilic 
magnetite nanoparticles. An obvious advantage of this approach is that the polyol acts for 
a triple role as high-boiling solvent, reducing agent, and stabilizer to efficiently control 
the particle growth and prevent interparticle aggregation. Thus, no further reducing agent 
and surfactants are required, which made this process easy to scale-up for mass. In 
addition, the decomposition in a bio-friendly polyol solvent reduces the chance of 
lowering the biocompatibility of the magnetite nanoparticles during the organic synthesis.   
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In this work, we have selected four different liquid polyols (diethylene glycol (bp 245ºC), 
tri ethylene glycol (bp 280ºC), tetra ethylene glycol (bp 300ºC) and poly ethylene glycol 
(bp 330ºC) and tried to optimize the reaction parameter to synthesize the high quality 
hydrophilic magnetite (Fe3O4) nanoparticles directly by the thermolysis of iron (III) 
acetylacetonate in these polyol media. The structure and properties of the as-prepared 
nanoparticles are characterized to explore their surface structure, morphology and 
colloidal stability. The hydrophilic nanoparticles are further investigated to evaluate their 
potentialities for the magnetic hyperthermia therapy and MRI imaging applications. 
 
6.2. Experimental 
Absolute ethanol and ethylacetate were used without purification. Di(ethylene glycol) 
(DEG, 99%), Tri(ethylene glycol), (TEG, 99%),  Tetra(ethylene glycol) (TTEG, 99%) 
poly(ethylene glycol) (PEG, 99%)
 
and Iron(III) acetylacetonate (Fe(acac)3, 97%) were 
purchased from Sigma-Aldrich. 
 
6.2.1. Synthesis of Hydrophilic Magnetite Nanoparticles  
Hydrophilic magnetite nanoparticles were prepared by a modified thermal decomposition 
method [26]. The reaction temperature was kept above 200ºC because the decomposition 
temperature of Fe(acac)3 is 200ºC. The flow chart for the above synthesis procedure is 


























Figure 6.1. Flow chart for synthesis of hydrophilic magnetite nanoparticles by thermal 
decomposition. 
 
Typically, 2 mmol of Fe(acac)3 was dissolved in a 20 ml of polyol (DEG, TEG, TTEG or 
PEG) medium into a three necked round bottom flask (RBF) and magnetically stirred 
under a flow of argon. The resulting solution was dehydrated at 120°C for 1 h, and then 
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quickly heated to a certain temperature (up to refluxing temperature) and kept at this 
temperature for 2 h reaction time. The resulting black supernatant solution was cooled to 
room temperature by removing the heat source. A 20 mL of ethyl acetate was added into 
the supernatant solution and the precipitated particles were collected by centrifugation at 
10000 rpm. The precipitated particles were washed several times using 1:2 (v/v) ethanol 
and ethyl acetate mixture followed by centrifugation. Finally, one half of the washed 
particles were dispersed in deionized (DI) water to get a stable aqueous ferrofluid 
suspension and the other half were dried overnight (at 40°C) in oven to obtain dry 
magnetite nanoparticles for characterizations. Thus, all the samples prepared using 
different reaction temperature is given in Table 6.1.  
 
Table 6.1. Hydrophilic magnetite nanoparticles samples and corresponding results. 
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6.2.2. Characterization of Nanoparticles  
Size and morphology of the as-prepared nanoparticles were determined using 
transmission electron microscopy (TEM, JEOL 2010) while their crystal structure was 
identified by X-ray diffraction (XRD, Bruker D8 Advance). Surface charge and surface 
coating of the nanoparticles were recognized by Fourier transform infrared spectroscopy 
(FTIR, Varian 3100), X-ray photoelectron spectra (XPS, Kratos AXIS Ultra DLD), 
thermogravimetric analysis (TGA, DMSE SDTQ600) and Laser Doppler anemometry 
(Zetasizer Nano-ZS, Malvern Instruments). Magnetic properties of the nanoparticles were 
studied by the superconducting quantum interference device (SQUID, Quantum Design, 
MPMS XL) and vibrating sample magnetometer (VSM, Lakeshore, Model 665).  
Cell viability studies were performed by MTT assay using MCF-7 mammalian breast 
cancer cells and NIH-3T3 mouse fibroblast cell lines. In one experiment, the MCF-7 
cancer cells were incubated for 24 h with media containing polyol (DEG, TEG, TTEG 
and PEG) coated nanoparticles at concentrations ranging from 0.625 – 10 mg/ml Fe. In 
another experiment, the both NIH-3T3 and MCF-7 cells were incubated for 24 h with 
media containing TEG coated (IO@250, prepared at 250 ºC) and Resovist® nanoparticles 
(Schering AG, BERLIN, Table 6.2) at concentrations ranging from 7 to 57 µg of Fe/well. 
The cellular uptake studies were performed by both qualitatively and quantitatively on 
the MCF-7 cancer cells using the IO@250 and Resovist® nanoparticles. AC magnetic 
field induced heating ability of the as prepared magnetite nanoparticles was determined 
from the time-dependent calorimetric measurements while in vitro cellular hyperthermia 
measurements were performed on MCF-7 cancer cells using a RF generator operating at 
240 kHz. The T1, T2
 
and T2* relaxation times of aqueous suspensions of IO@250 and 
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Resovist® containing various Fe concentrations of 0.0066 – 0.4 mM were measured using 
1.5T MRI scanner and 9.4T MRI scanner. In vivo MRI studies were carried out on Wistar 
rats and tumor-bearing SCID mice using a Bruker 7T Clinscan MRI.  
 
Table 6.2. Physical Properties of commercial Resovist® 
Component Water based ferrofluid consisting carboxydextran-
coated superparamagnetic iron oxide (SPIO) particles 
Hydrodynamic diameter (nm) between 45 and 60 
Viscosity at 37 °C (mPa x s) 1.03 
Density at 37° C (g/ml) 1.057 
PH 5.5 - 7.0 
 
 
6.3. Results and Discussion 
The boiling point (i.e. refluxing temp) of DEG, TEG, TTEG and PEG are 245, 280, 310 
and 330ºC respectively. The Fe3O4 nanoparticles are prepared at maximum reaction 
temperature i.e. at the corresponding refluxing temperature of DEG, TEG, TTEG and 
PEG and then prepared lowering the reaction temperature to compare their properties 
with those prepared at the refluxing temperature.  
 
6.3.1. Crystal structure 
Figure 6.2 (a), (b), (c) and (d) are the XRD patterns of the P1, P3, P6 and P9 samples 
prepared in DEG, TEG, TTEG and PEG at their refluxing temperature at 2h reaction 
interval. Position of the diffraction peaks match well with the standard XRD data for bulk 
magnetite (JCPDS file No. 19-0629) which indicating the formation of Fe3O4 phase.  













Figure 6.2. XRD patterns of the magnetite nanoparticles prepared in different polyols at 
their refluxing temperature: (a) DEG (245ºC), (b) TEG (280ºC), (c) TTEG (310ºC) and 
(d) PEG (330ºC).  
 
6.3.2. Size and Morphology 
Figure 6.3 shows the TEM images of the P1, P3, P6 and P9 samples prepared in DEG, 
TEG, TTEG and PEG at their refluxing temperature at 2h reaction interval. The average 
sizes of the particles are about 7, 11 and 14 and 13 nm respectively. TEM images (Figure 
6.3) indicate that the particles prepared in DEG and TEG are very well dispersed 
however, those prepared in TTEG and PEG are very much agglomerated in an aqueous 
medium. It is to note that the refluxing temperature of PEG (330 ºC) and TTEG (300 ºC) 
are quite higher than that of DEG (245 ºC) and TEG (280 ºC). The reason for the 
agglomeration of the magnetite nanoparticles which are prepared in TTEG and PEG 
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could be due to the degradation of these polyols at very high refluxing temperature. Thus, 
interests arise to synthesize magnetite nanoparticles without any agglomeration lowering 












Figure 6.3. TEM images of the magnetite nanoparticles prepared in different polyols at 
their refluxing temperature: (a) DEG (245ºC), (b) TEG (280ºC), (c) TTEG (310ºC) and 
(d) PEG (330ºC).  
 
Figure 6.4 shows the TEM images of the P10 and P11 samples prepared in PEG lowering 
the reaction temperature to 250 and 220 ºC respectively. It can be seen that particle size 
has been reduced from 13 to 4 nm while decreasing the reaction temperature from 330 
to220 ºC (Table 6.1) however, the TEM images (Figure 6.4) indicate that the particles 
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prepared in PEG medium below the refluxing temperature particularly at 220 ºC (Figure 
6.4 B) are very well dispersed without any agglomeration. In a similar way, well 









Figure 6.4. TEM images of the magnetite nanoparticles prepared in PEG medium using 










Figure 6.5. TEM images of the magnetite nanoparticles prepared in TEG medium using 
reaction temperature A. 250 and B. 220oC. 
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The magnetite nanoparticles prepared in TEG at refluxing temperature (330oC) are well 
dispersed as shown in Figure 6.3 (b). However, to explore the temperature effect on the 
particle size and distribution, the magnetite nanoparticles have also been synthesized in 
TEG medium at lower reaction temperature 250oC and 220oC. Figure 6.5 shows the TEM 
images of the P4 and P5 samples prepared in TEG using the reaction temperature 250 and 
220 ºC respectively. The average size of the magnetite particles are found to be reduced 
from 11 to 5 nm when the reaction temperature reduced from 280oC to 220oC (Table 6.1).  
 
Figure 6.6 shows the particle size distribution histogram based on the TEM images of the 
magnetite nanoparticles prepared using different reaction temperatures. The Gaussian 
size distributions (Figure 6.6) which are 9-14 nm, 7-11 and 3-7 nm corresponding to the 
reaction temperature 280oC, 250oC and 220oC, respectively, indicates that size 
distribution of the particles prepared at 250oC and 220oC are narrower than those 









Figure 6.6. Particle size distribution histogram of the magnetite nanoparticles prepared in 
TEG using reaction temperature A. 280, B. 250 and C. 220oC.  
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In summary, magnetite nanoparticles prepared in DEG and TEG are well dispersed while 
those prepared in TTEG and PEG are agglomerated in aqueous suspension. Well 
dispersed particles are obtained in TTEG and PEG by lowering the reaction temperature 
below the refluxing temperature. The size of the particles reduces with the lowering of 
reaction temperature while the size distribution of particles is significantly improved by 
lowering the reaction temperature below the refluxing temperature.  
 
Figure 6.7 shows the photo of aqueous suspension of magnetite nanoparticles prepared in 
TEG at 280oC. No phase separation of particles was observed when the aqueous 
suspension was exposed to a permanent magnet. The flow like liquid (Figure 6.7) in 










Figure 6.7. Photo of aqueous ferrofluid (in presence of a permanent magnet) consisting 
of magnetite nanoparticles prepared in TEG at 280oC.  
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Figure 6.8 A shows the selected area electron diffraction (SAED) of magnetite 
nanoparticles prepared in TEG at 250oC (P4 samples). Similar SAED pattern were 
observed for all the samples (Table 6.1) prepared in polyol medium. The clear diffraction 
rings attributed to the (220), (311), (400), (422), (511) and (440) planes also indicates the 
magnetite (Fe3O4) phase of the nanoparticles prepared in polyol medium. Figure 6.8 B 
shows the HRTEM image of a single magnetite nanoparticle, in which the lattice fringes 
are clearly observed, indicating that the resultant magnetite nanoparticles are well 
crystallized. The lattice spacing of 2.53 A˚, which is the spacing between two (311) 











Figure 6.8. A. Selected area electron diffraction (SAED) pattern of P4 samples B. 
HRTEM of a single magnetite nanoparticle. 
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6.3.3. Identification of Surface Charge and Surface Coating 
Figure 6.9 shows FTIR spectra of the P1, P3, P6 and P9 samples prepared in different 
polyols (DEG, TEG, TTEG and PEG) at the refluxing temperature of corresponding 
polyols. Similar FTIR peaks are observed for all of the particles prepared in different 
polyols. The peaks at about 2962-2809, 1632, 1455, 1350; 1251 and 1063 cm-1 are due to 
C–H stretching, O–H stretching, C–H bending, C–O bending and O–H bending vibration 
respectively, which are attributed to adsorbed polyol molecules onto the particle surface 
[47]. The broad band between 3600 and 3000 cm−1 centered at about 3400 cm−1 are due 
to the O–H stretching vibration attributed for water and polyol molecules adsorbed to the 
particle surface. In addition, the absorption bands at about 585 cm−1 are due to Fe–O 
stretching vibration for the Fe3O4 nanoparticles. Thus, the FTIR spectra (Figure 6.9) 
indicate that surface of the as-prepared magnetite nanoparticles are adsorbed with polyol 
coating.  
 
The similar trend of FTIR spectra (Figure 6.10 and Figure 6.11) are observed for the 
particles prepared in TEG and PEG medium using different reaction temperature. The 
intensity of the FTIR peaks increases with the decrease of the reaction temperature which 



















Figure 6.9. FTIR spectra of the magnetite nanoparticles prepared in different polyols: (a) 











Figure 6.10. FTIR spectra of the magnetite nanoparticles prepared in TEG medium at (a) 
280 (i.e. refluxing temperature), (b) 250 and (c) 220oC. 














Figure 6.11. FTIR spectra of the magnetite nanoparticles prepared in PEG medium at (a) 
330 (i.e. refluxing temperature), (b) 250 and (c) 220oC. 
 
 
The adsorbed polyols coating on the particle surfaces are furthered recognized by TGA 
measurements. Figure 6.12 depicts TGA curves of the P1, P3, P6 and P9 samples 
prepared in different polyols medium (DEG, TEG, TTEG and PEG) at the refluxing 
temperature of corresponding polyol. TGA curves reveal a two-stage weight loss in the 
temperature ranges of 25 – 200ºC and 200–800ºC. The first slight amount of weight loss 
is due to the evaporation of physically adsorbed water and the second major weight loss 
is due to the decomposition of surface adsorbed polyol coating from the particle.  
 














Figure 6.12. TGA curves of the magnetite nanoparticles prepared in different polyols: (a) 
DEG, (b) TEG, (c) TTEG and (d) PEG at their refluxing temperature.  
 
The total amount of weight losses are estimated as 16.7, 11, 9.3 and 9.8 wt% for the 
particles prepared in DEG, TEG and TTEG medium respectively. It can be seen that the 
amount of surface adsorbed polyol coating for the particles prepared in DEG and TEG 
media is higher than those prepared in TTEG and PEG media which could be due to the 
degradation of TTEG and PEG molecules at very high refluxing temperature. The similar 
pattern of TGA curves (Figure 6.13 and Figure 6.14) are observed for the particles 
prepared in TEG and PEG medium using different reaction temperature. The amount of 
polyol coating increases with the lowering of the reaction temperature and this trend are 
found to same for all the polyol coated particles. 













Figure 6.13. TGA curves of the magnetite nanoparticles prepared in TEG medium at (a) 














Figure 6.14. TGA curves of the magnetite nanoparticles prepared in PEG medium at (a) 
220, (b) 250 and (c) 330oC (i.e. refluxing temperature). 
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Thus, the FTIR and TGA analysis indicate that surface of the as-prepared magnetite 
nanoparticles are adsorbed with polyol coating and hence, they are suspendable in an 
aqueous medium due to the steric repulsions of the surface adsorbed polyol molecules.  
 
 
Figure 6.15 shows the zeta potential distribution plots of the P1, P3, P6 and P9 samples 






Figure 6.15. Zeta potential distribution plots of the magnetite nanoparticles prepared in 
different polyols: (a) DEG, (b) TEG, (c) TTEG and (d) PEG at their refluxing 
temperature.  
 
The positive zeta potential values indicate that surfaces of the polyol coated magnetite 
nanoparticles are adsorbed with positively charged ions which could be H+ ions produced 
due to the polarization of the polyol molecules (R-OH⇔R-O- + H+, where R≡(CH2-CH2-
O)x-H) at elevated reaction temperature [26]. The R-O- part of polyol molecules 
coordinates with Fe2+/Fe3+ of the Fe3O4 nanoparticle (which is confirmed by FTIR, XPS 
and TGA) while the H+ ions associates with the particles along with the R-O- and as a 
consequence surface of the nanoparticles become positively charged. Thus, adsorbed R-
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O- the is responsible for the steric repulsion of the particles while the associated 
positively charged H+ ions provide strong electrostatic repulsion between the particles to 








Figure 6.16. Steric and electrostatic interactions between the magnetite
 
nanoparticles in 
an aqueous suspension.   
 
Zeta potential values of all the samples prepared in different polyol medium using 
different reaction temperature are given in Table 6.1. Particles with zeta potentials more 
positive than +30 mV or more negative than -30 mV are normally considered stable. It 
can be seen that the zeta values of the particles prepared in DEG and TEG are above +30 
mV always however, the zeta values are +6 and + 17 mV for the TTEG and PEG coated 
particles prepared at their refluxing temperature. Thus, the measured zeta potential values 
indicate that colloidal stability of DEG and TEG coated magnetite particles are very good 
compare to the TTEG and PEG coated magnetite particles which corroborate with the 
previous TEM results. The zeta values are found to be increased with the decrease of the 
reaction temperature for all the polyol coated particles. This could be due to the increase 
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of the amount of adsorbed polyol coating with the decreasing of reaction temperature as 
confirmed by FTIR and TGA measurements. Thus, the colloidal stability of the TTEG 
and PEG coated particles are significantly improved (to +36 and 30 mV respectively) by 
reducing the reaction temperature to 220 °C.   
 
Figure 6.17 shows wide scan XPS spectra of the P4 samples which are prepared in TEG at 
250oC (leveled as IO@250). Inset (i) and (ii) of Figure 6.17 are the corresponding 
deconvoluted O(1s) and C(1s) spectra. The O(1s) peaks at 531.6 and 533.3 eV are due to 
O-H and C-O bond which arise from the adsorbed water and TEG coating, respectively 
[47]. The C(1s) peaks at 285.5 and 288 eV are due to C–C/C–H and C–O–C bond, 
respectively arise from the chemically adsorbed TEG coating to the particle surface. In 
addition, the Fe(3p3/2), O(1s), Fe(2p3/2) and Fe(2p1/2) peaks at about 55, 530.3, 710 and 
724 eV are due to Fe–O bond of the Fe3O4 nanoparticles. The ratio of the Fe2+ : Fe3+ is 
estimated as 1:2 from the intensity of the Fe(2p3/2) and Fe(2p1/2) peaks indicating that the 
particles consists of pure Fe3O4 phase which also corroborate XRD results (Figure 6.2). 
 
Figure 6.18 shows the zeta potential vs pH plot for the P4 samples which are prepared in 
TEG at 250oC (leveled as IO@250) suggesting that the isoelectric point (IEP) of the 
IO@250 nanoparticle is approximately pH 5.9. The colloid stability studies of the 
nanoparticles were also performed using dynamic light scattering measurements (DLS). 
Hydrodynamic diameter of the IO@250 nanoparticles suspended in water and cell culture 
media were initially (at 0 h) measured as 80 and 110 nm respectively. The hydrodynamic 
diameter was remained around 80 nm in water up to 30 hours, indicating the good 
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colloidal stability of the IO@250 nanoparticles in water. On the other hand, the 
hydrodynamic diameter was increased to 180 nm in cell culture media after 30 hours. 
This could be due to the replacement of TEG coating with ionic groups [48] and the 
subsequent particle aggregation may be one of the reasons for this size increase in the cell 
culture media. Although the hydrodynamic size of the particles in the cell culture medium 
was increased, however good colloidal suspension of the IO@250 nanoparticles was 
observed even after 30 hours.  
In summary, the aqueous stability of as-prepared hydrophilic magnetite nanoparticles 
fully depends on inter-particle steric and electrostatic interactions arising from the surface 
adsorbed polyol coating and positively charged H+ ions. The particles prepared in DEG 
and TEG are quite stable in an aqueous medium due to large amount of surface adsorbed 
polyol coating and positive charges. However, the particles prepared in TTEG and PEG 
are not stable in aqueous suspension due to less amount of polyol coating and charges 
and thereby less inter-particle interactions. The stability of the aqueous suspension of 
TTEG and PEG coated particles can be improved by reducing the reaction temperature to 
220 ºC. Thus, the aqueous suspension of the PEG coated particles prepared at the 
refluxing temperature is not good.  However, the aqueous stability of the PEG coated 
particles prepared at 220ºC are good due to the increase of amount of surface-adsorbed 
polyol coating (27 wt%) and associated positive charges (+30 mV). The aqueous 
suspension of the TEG coated IO@250 nanoparticles are highly stable at the biological 
pH = 7.4 (- 43mV).  
 













Figure 6.12. Wide scan XPS spectra of the of the p4 samples prepared in TEG at 250oC. 












Figure 6.18.  Zeta potential vs pH plot of the p4 samples prepared in TEG at 250oC. 
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6.3.4. Magnetic Properties 
Figure 6.19 shows the magnetization (M-H) curves of the P1, P3, P6 and P9 samples 
prepared in DEG, TEG, TTEG and PEG at their refluxing temperature. Figure 6.20 depict 
the M-H curves of the PEG coated particles prepared using different reaction 
temperature. The MS values of all the samples prepared under different reaction 
conditions are given in Table 6.1. The saturation magnetizations (Ms) of the TEG coated 
of magnetite nanoparticles i.e. IO@220, IO@250 and IO@280 nanoparticles (prepared at 
reaction temperature 220, 250 and 280°C respectively) were measured as 47, 57 and 65 
emu/g, respectively. TGA results showed the total amount of weight loss of IO@220, 
IO@250 and IO@280 nanoparticles as 23.5, 18.8, and 11 wt% (Figure 6.14), suggesting 
that the amount of magnetite (Fe3O4) core content of the corresponding TEG coated 
IO@220, IO@250 and IO@280 nanoparticles were 76.5, 81.2 and 89 wt% respectively. 
The MS values of IO@220, IO@250 and IO@280 nanoparticles were estimated as 62, 70 
and 73 emu/g considering only the magnetic core of the nanoparticles (Table 6.1). It can 
be seen that the MS value decreases with decrease of the reaction temperature which 
could be due to the decrease of the particle size (Table 6.1) or the crystallinity while 
reducing the reaction temperature. The zero coercivity and zero remanance on the M-H 
curves indicate that the polyol coated hydrophilic magnetite nanoparticles are 
















Figure 6.19. M-H curves of the magnetite nanoparticles prepared in different polyols: (a) 












Figure 6.20. M-H curves of the magnetite nanoparticles prepared in PEG medium at (a) 
330 (i.e. refluxing temperature), (b) 250 and (c) 220oC. 
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The zero-field cooled/field cooled (ZFC-FC) magnetization of the polyol coated 
magnetite nanoparticles was by SQUID under an applied field of 100 Oe. Figure 6.21 
shows the temperature dependence of the ZFC-FC magnetization of the magnetite 
nanoparticles prepared in TEG at 250oC (P4 samples). The similar feature of ZFC-FC 
curves were observed for all the samples prepared in different polyol medium (Table 
6.1). The feature of the ZFC-FC curves indicates that the polyol coated magnetite 
nanoparticles are of SPM in nature [47].  Inset of figure 6.21 shows the M-H curves of 
the P4 samples measure by SQUIS at 300 and 10 K. The feature of the M-H curves 
indicate that the particles are superparamagnetic at the room temperature but 











Figure 6.21. ZFC–FC magnetization curves of the magnetite nanoparticles prepared in 
TEG at 250 ºC. Inset is M-H curves at 10 and 300K. 
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6.3.5. In Vitro Cytotoxicity Studies 
Figure 6.22 shows the cytotoxicity profile of the different polyol (DEG, TEG, TTEG and 
PEG) coated magnetite nanoparticles using the MCF-7 breast cancer cells. It can be seen 
that MCF-7 cells do not show any cytotoxicity with the magnetite nanoparticles in the 
range of 0.625 – 10 mg Fe/ml concentrations. Thus, the polyol coated magnetite 
nanoparticles are biocompatible up to the iron concentration of 10 mg/ml with MCF-7 




















Figure 6.22. Cytotoxicity profile of the polyol (DEG, TEG, TTEG and PEG) coated 
nanoparticles on MCF-7 breast cancer cells.  
Figure 6.23 A and B represent the percentage cell viability of the IO@250 nanoparticles 
in comparison with Resovist® for NIH-3T3 fibroblast cells and MCF-7 breast cancer cell 
line respectively. It can be seen from the graph that the IO@250 nanoparticles showed 
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comparable cytotoxity with the commercial Resovist® nanoparticles at respective 
concentration of 7-57 µg Fe/well. From the cell viability studies, differences between the 
two samples were not significant as seen from their respective standard deviation. The 
samples did not show significant change of viability as compared to the control cells 
(untreated cell), where the cell viability was considered as 100%. Therefore, it can be 
inferred from the data that both the samples are cyto-compatible up to the concentration 




Figure 6.23. Cell toxicity study of IO@250 and Resovist® nanoparticles using A. NIH-
3T3 fibroblast cells B. MCF-7 breast cancer cell line.  
 
6.3.6. In Vitro Cellular Uptake Studies   
Cellular uptake study was performed by incubating IO@250 nanoparticles with MCF-7 
breast cancer cell line. Figure 6.24 A shows the TEM image of the MCF-7 cell uptaken 
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IO@250 nanoparticles and Figure 6.24 B depicts the cross sectional view of the IO@250 




Figure 6.24 A. TEM image of the IO@250 uptaken MCF-7 breast cancer cell. B. Cross 
sectional view of the IO@250 uptaken MCF-7 cell. C. Magnified view of the vesicle 
consisting IO@250 nanoparticles inside. Inset shows the IO@250 nanoparticles confined 
in the vesicles. D. Quantitative cellular uptake results using the MCF-7 cancer cell line. 
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It can be seen that the IO@250 nanoparticles get attached to the cell surface and then 
trapped into the cell by endocytosis and finally appeared within the cytoplasm. Figure 
6.24 C shows that a large amount of IO@250 nanoparticles were confined in the vesicles. 
Since the particles are positively charged (confirmed by zeta potential measurements in 
acidic condition) and the cell membrane are negatively charged, thus the IO nanoparticles 
are strongly attracted to the cell membrane and there by large amount of nanoparticles are 
adhered to cell surface which could possibly be a reason for higher cell uptake. Figure 
6.24 D depicts the quantitative cell uptake results of the IO@250 nanoparticles in 
comparison with the Resovist® nanoparticles. It can be seen that the cell uptake efficiency 
of the IO@250 nanoparticles are several folds higher than that for Resovist® 
nanoparticles at the incubation concentrations of 4-14 µg/well Fe.  
 
6.3.7. Magnetic Hyperthermia Studies 
Figure 6.25 shows the time dependent temperature rise of 1 ml aqueous suspension of the 
TEG coated magnetite nanoparticles (IO@250) with the iron concentrations of 0.5, 1, 2.5, 
5 and 10 mg/ml upon exposure to 89 kA/m AC magnetic field at 240 kHz frequency. The 
time required to raise the temperature up to 42ºC for the IO@250 nanoparticles with 
different iron concentration (0.5-10 mg/ml) are given in Table 6.3. The results indicate 
that the rate of temperature rise systematically increases with the iron concentration of 
the IO@250 nanoparticles (Figure 6.26). The heating of the superparamagnetic IO@250 
nanoparticles under AC magnetic field could be due to Neel and Brownian loss which 
arise from rotation of the magnetization vector and the nanoparticles itself, respectively 
[17]. Inset of Figure 6.25 depicts the field dependent SAR values of the IO@250 
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nanoparticles with 1 mg/ml iron concentration at 240 kHz frequency, indicating that the 
SAR values varies nearly with H2 as reported in literature  [49-50].  
The time dependent temperature rise for the nanoparticles prepared in different polyol 
media at the refluxing temperature are also performed at 240 kHz frequency using 89 
kA/m AC magnetic field. Figure 6.27 shows the time dependent temperature rise of 1 ml 
aqueous suspension of different polyol (DEG, TEG, TTEG and PEG) coated 
nanoparticles with the iron (Fe) concentration of 1 mg/ml. It can be seen that the required 
time to raise the temperature to 42 ºC is 12.3, 10.1, 8.9 and 9.6 minutes for the DEG 
(7nm), TEG (11nm), TETEG (14nm) and PEG (13nm) coated particles respectively 
which indicates that heating rate of the bigger size particles are faster than that of the 
smaller size particles. This could be due to the higher magnetization of the bigger size 
particles.  
Table 6.3. The time required to raise the temperature up to 42 ºC for the IO@250 and 
IO@APTES nanoparticles with different Fe concentrations. 
Sample Fe Concentration 
(mg/ml) 

































Figure 6.25. Time dependent temperature rise of 1 ml IO@250 sample with different 







Figure 6.26. The time required time to raise the temperature up to 42 ºC for the IO@250 
nanoparticles with different Fe concentrations.  











Figure 6.27. Time dependent temperature rise of 1 ml aqueous suspension of the 
nanoparticles prepared in different polyols: (a) DEG, (b) TEG, (c) TTEG and (d) PEG.  
 
6.3.8. In vitro Hyperthermia 
Figure 6.28 A shows the in vitro cytotoxic effect on MCF-7 breast cancer cells treated 
with magnetic hyperthermia using the IO@250 nanoparticles (1 mg/ml of Fe 
concentration) upon exposure to 89 kA/m AC field at 240 kHZ frequency. As a 
comparison, the cancer cells were also exposed to only magnetic field i.e. 89 kA/m AC 
(without adding any IO@250 nanoparticles) and only IO@250 nanoparticles (without 
exposing to the magnetic field) with 1mg/ml of Fe concentration.  






Figure 6.28 A. Cell viability plot shows the cytotoxic effect on MCF-7 breast cancer 
cells treated with magnetic hyperthermia (~ 45ºC), treated with IO@250 only, and treated 
with magnetic field only in comparison with the control cells. B., C. and D are optical 
microscope images of MCF-7 breast cancer cells treated with IO@250 only, magnetic 
field only and treated with magnetic hyperthermia. 
Results (Figure 6.28 A) show that the magnetic hyperthermia at 45°C caused 60% cell 
death, while cell viability in the case of exposure to only the magnetic field or only 
IO@250  nanoparticles were comparable to that of the control. Thus, it was confirmed 
that about 60% loss of MCF-7 cancer cell viability was due to the magnetic hyperthermia 
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treatment. Figure 6.28 B, C and D show optical microscope images of MCF-7 breast 
cancer cells treated with only IO@250 (without magnetic field), only AC magnetic field 
(without IO@250), and with magnetic hyperthermia (using both IO@250 and magnetic 
field). It was observed that the cells treated with magnetic hyperthermia, lost their ability 
to attach to the surface and fail to grow (as shown in Figure 6.28 D) while the cells 
treated with only IO@250 (as shown in Figure 6.28 B) and the cells treated with only 
magnetic field (as shown in Figure 6.28 C) are attached to the surface which clearly 
indicates that the losses of cell viability (also as shown by the MTT assay) are due to the 
magnetic hyperthermia treatment using the IO@250 nanoparticles.  
Although our in vitro hyperthermia results show promising results, the issues 
which need to be taken care for successful in vivo magnetic hyperthermia applications 
using the magnetic (IO@250 and IO@14) nanoparticles are as follows: 
1) Direct injection of magnetic nanoparticles (MNPs) locally in tumor to have 
sufficient amount (~ 1-2 mg) of MNPs in the tumor area which would enable 
heating of tumor substantially up to 42-46oC under AC magnetic field.  
2) Another option could be administration of MNPs in the tumor feeding blood 
vessel or intravenously where accumulation of MNPs in the tumor area can be 
enhanced by an external permanent magnet using principle of magnetic drug 
targeting (MDT) concept [51]. Further, surface functionalization of MNPs 
with a biological targeting ligand such as folate receptor or monoclonal 
antibodies could be helpful for accumulation of MNPs with substantially 
higher amount in tumor area under the influence of permanent magnet [52]. 
                              Chapter 6: One Step Synthesis of Hydrophilic Magnetite Nanoparticles 
200 
 
Also, localized exposure of AC magnetic field needs to be done to avoid 
heating of the undesired organs such as liver, lung, spleen, where the MNPs 
may be extravassated following intravenous administration and thus an 
optimized design of coil with AC magnetic field generator is required for 
successful application of magnetic hyperthermia in vivo, particularly in 
human patient [53].  
 
6.3.9. MRI Relaxivity Studies 
Figure 6.29 shows the transverse relaxation rates (1/T2
 
and 1/T2* at 1.5 T) vs Fe 
concentration of IO@250 and Resovist® nanoparticles. The corresponding relaxivities 
(r1, r2, and r2* at 1.5 T) were calculated (Table 6.4). It is clear that the r2 and r2* 
relaxivities of IO@250 are greater than those of Resovist®. In particular, the r2* 
relaxivities of IO@250 reached 617.5s-1mM-1, which is much higher than that of 
Resovist®, suggesting IO@250 nanoparticles are very promising for T2 contrast agent 
application. The higher r2* of IO@250 nanoparticles could be due to their fine size and 
the presence of TEG coating onto the nanoparticle surface. Thus the MRI relaxivities of 
the nanoparticles depend on the coating materials and size of the nanoparticles. Figure 
6.30 shows the transverse relaxation rates (1/T2
 
and 1/T2*) of the IO@250 nanoparticles 
at 9.4 T. The corresponding relaxivities (r1, r2, and r2*) values are estimated as 0.589, 
205.6 and 309.2, respectively which further indicates that the IO@250 nanoparticles are 
very promising for T2 MRI contrast agent.  






Figure 6.29. Transverse relaxation rates (1/T2
 
and 1/T2*) vs Fe concentration of A. 








Figure 6.30. Transverse relaxation rates (1/T2
 
and 1/T2*) vs Fe concentration of IO@250 
nanoparticles measured at 9.4 T. 
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Table 6.4. Relaxivity of IO@250 and Resovist® nanoparticles. 
Samples Relaxivity (mM-1s-1) 
r1 r2 r2* 
Resovist® (at 1.5 T) 11.3 226.3 245.2 
IO@250 (at 1.5 T) 9.5 336.5 617.5 
IO@250 (at 9.4 T) 0.589 205.6 309.2 
 
8.3.10. In Vivo MRI Imaging 
Figure 6.31 A, B, C and D show the coronal images of the rat liver and kidney before 
injection (A and B) and after injection of the IO@250 nanoparticles (C and D). Figure 
6.31 E, F, G and H show the coronal images of the rat liver and kidney before injection 
(E and F) and after injection of the Resovist® nanoparticles (G and H).  Signal reduction 
was observed in liver and kidney for both the nanoparticles. 
Signal change from the MRI over the first half an hour after administration of the 
nanoparticles was studied to understand the kinetics of the contrast agent. Figure 6.32 
shows the % normalized contrast from the liver and kidney. The % normalized contrast 
of IO@250 nanoparticles in the liver was smaller than that of the Resovist® nanoparticles. 
It can be seen that the Resovist® nanoparticles accumulated rapidly in liver and saturated 
there soon within a few minutes after the injection while IO@250 nanoparticles 
accumulated slowly within about 15 min. In the kidney, there was a transient increase of 
Resovist® nanoparticles but did not accumulate there. On the contrary, IO@250 
nanoparticles started to accumulate in the kidney about 10 min after injection, suggesting 
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that part of them might have been excreted through the kidney. These also indicated that 
IO@250 nanoparticles had different biodistribution behavior than Resovist® 
nanoparticles, which could be due to their relatively smaller size and surface chemistry of 
the coating. The slower accumulation of IO@250 nanoparticles in the liver and kidney 
also implied potentially longer blood circulation time and slower excretion by the 
reticuloendothelial system (RES). It has already been reported that the polyol coated IOs 
(ClariscanTM, PEG-IO, NC100150) could be used as blood pool contrast agent due to 
their long circulation time [54]. The long circulation time could be used to facilitate the 
delivery of the nanoparticles to the site of interest using a localized magnetic field 
gradient.  
 
Figure 6.31. Top (A and C) and bottom (B and D) shows the coronal image of the rat 
liver and kidney before (left) and after (right) injection the IO@250 nanoparticles 
respectively. Top (E and G) and bottom (F and H) shows the coronal image of the rat 
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liver and kidney before (left) and after (right) injection of the Resovist® nanoparticles 









Figure 6.32. The % SNR change time courses for (a) IO@250 in liver; (b) IO@250 in 
kidney; (c) Resovist® in liver; (d) Resovist® in kidney (the solid-lines as a guide to eyes). 
 
We further exploited the IO@250 for the application for in vivo tumor imaging. Figure 
6.33 shows the signal intensity normalized by the signal in the saline phantom at different 
time points in tumor (red line), muscles (blue line) and liver (green line). It can be seen 
that the signal reduction for the liver and tumor is higher as compared to that for the 
muscles.  Figure 6.34 shows the axial image of tumor before and after 10.5 hours of 
injection of IO@250 nanoparticles in tumor induced on the right flank of the SCID mice. 
IO@250 nanoparticles have the tendencies to accumulate at tumor sites by a means of 
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passive targeting called enhanced permeation and retention (EPR), as a result of leaky 
vasculature of the tumor site due to ill formed blood vessels (angiogenesis). From the 
signal trend and from the heterogeneity which was developed in the tumor site after 10.5 
hours, it can be concluded that IO@250 nanoparticles accumulate at the tumor site 
through passive targeting. The long retention in the tumor indicates that the IO@250 
nanoparticles have high affinity towards tumor and thus could be applicable as tumor 
sensitive contrast agent as well as for hyperthermia therapy. 
 
In the present study, the IO@250 nanoparticles have been demonstrated to be useful for 
in vitro magnetic hyperthermia as well as in vitro and in vivo magnetic resonance 
imaging applications. Thus simultaneous applications of magnetic hyperthermia and 
magnetic resonance imaging of tumor using the IO@250 nanoparticles may be realized. 
However, the major difficulty which may be confronted is to achieve substantial amount 
of IO@250 nanoparticles (in mg) in the tumor area. In this regard, efficacy of magnetic 
field guided targeting of IO@250 nanoparticles equipped with targeting ligands in vivo 
















Figure 6.33. The normalized signal change at different time points in tumor tissue (red 








Figure 6.34. Axial image of tumor (pointed by solid arrow) before (a) and after 10.5 
hours (b) of the injection of IO@250 nanoparticles in the tumor mouse. 




The stability of the aqueous suspension of the magnetite nanoparticles prepared in polyol 
medium depends on the the amount of polyol coating attached on to their surface. The 
PEG and TTEG coated particles prepared at the refluxing temperature (300 and 330 °C 
respectively) are agglomerated as compared to the DEG and TEG coated particles which 
are well dispersed in an aqueous medium. However, the water solubility of the PEG and 
TTEG coated particles can be significantly improved by reducing the reaction 
temperature. 
 
The reaction temperature has been optimized to 250 °C to synthesize highly water soluble 
well dispersed superparamagnetic IO@250 nanoparticles. In vitro studies demonstrated 
that the IO@250 nanoparticles have high cellular uptake and low cytotoxicity to the 
biological cells. The IO@250 nanoparticles demonstrated high r2* relaxivity value 
(617.5s-1mM-1 Fe) as compared to commercial Resovist® nanoparticles (245.2 s-1mM-1) 
which could be ascribed to their fine size and surface charge due to polyol coating onto 
their surface. In vivo MRI imaging studies of the IO@250 nanoparticles have 
demonstrated very promising contrast in vivo tumor imaging. In vitro hyperthermia 
studies have confirmed that the IO@250 nanoparticles are able to produce significant 
temperature rise upon exposure to AC magnetic field (SAR~135 Watt/g) and thus, 60% 
loss of cancer cell viability was observed due to the magnetic hyperthermia treatment. It 
can thus be concluded that the IO@250 particles are very promising candidate for clinical 
MRI imaging as well as for cancer hyperthermia therapy. 
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Superparamagnetic iron oxide (particularly magnetite (Fe3O4) and maghemite (γ-Fe2O3) 
nanoparticles have been studied extensively for the biomedical applications such as 
magnetic separation [1-3], drug delivery [4-6], hyperthermia treatment for tumors [7-9] 
and contrast agents in magnetic resonance imaging (MRI) [10-12]. Recently, many 
groups have also found that the superparamagnetic iron oxide nanoclusters are very 
promising in biological applications [13-16]. In all these studies, the iron oxide 
nanoclusters have been synthesized using the traditional approach which relied on the 
aqueous coprecipitation of ferrous and ferric salts using a base such as ammonium 
hydroxide or sodium hydroxide and then stabilized them with polymer [13], oleic acid 
[14] and citrate ligands [15-16]. The main problem in this approach is the uncontrolled 
aggregation of particles which eventually leads to polydisperse size of the nanoclusters 
and secondly, the obtained nanoclusters are semi-amorphous in nature due to the lower 
reaction temperature (below 80ºC) which eventually leads to very low saturation 
magnetization (Ms) (below 40 emu/g) of the nanoclusters. Thus, the synthesis of stable 
colloidal magnetic nanoclusters with high magnetization is very challenging. To date, the 
thermal decomposition method is very promising technique to fabricate high-quality 
monodisperse superparamagnetic iron oxide nanoparticles with high Ms (above 60 
emu/g) [17–20]. Typically, this method involves decomposition of Iron (III) 
acetylacetonate, Fe(acac)3 in a high-boiling temperature solvent in presence of stabilizing 
surfactants and reducing agent such as oleic acid and oleylamine. However, the obtained 
magnetite nanoparticles are organic soluble which makes them inappropriate for bio-
medical applications. Therefore, many groups have further developed the thermal 
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decomposition method to directly synthesize water-soluble magnetic nanoparticles [21-
23]. We have also studied (Chapter 6) and reported the synthesis of water stable 
superparamagnetic magnetite nanoparticles by the high temperature decomposition of Fe 
(acac)3 in TEG medium in which the TEG has been used for a triple role as high-boiling 
solvent, reducing agent and stabilizer to efficiently control the particle growth and 
prevent interparticle aggregation [24-25]. Here, we have tried to fabricate magnetite 
nanoclusters by the thermolysis of Fe (acac)3 either completely replacing TEG with other 
more polar solvent or adding more polar solvent with TEG. The ratios and reaction time 
interval have been systematically varied to optimize for obtaining well dispersed 
magnetite nanoclusters. The idea behind the replacing with or addition of more solvent 
with the TEG is to reduce the stabilizing effect of the TEG so that clustering of 
nanoparticles happens either to reduce their surface energy or due to the strong inter 
particle attractive magnetic force. The structure, morphology, magnetic properties, MRI 
imaging and magnetic hyperthermia studies of the as-prepared nanoparticles have been 
investigated to evaluate their potentiality in magnetic hyperthermia and MRI imaging 
applications. We hypothesize that due to clustering of multiple magnetic nanoparticles 
into single magnetic nanocluster, saturation magnetization (Ms) would be increased and 
thereby their heating efficiency under alternating current (AC) magnetic field and 
contrasting effect in MRI would be maximized and thus the magnetic nanoclusters would 
be better candidate for both magnetic hyperthermia and MRI applications as compared to 
their individual magnetic nanoparticles form.   
 
 




Ethanol amine (EA), diethanol amine (DEA), triethanol amine (TEA), DEG, TEG) and 
Fe(acac)3 were purchased from Sigma-Aldrich. 
 
7.2.1. Synthesis of cluster particles  
Magnetite nanoparticles were prepared by thermolysis of Fe(acac)3 either in a pure 
solvent or in a solvent mixture. Typically, 2 mmol of Fe(acac)3 was dissolved in a 20 ml 
of solvent or in a solvent mixture (Table 7.1). The resulting mixture solution was 
magnetically stirred under a continuous flow of argon. The solution was dehydrated at 
120°C for 1 h, and then quickly heated to reflux and maintained at the refluxing 
temperature under the argon flow for different time intervals (Table 6.1). Thereafter, the 
black solution was cooled to room temperature and the nanoparticles were precipitated by 
addition of ethyl acetate. Finally, the obtained magnetite nanoparticles were washed 
several times with the ethanol and ethyl acetate (1:2 v/v) mixture followed by 
centrifugation. All the samples prepared using different reaction conditions are given in 
Table 7.1. 
7.2.2. Characterization of Nanoparticles  
Structure of the as-prepared magnetite nanoparticles was identified by XRD, FTIR, XPS 
and TGA. Morphology of the particles was determined using TEM. Magnetic properties 
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Reaction time Pure Solvent / Solvent 
Mixture (v/v ratio) 
A reflux (180ºC) 1/2 and 16h EA 
B reflux (220ºC) 1/2, 1, and 2h DEA 
C reflux (245ºC) 1/2, 1, and 2h TEA (0:1 TEG:TEA) 
D reflux (245ºC) 1/2 and 2h 2:1 and 1:1 DEG:DEA 
E reflux (270ºC) 1/2, 1, 2 and 4h 4:1 TEG:TEA 
F reflux (250ºC) 1/2, 1, 2 and 4h 2:1 TEG:TEA 
G reflux (250ºC) 1/2, 1, 2 and 4h 1:1 TEG:TEA 
H reflux (250ºC) 1/2, 1, 2 and 4h 1:2 TEG:TEA 
I reflux (245ºC) 1/2, 1, 2 and 4h 1:4 TEG:TEA 
 
Cell viability studies were performed by MTT assay using MCF-7 mammalian breast 
cancer cells. For this, the MCF-7 cancer cells were incubated for 24 h with media 
containing TEA coated magnetite nanoclusters (IO@14 which is prepared at 1h using 1:4 
TEG:TEA ratio) at concentrations ranging from 0.625 – 10 mg/ml Fe. AC magnetic field 
induced heating ability of the magnetite nanoclusters was determined from the time-
dependent calorimetric measurements using a RF generator operating at 240 and ~400 
kHz. In vitro cellular hyperthermia measurements were performed on MCF-7 cancer cells 
using a RF generator operating at 240 kHz. The T1, T2
 
and T2* relaxation times of 
aqueous suspensions of IO@14 nanoclusters containing various Fe concentrations of 
0.0066 – 0.15 mM were measured using 9.4T MRI scanner. In vivo MRI studies were 
carried out on tumor-bearing SCID mice using a Bruker 7T Clinscan MRI.  
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7.3. Results and Discussion  
7.3.1. Morphology 
Figure 7.1, 7.2 and 7.3 show the TEM images of the nanoparticles prepared in EA, DEA 
and TEA respectively using different reaction time intervals. It can be seen that the 
magnetite nanoparticles prepared in ethanol amine (EA) are isolated single particle even 
after 16 hours of reaction time interval (Figure 7.1 A2). However, the particles prepared 
in diethanol amine (DEA) and triethanol amine (TEA) are aggregated with each other to 
form dumbbell and flower shaped magnetite nanoclusters at shorter reaction time (as 
shown in Figure 7.2 B1 and Figure 7.3 C1). These dumbbell and flower shaped magnetite 
nanoclusters are gradually liked with each other to form chain like structures while 
prolonging the reaction time (as shown in Figure 7.2 B3 and Figure 7.3 C3). Figure 7.4 









Figure 7.1. TEM images of the magnetite nanoparticles prepared in EA using the 
reaction time of A1. 30 min and A2. 16h. 
 
















Figure 7.2. TEM images of the magnetite nanoparticles prepared in DEA using the 
reaction time of B1. 30 min, B2. 1h, and B3 ; B4. 2h. Inset of B3 shows the HRTEM of 




















Figure 7.3. TEM images of the magnetite nanoparticles prepared in TEA using the 
reaction time of C1. 30 min, C2. 1h, and C3 ; C4. 2h. Inset of C4 shows the HRTEM of 













Figure 7.4. Chemical structure of ethanol amine (EA), diethanolamine (DEA) and 
triethanol amine (TEA) molecules. 
 
The magnetite (Fe3O4) nanoparticles formed by thermal decomposition of Fe(acac)3 are 
immediately coated with EA or DEA or TEA molecules through the reactive OH groups 
(Figure 7.5). For this, OH group(s) of EA/DEA/TEA molecules easily donates two lone 
pairs to coordinate with the Fe ions of the Fe3O4 nanoparticles. The DEA and TEA coated 
particles are further interconnected with each other through the other end OH groups to 
develop dumbbell shaped and flower shaped particles. Here, the DEA and TEA 
molecules play the key role to interconnect the magnetite nanoparticles into dumbbell 
(Figure 7.6) and flower structure respectively (Figure 7.7). The magnetite nanoparticles 
which are initially nucleated by the decomposition of Fe(acac)3  (Figure 7.5) comes close 
to each other due to magnetic dipole-dipole interactions and thus favor the interaction of 
the multiple hydroxyl (-OH) groups of the surface adsorbed DEA or TEA molecules 
leading to condensation of the nanoparticles into a dumbbell (Figure 7.6) or flower 
(Figure 7.7) like structure followed by removal of water.  
 
 












Figure 7.5. Schematic representations of EA, DEA and TEA coated Fe3O4 nanoparticles 
which are formed by thermal decomposition of Fe(acac)3 in EA, DEA and TEA at the 





Figure 7.6. Mechanism of formation of dumbbell shaped magnetite particles through 
condensation of hydroxyl groups of DEA molecules adsorbed to surface of the spherical 
nanoparticles which are initially formed by thermal decomposition of Fe(acac)3 in DEA. 











Figure 7.7. Mechanism of formation of MNF particles through condensation of hydroxyl 
(OH) groups of TEA molecules adsorbed to surface of the spherical nanoparticles which 
are initially formed by thermal decomposition of Fe(acac)3 in TEA.  
 
The dumbbell and flower shaped nanoparticles are rapidly interconnected with each other 
to form long chain structure (as shown in Figure 7.2 B3 and Figure 7.3 C3). Therefore, 
we have added DEG and TEG with the DEA and TEA separately to develop uniformly 
dispersed dumbbell or flower shaped magnetite nanoparticles. Figure 7.8 show the TEM 
images of the nanoparticles prepared using different ratio of DEG:DEA (v/v) at different 
reaction time intervals. It can be seen that uniformly dispersed nanoparticles can be 
prepared in the mixture solvent of DEG and DEA even at prolonged reaction time of 2h 
(Figure 7.8 D4). 
 























Figure 7.8. TEM images of the nanoparticles prepared using different (v/v) ratio of DEG: 
DEA at the reaction time intervals:  D1. 2:1; 2h, D2. 1:1; 1/2 h, D3 & D4. 1:1; 2h. 
 
Figure 7.9 to Figure 7.13 show the TEM images of the nanoparticles prepared using 
different ratio of TEG:TEA (4:1 to 1:4 v/v) at different reaction time intervals (1/2 to 4 
h). It can be seen that as usual isolated spherical shaped nanoparticles are formed when 
the concentration of TEA is low (TEG:TEA ≥ 2:1). However, with increasing the TEA 
concentration (TEG:TEA <2:1), the flower shaped nanoparticles gradually developed. 
Figure 7.11 show that about 4-5 spherical particles are interconnected with each other to 
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develop flower like structure. Thus, the flower structure starts to develop with the ratio of 
TEG:TEA = 1:1. Figure 7.12 and Figure 7.13 indicate that more number of spherical 
particles are gradually linked into the flower structure while increasing the TEA 
concentration (TEG:TEA = 1:2 and 1:4). Moreover, the flower particles are prepared 
using shorter react time interval (up to 1h) are dispersed separately while they are 






















Figure 7.9. TEM images of the nanoparticles prepared using 4:1 (v/v) ratio of TEG: TEA 
at the reaction time of E1. 30 min, E2. 1h, E3. 2h and E4. 4h. All scale bars are 20 nm. 










Figure 7.10. TEM images of the nanoparticles prepared using 2:1 (v/v) ratio of TEG: 





































Figure 7.11. TEM images of the nanoparticles prepared using 1:1 (v/v) ratio of TEG: 































Figure 7.12. TEM images of the nanoparticles prepared using 1:2 (v/v) ratio of TEG: 




















Figure 7.13. TEM images of the nanoparticles prepared using 1:4 (v/v) ratio of TEG: 
TEA at the reaction time of I1. 1/2 h, I2. 1h, I3. 2h and I4. 4h.  
 
In summary, the spherical shaped nanoparticles are formed up to the 2:1 ratio and 
thereafter (i.e. <2:1); the shape of the particles is gradually transformed into the flower 
like structure. The MNF particles prepared using the shorter reaction time (≤1h) are very 
well dispersed but, they are progressively self-assembled into chain like patterns while 
prolonging the reaction time (>1h).  
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Figure 7.14 I5 shows the HR-TEM image of a single IO@14 nano-cluster particle which 
clearly indicates that each of the flower particles consists of inter-connected many small 
(~ 10 nm) spherical nanoparticles. Figure 7.14 I6 indicates that IO@14 nano-clusters are 
self-assembled into the chains which could be due to the increased magnetic interactions 










Figure 7.14. I5. HRTEM images of a single IO@14 nano-cluster particle I6. Self-
assembled magnetite nano-cluster particles. Inset is SAED patterns of the nano-flower 
particles. 
 
7.3.2. Structural Characterization 
Figure 7.15 shows XRD patterns of the nanoparticles prepared using different TEG: TEA 
ratio at 1h reaction time interval. Positions of the diffraction peaks match well with the 
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standard XRD patterns for bulk magnetite (JCPDS file No. 19-0629) indicating that the 














Figure 7.15. XRD patterns of the nanoparticles prepared using different TEG: TEA ratio: 
(a) 4:1, (b) 1:1, (c) 1:4 and (d) 0:1 at 1h reaction time interval.  
 
Figure 7.16 depicts FTIR spectra of the nanoparticles prepared using different TEG: TEA 
ratio at 1h reaction time interval. The peaks at about 2962–2809, 1681-1534, 1485-1340, 
1084, 910 cm-1 are due to C–H stretching, O–H stretching, C–H bending, C–O stretching 
and O–H bending vibrations respectively [25-27], which are attributed to the TEG and 
TEA molecules adsorbed on to the particle surface. The broad band between 3600 and 
3000 cm−1 centered at about 3400cm–1 is assigned to O–H stretching vibration which 
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arises due to the adsorbed water molecules. In addition, the strong absorption band at 














Figure 7.16. FTIR spectra of the nanoparticles prepared using different TEG: TEA ratio: 
(a) 4:1, (b) 1:1, (c) 1:4 and (d) 0:1 at 1h reaction time interval.  
 
Figure 7.17 (b) and (c) show the wide scan XPS spectra of the nanoparticles prepared 
using the 1:4 and 0:1 TEG: TEA ratio at 1h reaction time interval. The nanoparticles 
prepared using the 1:1 and 4:1 ratio show the similar XPS spectra. It can be seen that the 
peaks except the N(1s) peak are very similar to that of the nanoparticles prepared using 
the 1:0 TEG:TEA ratio (Figure 7.17 (a)). The deconvoluted N(1s) spectra is shown in the 
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inset of Figure 7.17 while the deconvoluted O(1s) and C(1s) spectra are similar to that of 
the 1:0 nanoparticles as shown in the insets of Figure 6.12 (Chapter 6).  The O(1s) peaks 
at 533.3; 531.6 eV and the C(1s) peak at 285.5 eV, which are assigned to C-O; O-H and 
C–C/C–H bond respectively [25, 29], are due to the adsorbed TEG/TEA molecules. The 
peaks at about 288 eV (C(1s)) and 399.5 eV (N(1s)) are due to C–O–C  and C-N bond of 
the adsorbed TEG and TEA molecules, respectively [25,30]. In addition, the Fe(3p3/2), 
O(1s), Fe(2p3/2) and Fe(2p1/2) peaks at about 55, 530.3, 710 and 724 eV are due to Fe–O 










Figure 7.17. XPS spectra of the nanoparticles prepared using different TEG: TEA ratio: 
(a) 1:0, (b) 1:4 and (c) 0:1 at 1h reaction time interval. Inset of C shows the deconvoulted 
N(1s) spectra. 
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Figure 7.18 shows the TGA curves of the nanoparticles prepared using different TEG: 
TEA ratio at 1h reaction time interval. The TGA curves represent two-stage weight loss: 
the first weight loss (between 25–200ºC) is due to the evaporation of water and the 
second weight loss (between 250–800ºC) is due to the decomposition of surface adsorbed 
chemically adsorbed organic coating from the particle surface. It is estimated from the 
TGA result that the amount of the adsorbed TEG and TEA coating on the surface of the 








Figure 7.18. TGA curves of the nanoparticles prepared using different TEG: TEA ratio: 
(a) 4:1, (b) 1:1, (c) 1:4 and (d) 0:1 at 1h reaction time interval.  
Thus, the XRD, FTIR, XPS and TGA studies confirm that the as-prepared nanoparticles 
are consisting of pure magnetite phase and their surfaces are coated with TEG and/or 
TEA molecules. 
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7.3.3. Magnetic Properties 
Figure 7.19 A shows the VSM magnetization (M-H) curves of the particles prepared 
using different TEG: TEA ratio at 1h reaction time interval and Figure 7.19 B shows the 
M-H curves of the particles prepared using the 1:4 ratio at different reaction time 
intervals. It can be seen that the saturation magnetization (Ms) value of the particles 
increases from 67 to 80 emu/g with decreasing TEG:TEA ratio from 4:1 to 0:1 and 
increases from 75 to 86 emu/g with increasing reaction time from 1 to 4h for the samples 
prepared using the 1:4 TEG:TEA ratio. This increase of Ms value could be either due to the 
clustering of more and more number of magnetic nanoparticles into single a structure or 
due to self-assembly of the nanoclusters into the chain like structures while prolonging 
the reaction time as shown by above TEM studies (Section 7.2.1).      
 
Figure 7.20 A and B shows the temperature dependence of the zero-field cooled/field 
cooled (ZFC-FC) SQUID magnetization curves of the magnetite nanoclusters prepared 
using at 1h and 2h reaction time intervals.  It can be seen that the nanoclusters prepared at 
1h reaction time are superparamagnetic in nature with the blocking temperature (TB) at 
around 270 K (Figure 7.20 A). However, the nanoclusters prepared at 2h reaction time 
are no more superparamagnetic at the room temperature, which could be due to the self-
assembly of the magnetite nanoclusters into a chain like structures as shown by the above 
TEM studies (Section 7.2.1). Thus, we have optimized the TEG: TEA ratio to 1:4 and 
reaction time at 1h for the preparation of well dispersed superparamagnetic IO@14 
nanoclusters with high MS (75 emu/g) and their potentialities for the magnetic 
hyperthermia and MRI applications were further investigated. 





Figure 7.19. M-H curves the nanoparticles prepared A. using (a) 4:1, (b) 1:1, 1:4 (c) and 
(d) 1:4 TEG:TEA ratio at 1h reaction time interval. B. at (a) 2h and (b) 4h reaction time 
intervals  using 1:4 TEG:TEA ratio.  
  
 
Figure 7.20. Zero-field cooled/field cooled (ZFC/FC) magnetization of A. I2 and B. I3 
samples prepared at 1h and 2h respectively, under an applied field of 50 Oe.  
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7.3.4. In vitro Cytotoxicity Studies 
Figure 7.21 shows the cytotoxicity profile of the TEA coated (IO@14) magnetite 
nanoparticles using the MCF-7 breast cancer cells. It can be seen that the IO@14 
nanoparticles do not show any cytotoxicity in MCF-7 cells. Thus, the TEA coated 
magnetite nanoparticles are biocompatible up to the iron concentration of 10 mg/ml with 
MCF-7 breast cancer cells. Cell viability found to be increased at 10 mg Fe/ml as 
compared to 0.625 mg Fe/ml which could be due to increased cell mitochondria 













Figure 7.21. Cytotoxicity profile of the TEA coated (IO@14) nanoparticles on MCF-7 
breast cancer cells.  
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7.3.5. Magnetic Hyperthermia Studies 
Figure 7.22 show the time dependent temperature rise of 1 ml aqueous suspension of the 
TEA (1:4 TEG:TEA) coated (IO@14) nanoparticles with the iron concentrations of 0.5, 
1, 2, 4 and 8 mg/ml upon exposure to 89 kA/m AC magnetic field at 240 kHz frequency. 
Inset of Figure 7.22 depicts the field dependent SAR values of the IO@250 nanoparticles 
with 1 mg/ml iron concentration at 240 kHz frequency, indicating that the SAR values 
varies nearly with H2 as reported in literature  [49-50]. The SAR values under 89 kA/m 
AC magnetic field at 240 kHz frequency is about 500 Watt/g for the IO@14 nanoclusters 
with the 0.5 mg/ml iron concentration.  
The time required to raise the temperature up to 42ºC for the IO@14 nanoparticles with 
different iron concentration (0.5- 8 mg/ml) using different frequency (240 and ~ 400 
kHz) are given in Table 8.2 and Table 8.3 respectively. The results indicate that the rate 
of temperature rise systematically increases with the iron concentration of IO@14 
nanoparticles. Moreover, the rate of temperature rise depends on the applied frequency 
and AC magnetic field. The heating of the IO@14 nanoparticles could be due to 
Neel/Brownian relaxation or hysteretic loss when they are exposed to an alternating (AC) 



















Figure 7.22. Time dependent temperature rise of 1 ml IO@14 sample with different iron 
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Table 7.2. The time required (within 600 second of experiment) to raise up to 42 ºC for 




Time required to 































   0.4 × 1010 
4 283 
2 462 
1 Not reached (32 ºC) 
0.5 Not reached (27 ºC) 







    
 




0.5 Not reached (36 ºC) 
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Table 7.3. The time required (within 600 second of experiment) to raise up to 42 ºC for 




Time required to 






















8 250           
 
         17 




       ~400 
    
 
0.7 × 1010 
4 419 
2 Not reached (32 ºC) 
1 Not reached (29 ºC) 
0.5 Not reached (27 ºC) 
8 112  
 
         35 
    (100A) 
      
 
      ~400 
    
 
1.4 × 1010 
4 167 
2 491 
1 Not reached (35 ºC) 
0.5 Not reached (30 ºC) 
8 61  
 
        69 
     (200A) 
 
 
     ~400 
    
 
2.8 × 1010 
4 124 
2 308 
1 Not reached (41 ºC) 
0.5 Not reached (33 ºC) 
8 55  
 
       104 
     (300A) 
 
 
      ~400 
    
 




0.5 Not reached (37 ºC) 
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7.3.6. In vitro Hyperthermia 
Figure 7.23 A shows the in vitro cytotoxic effect on MCF-7 breast cancer cells treated 
with magnetic hyperthermia using the IO@14 nanoparticles (0.5 mg/ml of Fe 
concentration) upon exposure to 89 kA/m AC field at 240 kHZ frequency. As a 
comparison, the cancer cells were also exposed to only magnetic field (89 kA/m AC, 
without adding any IO@14 nanoparticles) and only IO@14 nanoparticles with 0.5 mg/ml 
of Fe concentration (without exposing to the magnetic field). Results (Figure 7.23 A) 
show that the magnetic hyperthermia at 45°C caused 74% of cell death, while cell 
viability in the case of exposure to only the magnetic field or only IO nanoparticles were 
comparable to that of the control. Thus, it was confirmed that about 74 % loss of MCF-7 
cancer cell viability was due to the magnetic hyperthermia treatment. Figure 7.23 B, C 
and D show optical microscope images of MCF-7 breast cancer cells without any 
treatment (i.e. control) and the cells treated with only AC magnetic field (without 
IO@14), and with magnetic hyperthermia (using both IO@14 and magnetic field). It was 
observed that the cells treated by magnetic hyperthermia, lost their ability to attach to the 
surface and fail to grow (as shown in Figure 7.23 D) while the control cells (as shown in 
Figure 7.23 B) and the cells treated with only magnetic field (as shown in Figure 7.23 C) 
are attached to the surface, which clearly indicates that the losses of cell viability (also as 
shown by the MTT assay) are due to the magnetic hyperthermia treatment using the 
IO@14 nanoparticles.  
The percentage loss of MCF-7 cancer cell viability due to the IO@14 nanoparticles as 
well as the IO@250 nanoparticles (which are prepared by refluxing Fe(acac)3 in TEG) 
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are compared in Table 8.4. It can be seen that the percentage cell death is greater for the 
IO@14 nanoparticles (74%) than IO@250 nanoparticles (60%). This could be due to the 
clustering of magnetite nanoparticles which leads to greater Ms  (75 emu/g) and higher 
SAR value (500 Watt/g) and thereby faster heating rate of IO@14 nanoparticles under the 
AC magnetic field as compared to unclustered IO@250 nanoparticles (60 emu/g, 135 
Watt/g). Thus, the IO@14 nanoparticles are much better for magnetic hyperthermia 
applications than the IO@250 nanoparticles as the amount of magnetic materials required 
for the treatment would be less and undesired toxicity which may arise due to high dose 
in vivo can be avoided. 
Table 7.3. Average particle size, saturation magnetization (Ms), SAR and percentage cell 
death for IO@250 nanoparticles and IO@14 nanoclusters. 








IO@10 10 60 135 60  
IO@14 44 75 500 74  
 
 






Figure 7.23. A. Cell viability plot shows the cytotoxic effect on MCF-7 breast cancer 
cells treated with magnetic hyperthermia (~ 45ºC), treated with IO@14 only, and treated 
with magnetic field only in comparison with the control cells. B. is optical microscope 
images of control MCF-7 breast cancer cells C. and D. are optical microscope images of 
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7.3.7. MRI Relaxivity Studies 
Figure 7.24 show the transverse relaxation rates (1/T2
 
and 1/T2*) various Fe 
concentration of IO@14 nanoclusters measured at 9.4 T. The corresponding relaxivities 
(r2, and r2*) were estimated as 294.99 and 450.05 s-1mM-1 suggesting that IO@14 










Figure 7.24. Transverse relaxation rates (1/T2
 
and 1/T2*) vs Fe concentration of IO@14 
nanoparticles measured at 9.4 T. 
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7.3.8. In vivo MRI Imaging                                                                                                
We further evaluated the efficacy of the IO@14 nanoclusters for in vivo MRI imaging 
application. The IO@14 nanoclusters were injected in SCID mice having subcutaneous 
xenograft tumor of MCF-7 cancer cells. Figure 7.25 shows the signal intensity 
normalized by the signal in the background at different time points in tumor (blue line), 
liver (red line) and kidney (green line). Left images in Figure 7.26 show the 
corresponding axial image of tumor (top left) and liver & kidney (bottom left) before 
injection while right images in Figure 8 show the axial image of tumor (top right) and 
liver & kidney (bottom right) after 6 hours injection of the IO@14 nanoclusters. It can be 
seen that the percentage of signal reduction for the liver is higher as compared to kidney 
and tumor (Figure 7.25) and this is also obvious from the large signal intensity reduction 
in post contrast image of liver (Figure 7.26) which is due to massive accumulation of the 
IO@14 nanoclusters in the liver. The contrast change in kidney suggests that the IO@14 
nanoclusters are accumulated in kidney however they are excreted quickly. It can also be 
observed that there is some contrast changes in tumor which is relatively less as 
compared to that of liver (Figure 7.25). However, there is a significant reduction of signal 
intensity in post contrast tumor image which is obvious from the colored intensity scale 
(Figure 7.26) also indicating the accumulation of the IO@14 nanoclusters in the tumor 
region and thereby reduces the T2 of the tumor tissue. Thus it can be concluded that the 
IO@14 nanoclusters could be used as a potential MRI contrast agent and have the 
tendencies to accumulate at tumor sites by a means of passive targeting in which the 
nanoparticles penetrate through the leaky vasculature of the tumor site by enhanced 
permeation and retention (EPR) mechanism. However, tumor accumulation of the 
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IO@14 nanoclusters can be further increased by using permanent magnetic field gradient 
near tumor area following the principle of magnetic drug targeting (MDT) [33].  
 
 
Taken together, the IO@14 nanoclusters are able to heat up efficiently under AC under 
magnetic field and can be detected by MRI due to their high T2 contrast enhancement 
properties. Thus, IO@14 nanoclusters are very promising for both cancer diagnostic and 
therapeutic (theranostic) purposes. However, further in vivo investigations are warranted 









Figure 7.25. The normalized signal change at different time points in tumor (blue line), 
liver (red line) and kidney (green line). 














Figure 7.26. Top images show the axial image of tumor (marked by arrow ) and bottom 
images show the axial image of liver & kidney (marked by arrow) before injection (left) 
and after 6 hours of injection (right) of the IO@14 nanoparticles. The change in signal 








Magnetite nanoclusters have been successfully synthesized by a facile one-step thermal 
decomposition of Fe(acac)3 in a liquid mixture of TEG and TEA. To the best of our 
knowledge, this is the first report on the single-step facile synthesis of magnetite 
nanoclusters using a thermal decomposition method. The well dispersed 
superparamagnetic IO@14 nanoclusters obtained at an optimized 1:4 TEG:TEA (v/v) 
ratio resulted higher Ms (75 emu/g) than similar unclustered magnetic nanoparticles (65 
emu/g). The IO@14 nanoclusters are found to be cytocompatible. In vitro hyperthermia 
studies have confirmed that the Fe3O4 nanoclusters are able to produce significant 
temperature rise upon exposure to AC magnetic field and yielded high specific absorption 
rate (SAR~500 Watt/g) values. The heating rate of IO@14 nanoclusters under AC 
magnetic field are faster and thus cause more percentage loss of MCF-7 cancer cell 
viability (74%) than that for the Fe3O4 nanoparticles (60%). Moreover, IO@14 
nanoclusters showed significant r2 and r2* relaxivities (294.99 and 450.05 s-1mM-1) and 
promising contrast in vivo MRI imaging too. Thus, the novel IO@14 nanoclusters are 
very promising candidate for for magnetic hyperthermia treatment of cancer and they 
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 Monodispersed & superparamagnetic hydrophobic Fe3O4 nanoparticles with 
improved Ms (74 emu/g) are synthesized by solvent free thermal decomposition 
(SFTD) method.  
 The hydrophobic Fe3O4 nanoparticles are converted into hydrophilic (i.e. water 
soluble) by functionalization and polymeric encapsulation to make them useful for 
biomedical applications.  
 Other metal oxide and luminescence NPs like CoO, ZnO, Y2O3:Eu, NaYF4:Yb,Er 
NPs have also been synthesized using the TD method. 
 Hydrophilic superparamagnetic Fe3O4 nanoparticles have been synthesized directly 
by one-step polyol synthesis method. 
 Hydrophilic superparamagnetic Fe3O4 nanoclusters with high saturation 
magnetization (Ms ~ 86 emu/g) have been synthesized by one-step synthesis method.  
 In vitro cell viability studies have demonstrated high cellular uptake and low 
cytotoxicity of the Fe3O4 nanoparticles and nanoclusters.  
 MRI relaxivity measurements have confirmed higher r2* relaxivity (617.5 s-1mM-1) of 
the Fe3O4 nanoparticles as compared to commercial resovist nanoparticles (245.2 s-
1mM-1). 
  In vivo MRI imaging studies of the Fe3O4 nanoparticles and nanoclusters have 
demonstrated very promising contrast in vivo tumor imaging. 
 In vitro hyperthermia studies have confirmed that the Fe3O4 nanoparticles and 
nanoclusters are able to produce significant temperature rise upon exposure to AC 
magnetic field (SAR~ 135 Watt/g for the nanoparticles and ~500 Watt/g for 
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nanoclusters) and thus, 60-74% loss of cancer cell viability was observed due to the 
magnetic hyperthermia treatment. 
 
It can thus be concluded that the Fe3O4 nanoparticles and nanoclusters are very promising 
candidate for clinical MRI imaging as well as for magnetic hyperthermia treatment of 
cancer. 
 
8.2. Future Work 
The magnetic nanoparticles (MNPs) could be combined with the anticancer drugs 
(chemotherapeutic agents) to develop the multifunctional nanoparticles which are very 
efficient to target MNPs and chemotherapeutic agent to a specific tumor site and thereby 
to produce combined magnetic hyperthermia and chemotherapeutic effect for cancer 
treatment. With this combined therapy, various side effects of chemotherapy could be 
avoided as lower chemotherapeutic dose is required and it could be possible to selectively 
heat up tumors by applying AC magnetic field to the targeted nanoparticles. However, 
improvements of combined therapeutic modality are still needed for more successful 
treatment of cancer. In this context, there is a need of efficient drug delivery systems to 
selectively deliver MNPs and chemotherapeutic agents to tumor cells and then apply 
localized hyperthermia to tumor site. There are three general directions to deliver 
chemotherapeutic agent and MNPS into specific cancer tissue avoiding the side effects: 
(i) Magnetic drug targeting, (ii) Site-specific active targeting and (iii) Site-specific 
triggering.  
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8.2.1. Magnetic Drug Targeting 
 
Magnetic drug targeting (MDT) is the site specific delivery of chemotherapeutic agents to 
their target using magnetic nanoparticles (ferrofluids) bound to these agents, with an 
external magnetic field generated at the tumor site [1]. In this approach, magnetic 
particles along with the drug are formulated into a pharmaceutically stable formulation 
which can be held in position at the target site (or tumor) using an external magnetic field 
[1-3]. This approach helps in localizing the drug to the desired site, thereby minimizing 
the potential for accumulation of the drug in healthy tissues. A combination of improved 
target selectivity and enhanced duration of drug exposure to the target also reduces the 
overall amount of drug taken up by the RES. MDT uses much smaller doses of drug 
leading to several fold increased drug efficacy and reduced drug toxicity [1, 3-7]. In 
addition to some of the key advantages of MDT already mentioned above, the magnetic 
nanoparticles used in MDT also offer distinct advantages. They are:  
a) The magnetic nanoparticles are biocompatible, non-immunogenic and injectable.  
b) They are non-toxic, even if injected in larger quantities. They are metabolized by the 
hepato-renal system and used in the synthesis of hemoglobin. 
c) They have controllable sizes (from a few nanometers to tens of nanometers). 
d) They have high magnetic susceptibility and show high accumulation in the desired 
target tissue or organ. 
e) They can be made to respond resonantly to an alternating magnetic field, with 
advantageous results related to the transfer of energy from the exciting field to the 
nanoparticle, as in case of hyperthermia. 
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f) They are superparamagnetic; hence they preferentially deliver the ferrofluid bound 
drug at the desired site under the influence of an external magnet. This reduces the 
amount of drug required and thus the side-effects owing to the drug [7-9]. 
 
Magnetic liposomes or magnetoliposomes are magnetic derivatives of liposomes and can 
be prepared by entrapment of ferrofluids within the liposomal core. In other words, they 
consist of magnetic nanoparticles wrapped in a phospholipid bilayer [2, 8]. 
Magnetoliposomes offer a promising tool for passive targeting with regard to the drug 
delivery of magnetic nanoparticles [8]. An advantage in formulating magnetic particles 
within liposomes is the enhanced protection against aggregation and oxidation when 
incorporated in liposomes [9]. Magnetic liposomes like conventional liposomes have 
biokinetic and structural advantages, like their ability to spontaneously encapsulate drugs 
or genes along with magnetite [8, 10-11].  Furthermore, their surface can be modified 









Figure 8.1. Magnetic cationic liposomes (MCLs) relatively biocompatible lipids [8].  
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Magnetic cationic liposomes (MCLs) are made of positively charged (cationic) and 
relatively biocompatible lipids (Figure 8.1). They have a positive charge on their surface, 
which is useful in the interaction of these liposomes with the negatively charged tumor 
vascular surface. Liposomes containing fluid MAG-C (magnetite) can maintain a positive 
charge potential and hence they have potential to target the tumor vasculature in the 
presence of the magnetic material. The liposomes have been shown to be taken up by the 
tumor endothelial cells and cancer cells as well. The application of an external magnet 
can thus enhance the vascular accumulation in tumors. It has also been shown that MCLs 
show superparamagnetic behavior and with an increase in the MAG-C content the 
saturation magnetization values of the MCLs significantly increase [6, 10]. 
For MDT, it is important to know if the ferrofluid micro-circulation and diffuses freely 
into interstitial space, or whether the complex remains within the vascular space [6,12]. 
Other important aspects to be considered for MDT are: 1) The type and concentration of 
the ferrofluid employed, 2) the magnetic strength of the external magnetic field, 3) the 
time duration for which the target tissue is exposed to the external magnet, 4) 
bioavailability of ferrofluid as well as the in vivo desorption time of the drug [6,12]. 
The application of hyperthermia is favored if phospholipids with transition temperature 
slightly above the physiological temperature are incorporated into liposomes. For drug 
loaded MCLs, the magnetic nanoparticles embedded within the lipid bilayer get heated 
by means of an AC field. The thermal energy is then transferred to the liposome bilayer 
which gets heated to its phase transition temperature. The bilayer then melts and results 
in efficient release of the incorporated drug substance [9, 13].  
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8.2.2. Site-specific Active Targeting 
 
For the site-specific active targeting, first the drugs are immobilized on carrier particle 
and then surface of the particle is labelled with ligands or antibodies that target over 
expressed receptors in the tumor tissue [7, 14-15]. Liposomes [16-18], polymeric 
nanoparticles [19-22], micelles [23] and dendrimers [24-25] have been extensively used 
as a carrier for the delivery of drugs to tumors. Among these, the polymeric nanoparticles 
have been received most attention due to their high chemical stability [26-27]. A number 
of different polymers have been utilized as drug carriers, but PLA-PEG [14, 28.30] and 
PLGA-PEG [14, 30-33] diblock copolymers have been the focus of intense research on 
drug delivery over the past two decades because of their following characteristics: 
1. biodegradability 
2. excellent biocompatibility 
3. “stealthy,” i.e., not recognizable by the reticulo-endothelial (RES) system and 
thus  reduce RES clearance and facilitates extravascular uptake  
4. longer blood circulation due to hydrophilicity, flexibility and charge neutrality of 
PEG chains  
5. consisting of both hydrophobic (PLA/PLGA) and hydrophilic (PEG) part and thus 
capable of encapsulating both the hydrophobic and hydrophilic materials 
6. able to control drug release rate through tunable degradation 
7. availability of functional groups to the distal end of a few PEG molecules for the 
conjugation with cell-specific ligands (folic acid, monoclonal antibodies etc.). 
Polymeric nanoparticles can be prepared by several techniques (emulsification-solvent 
evaporation methods, solvent displacement methods, salting out methods.), depending on 
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the nature of the polymeric material and the characteristics of the drug to be loaded. 
Emulsification-solvent evaporation method is widely used for the preparation of 
nanoparticles made of PLA-PEG, PLGA-PEG block copolymers [28-31]. Thus, MNP 
and the drugs are encapsulated within PLA/PLGA-PEG and the obtained nanoparticles 
are called as pegylated nanoparticles (PNs). For increasing the probability of redirecting 
long-circulating PNs to the desired target, their surfaces are labeled with either the 
specific antibodies or the ligands targeting proteins expressed on cancer cell membranes 
or endothelial cells lining the newly generated blood vessels in the tumor. Antibody 
labelled PNs (pegylated immune-nanoparticles, PINs) consist of monoclonal antibodies 
(MAb) or antibody fragments, F(ab)2  coupled to their surface, which causes the PINs to 
bind selectively to antigens or receptors that are either uniquely expressed or over-
expressed on cancer cells, leading to increased drug delivery to the target cells. PNs 
conjugated with MAb not only selectively target cancer cells, but they could also improve 
the internalization of the encapsulated drugs into the targeted cancer cells. Several studies 
have dealt with PNs targeting through the attachment of the antibody directly to the tip of 
the PEG strands [26, 34-35]. For effective targeting, PINs should bear optimum number 
of antibody molecules to facilitate binding to target molecule as well as to escape RES 
uptake which needs fine tuning and optimization for different targeting molecules. PINs 
can be targeted to surface molecules expressed either in the vascular system or in the 
extra vascular system on tumor cell membranes. The most readily accessible target sites 
for PINs are the vascular endothelial surface of growing tumors and circulating cells 
related to the immune system. In this regard, different antibody molecules like anti-
CD19, anti–CD20, anti-ICAM-1 antibody and anti-HER-2 can be attached to PNs and 
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hence targeting to specific cancers expressing corresponding antigens could be achieved. 
Another approach for PNs based targeting is folic acid mediated targeting. Folic acid is a 
vitamin that is essential for the biosynthesis of nucleotides. PNs conjugated with folic 
acid appeared to localize in the cell cytoplasm as a consequence of folate receptor-
mediated endocytosis taking advantage of the frequent overexpression of folate receptors 
(FR) onto the surface of human cancer cells [34]. FR targeted PNs have proven effective 
in delivering doxorubicin in vivo [36] and have been found to bypass multidrug resistance 
in cultured tumor cells [37]. Thus, PNs labelled with MAb or FR are the potential 
candidates for the cancer-specific active drug targeting.   
 
 
8.2.3. Site-specific Triggering 
 
For the site-specific triggering, the drugs are immobilized on stimuli-resposive polymers. 
Various polymer matrices like gelatine [38], poly(vinylalcohol) [39], hydroxypropyl 
cellulose [40], poly(N-isopropylacrylamide) [41] or poly(N-isopropylmethacrylamide), 
[42] etc. have been explored. Their heat sensitive behaviour offers enormous possibilities 
for temperature triggered drug release at the pathological sites such as cancer. Amongst 
all, much attention has been paid on poly (N-isopropylacrylamide) (PNIPAAm) as a 
promising thermosensitive drug delivery system as its transition temperature (which is 
defined as lower critical solution temperature, LCST ~32-34 ºC) is very close to human 
body temperature. Its aqueous solubility has been well-studied by many researchers and 
they found that it exhibits inverse solubility with temperature [43]. Below this critical 
temperature (CT), the polymer chains are excessively hydrated (swollen) and form 
expanded structures (coil form). Above the CT (Lower Critical Solution Temperature, 
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LCST), the chains rapidly dehydrate (collapse) and aggregate to form compact structures 
(globule form). It contains hydrophilic moiety acryl amide and relatively hydrophobic 
isopropyl group which results in hydrophobic-hydrophilic interaction with aqueous 
medium that ultimately determines its solubility in water at a given temperature. The 
conformational change in a single chain segment upon heating is also well observed in 
PNIPAAm based macroscopic bulk hydrogels, crosslinked copolymers, microgels, 
latexes, interpenetrating networks (IPNs) and colloidal particles as well [44-45].  
Redox polymerization of aqueous PNIPAAm in presence of sulphate initiators at some 
elevated temperature promotes the growing polymer chains to form highly monodisperse 
colloidal particles [46]. The polymer gels containing particles rather than interpenetrating 
network have their own advantages for in vivo biomedical studies like internalization into 
body cells. Being in particle form, these offer easy surface tailoring to attach desired 
drugs, enzyme etc. and release them by certain physical/chemical triggering mechanisms. 
Their higher electrophoretic mobility and submicron to nano size range (200-300 nm) can 
also be advantageous as a matrix for drug delivery systems to carry drug as well as 
magnetic nanoparticles in case of magnetic hyperthermia and DNA diagnosis [47]. Here 
magnetic nanoparticles could be used to generate heat under AC magnetic field and 
temperature triggered release of drug can occur through thermoresponsive polymeric 
colloidal system. In addition, these polymeric colloidal nanogel particles because of their 
higher mechanical strength and durability over other drug carriers like liposomal and bulk 
hydrogels have been proved to provide prolonged circulation and effectively release drug 
in controlled manner by diffusion from the carrier-polymer or by decomposition of the 
carrier itself. PNIPAAm colloidal gel particle surfaces need to be modified or to be 
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conjugated with some other biodegradable polymers in order to achieve an ideal 
biocompatible and biodegradable drug delivery system [48]. Chitosan, being a natural 
carbohydrate polymer is an excellent alternative of which the biocompatibility and 
biodegradability is well studied [49]. It is pH sensitive and association with PNIPAAm 
can formulate pH as well as thermoresponsive drug delivery systems [50]. One of the key 
challenges with the use of thermoresponsive PNIPAAm based gels has been to modulate 
its LCST above body temperature and favourably up to 42-43oC, which is a desired 
temperature for hyperthermia treatment of cancer. Recently, an attempt has been made by 
Misra et al. [51], wherein, they reported the change in LCST by hydrophilic modification 
of PNIPAAm. Copolymerizing PNIPAAm with N,N’-dimethylacrylamide (DMAAm) 
caused a shift in LCST from 32oC to 38oC. However, the field is still in infancy stage and 
much research is needed to develop a PNIPAAm based drug delivery systems, which will 
contain both the drugs and magnetic nanoparticles and thus could be used for triggered 
drug delivery and cancer therapy by magnetic hyperthermia and chemotherapy. 
Moreover, photodynamic therapy (PDT) based on the upconverting luminescence 
nanoparticles has been recognized as a promising therapy for cancer treatment which 
involves killing of diseased cells by excitation of photosensitizer chemicals with high-
energy light to produce cytotoxic oxygen species from surrounding dissolved oxygen 
[52-53]. Thus, the development of the multifunctional nanoparticles encapsulating the 
MNP combined with the photosensitizer and anticancer drugs will be a very good 
breakthrough in cancer treatment due to the effective killing of the cancer cells using the 
combined magnetic hyperthermia, photodynamic therapy and chemotherapeutic effect. 
The approaches of future plan of work will be as follows- 
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A. Development and characterization of the multifunctional nanoparticles (MFNs).  
B. Optimization of the MFNs in terms of their stability, encapsulation efficiency, 
release study, temperature sensitivity, luminescence efficiency, relaxivity and 
specific absorption rate (SAR).  
C. in vitro biocompatibility study of the MFNs. 
D. in vitro internalization study of the MFNs. 
E. Conjugation of cancer specific folate ligand/monoclonal antibody to the MFNs.  
F. Evaluation of folate receptor/monoclonal antibody mediated active targeting to 
the tumor site using a mice model. 
G. Evaluation of external magnetic field guided magnetic targeting. 
H. Evaluation of localization, retention and bioavailability of MFNs in vivo. 
I. Evaluation of bio-imaging and MRI imaging efficacy  
i. In vitro imaging using different cancer cell lines. 
ii. In vivo imaging in animal surface tumor models. 
J. Evaluation of therapeutic efficacy (chemotherapy and hyperthermia)  
i. In vitro using different cancer cell lines. 
ii. In vivo using animal tumor models. 
 
8.2.4. Significance and novelty of the proposed future work 
Controlled drug delivery technology represents one of the most rapidly advancing areas 
in biomedical research field. Delivery systems offer many advantages over conventional 
dosage forms, including improved efficacy, reduced toxicity, improved patient 
compliance, and cost effective therapeutic treatment. In particular, controlled and site 
specific release is strongly required for chemotherapeutic drugs to be efficiently used for 
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cancer therapy. As most of the chemotherapeutic drugs are equally toxic to normal cells, 
controlled targeted release of the drug will help to minimize the dose and undesirable 
toxic effects and to achieve the therapeutic outcome. There is number of 
chemotherapeutic drugs which is not being used to its full potential due to lack of 
efficient delivery system. Though the research has been going on since long, only a few 
have reached to the clinical trials. However, with the advent of nanotechnology, recently 
there is a lot of interest on the development of multifunctional smart (controlled and 













Figure 8.2. A. Encapsulated and B. Core-shell type multifunctional nanoparticle (MFNs) 
has the capability to simultaneously carry therapeutic agents, targeting ligand such as 
conjugated antibodies or folate receptor, and imaging probes.  
 
Though there is a lot of research on the development of different polymers and 
phospholipids based nanoparticles for drug delivery on the last decade, research on the 
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designing of smart drug delivery system which releases its content specifically at the 
pathological site is at its infant stage. Thus, main focus of this project is the development 
of smart polymeric nanoparticles for drug delivery to cancers. Different polymers 
(biodegradable and thermosensitive) will be used to encapsulate drug, magnetic 
nanoparticles (MNP) and luminescence nanoparticles (LNP). The polymeric 
nanoparticles encapsulating drugs, PS, MNP and LNP will be concentrated in the tumor 
cells actively by ligand (folic acid or antibody) attached to the surface of the 
nanoparticles and passively by permanent magnet and release of the drugs will controlled 
by hyperthermia created by applying AC magnetic  field.  
Cancer is an international cause of concern in the medical science. Hyperthermia at 42 to 
46 ºC is a promising therapy for cancer treatment. Heat may help to shrink tumors by 
damaging cells or depriving them of substances they need to live. Hyperthermia is also 
used with other forms of therapy (radiation therapy, chemotherapy, and biological 
therapy) to increase their effectiveness. In this proposal, hyperthermia based treatment of 
solid tumors is discussed in view of intracellular delivery of magnetic nanoparticles (with 
the help of a suitable delivery system). In the presence of AC magnetic field these 
intracellular localized magnetic particles will act as heat sources providing sufficient heat 
to build up necessary temperature to destroy the affected tissue. In the proposed therapy 
selective destruction of tumor cells will be tried out in vitro and in vivo on animal tumor 
models. 
Photodynamic therapy (PDT) based on the upconverting luminescence nanoparticles has 
also been recognized as a promising therapy for cancer treatment. Thus, the development 
of the multifunctional nanoparticles encapsulating the MNP combined with the 
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photosensitizer and anticancer drugs will be a breakthrough in cancer treatment due to the 
effective killing of the cancer cells using the combined magnetic hyperthermia, 
photodynamic therapy and chemotherapy. It is also very crucial to continuously monitor 
the state of tumor during therapy to determine the therapy parameters. Because of the 
encapsulation of luminescence nanoparticles, the polymeric nanoparticles have the 
capability to provide a fast and non-invasive visible light imaging of tumor tissue and 
thus, the multifunctional nanoparticles (as shown in Figure 8.2) may be promising for the 
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Synthesis of Various Nanoparticles using 














Absolute ethanol (EtOH), ethyl acetate (EtAc) and acetylacetone (Hacac) were used 
without purification. Oleylamine (OM), tri(ethylene glycol), (TREG), iron(II) acetate 
(Fe(ac)2), iron(III) citrate (Fe(cit)3), iron(III) hydroxide oxide (Fe(hyd)), zinc 
acetylacetonate hydrate (Zn(acac)2.xH2O), cobalt (III) acetylacetonate (Co(acac)3), 
yttrium(III) oxide (Y2O3) and europium(III) oxide (Eu2O3) were purchased from Sigma-
Aldrich. Yttrium acetylacetonate (Y(acac)3) and europium acetylacetonate (Eu(acac)3) 
were prepared according to the procedure reported by Si et al. [1].  
 
Synthesis of ZnO nanoparticles 
ZnO
 
nanoparticles were prepared using the STD method. Typically, 2 mmol of 
Zn(acac)2.xH2O precursor was dissolved in a 20 mL of stabilizing media (OM or TEG) 
and magnetically stirred under a flow of argon. The solution is dehydrated at 120°C for 1 
h, and then quickly heated to 320°C (for OM) or 260°C (for TEG) and kept at this 
temperature for 1 h. The white solution was cooled to room temperature (RT) by 
removing the heat source. Then, 20 mL of ETOH (for OM) or ETOH/ETAc (1:2 v/v) 
mixture (for TEG) was added into the solution and the precipitated particles were 
collected by centrifugation at 8000 rpm followed by three times washing with ETOH or 
the ETOH/ETAc mixture. Finally, the washed particles were dried overnight in oven to 
obtain dry ZnO nanoparticles. 
 
 Synthesis of Fe3O4 nanoparticles 
Fe3O4 nanoparticles were prepared using the above mentioned STD procedure in presence 
of OM and TEG using different organometallic precursors like Fe(ac)2, Fe(cit)3 and 
Fe(hyd).  
 
Synthesis of CoO nanoparticles 
CoO
 
nanoparticles were prepared using the above mentioned STD procedure in presence 





Synthesis of Y2O3:Eu nanoparticles 
Y2O3:15%Eu nanoparticles were prepared using the above mentioned STD procedure in 
presence of OM using stoichiometric amount of Y(acac)3 (1.81 mmol) and Eu(acac)3 
(0.19 mmol) precursors.   
 
Synthesis of NaYF4:20%Yb,2%Er nanoparticles 
 NaYF4:20%Yb,2%Er nanoparticles were prepared using a modified procedure [2]. 
Typically, 1.56 mmol of Y2O3, 0.4 mmol of Yb2O3 and 0.04 mmol of Er2O3 were 
dissolved in 20 mL of 50% aqueous CF3COOH at 80ºC. The residual water and acid were 
slowly evaporated to dryness at 80ºC. Then 4 mmol of CF3COONa and 20 mL of OM 
were added to the reaction vessel. The resulting solution was magnetically stirred and 
dehydrated at 120°C for 1 h under a flow of argon. The solution was then quickly heated 
to 310°C and kept at this temperature for 1 h. The resulting yellow colloidal solution was 
cooled to RT and 20 mL of ETOH was added into the solution. The precipitated 
nanoparticles were collected by centrifugation at 8000 rpm followed by three times 
washing with ETOH. Finally, the washed particles were dried overnight in oven to obtain 
dry NaYF4:Yb,Er nanoparticles.  
 
Structure of the as-prepared nanoparticles was recognized by XRD, FTIR and TGA while 
their morphology was determined using TEM. Magnetic properties of the Fe3O4 and ZnO 
nanoparticles were measured VSM. Fluorescence spectra of the Y2O3:Eu and 
NaYF4:Yb,Er nanoparticles were recorded on a LS-55 luminescence spectrometer using 
the excitation wavelength of 260 nm and 980 nm, respectively. 
 
 
A2. Results and Discussion 
 
A2.1. Structural characterization 
 
Figure A1 shows the XRD patterns of as-prepared nanoparticles. Position of the 




file No. 80-0075), Fe3O4 (JCPDS file No. 19-0629), CoO [3], Y2O3:Eu (JCPDS file No. 
25-1011) and NaYF4:Yb,Er (JCPDS file No. 28-1192) phase of the nanoparticles, 





























Figure A1. XRD patterns of A. ZnO, B. Fe3O4, C. CoO, D. Y2O3:Eu and E. 
NaYF4:Yb,Er nanoparticles.  
 
Figure A2 A and B show the FTIR spectra of the ZnO nanoparticles prepared in OM and 
TEG respectively. The peaks in Figure A2.A at about 2926; 2854, 1591-1501 and 1473-
1402 cm-1 are due to C–H stretching, N–H bending and C–N stretching vibration, 
respectively attributed for chemically adsorbed OM coating to the hydrophobic ZnO 
nanoparticle surface [4-6]. On the other hand, the peaks in Figure A2.B at about 2962-




stretching, C–H bending, C–O stretching and O–H bending vibration, respectively 
attributed for chemically adsorbed TEG coating to the hydrophilic ZnO nanoparticle 
surface [4-6]. The broad band between 3000-3600 cm−1 centered at ~ 3400 cm−1 is due to 
the O–H stretching vibration arising from the water adsorbed to the particle surface. The 
similar FTIR patterns were observed for the other OM / TEG coated Fe3O4, CoO, 





















Figure A2. FT-IR spectra of A. OM coated and B. TEG coated ZnO nanoparticles, 
respectively. 
The organic coating was further confirmed by TGA analysis. Figure A3.A and B show 
the TGA curves of the ZnO nanoparticles prepared in OM and TREG, respectively. TGA 
curves represent two-stage weight loss on heating of the samples from room temperature 
to 800oC. The first weight loss up to 200oC is due to the evaporation of the surface 
adsorbed water and the second major weight loss between 200 - 800oC is due to the 


























The resulting nanoparticles were highly dispersed without any agglomeration. Figure 
A4.A and B show the TEM images of the ZnO nanoparticles prepared in OM and TEG 
using the Zn(acac)2 precursor. Figure A4.C and D show the TEM images of the Fe3O4 
nanoparticles prepared in OM and TEG using the Fe(ac)2 precursor.  Figure A4.E and F 
show the TEM images of the Fe3O4 nanoparticles prepared in OM using Fe(cit)3 and 
Fe(hyd) precursor, respectively. Figure A4.G, H and I show the TEM images of the CoO, 
Y2O3:Eu and NaYF4:Yb,Er nanoparticles prepared in OM using Co(acac)3 and 
Y/Eu(acac)3 precursor, respectively. It can be seen that the highly dispersed different 




agglomerated Fe3O4 nanoparticles which are prepared in OM using the Fe(cit)3 and 
Fe(hyd) precursors. Thus, the TEM results indicate that highly dispersible hydrophobic or 
hydrophilic nanoparticles with diverse morphology can be synthesized by thermolysis of 


































































Figure A4. A and B are TEM images of OM and TEG coated ZnO nanoparticles; C and 
D are TEM images of OM and TEG coated Fe3O4 nanoparticles prepared using Fe(ac)2 
precursor; E and F are TEM images of OM coated Fe3O4 nanoparticles prepared using 
Fe(cit)3 and Fe(hyd) precursor, respectively; G, H and I are OM coated CoO, Y2O3:Eu 
and NaYF4:Yb,Er nanoparticles, respectively. 
 
A2.3. Magnetic properties 
Figure A5 A, B and C show the magnetization (M-H) curves of OM coated ZnO, Fe3O4 
and CoO nanoparticles, respectively. The corresponding saturation magnetization (MS) 
were measured at 20 kOe as ~5×10-3, 64 and ~ 1 emu/g, respectively. Figure 5 A depicts 
the ferromagnetic nature of the ZnO nanoparticles while Figure A5 C indicates the 



















Figure A5. A. Room temperature M-H curves of OM coated A. ZnO, B.  Fe3O4 and C. 
CoO nanoparticles, respectively. 
 



















Figure A6. Room temperature luminescence emission spectra of (a) Y2O3:Eu and (b) 
NaYF4:Yb,Er nanoparticles. 
Figure A6 (a) and 5 (b) show the fluorescence spectra of Y2O3:Eu and NaYF4:Yb,Er 
nanoparticles, respectively. The emission peaks of the Y2O3:Eu nanoparticles at about 
591, 611-624, and 653 nm are due to the 5 70 1D F→ , 
5 7
0 2D F→ and 
5 7
0 3D F→ transitions while the emission peaks of NaYF4:Yb,Er nanoparticles at about 
522, 540 and 656 nm are due to the 2 411/2 15/2H I→ , 
4 4
3/2 15/2S I→ and 
4 4




Highly dispersed hydrophobic and hydrophilic nanoparticles with diverse morphologies 
can be successfully prepared by the STD thermolysis of appropriate organometallic 
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